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ABSTRACT 
 
While peptides have impeccable potential due to their biological and therapeutic abilities, 
they are inherently limited in clinical practice due to their instability towards proteolysis and poor 
bioavailability. In the past few years peptidomimetics have emerged as a powerful class of 
compounds that overcomes the shortcomings associated with peptides. Peptidomimetics 
essentially mimic a natural peptide or protein in its chemical composition, structure and its ability 
to perform a biologically relevant role. In addition to increased stability and bioavailability, 
peptidomimetics can also have increased receptor binding affinity and selectivity, thereby making 
these mimics lead compounds in the field of drug design and discovery. Most recently, 
modifications to the peptide backbone have been introduced to increase the versatility of 
peptidomimetic applications. This thesis work is based on the unrestricted ability to modify amino 
acid side chain residues within biologically relevant peptides and form new classes of 
peptidomimetics for studying their structure-function properties.  
Motivated by the idea of introducing a multipurpose moiety to increase the functionality 
of peptides, we sought to incorporate the cyclic urethane moiety otherwise known as 2-
oxazolidinone and to explore the plethora of applications that accompany this incorporation. In the 
process of designing cyclic urethane containing peptides, we sought to peruse an approach where 
the cyclic urethane moiety would be derived from naturally occurring amino acids serine, 
threonine, glutamic acid, and/or cysteine. 
Modification of serine’s hydroxymethyl side chain to a 2- oxazolidinone moiety activates 
the peptide backbone chain and increases its susceptibility towards cleavage. Due to the versatility 
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of this moiety, 2-oxazolidinone has been used to explore various applications such as protease 
mimics, formation of peptide thioesters, and modified C-terminal peptides. When used as a 
protease mimic, formation of 2-oxazolidinone allows for site-selective cleavage of extremely 
unreactive peptide bonds using neutral aqueous conditions. This method exhibits broad substrate 
scope and selectively cleaves various bioactive peptides with post-translational modifications (e.g. 
N-acetylation and N-methylation) and mutations (D- and β-amino acids), which are unsuitable 
substrates for enzymes. Further application of this method has been demonstrated by the 
sequencing of cyclic peptides which is difficult to achieve by utilizing traditional methods such as 
Edman’s degradation and MS/MS. Identifying the sequence of macrocyclic peptides is vital in 
exploring potential therapeutic candidates found in nature and/or created through split and pool 
techniques. Building on the susceptibility of 2-oxazolidinone to cleavage, this moiety was also 
utilized for the formation of peptide thioesters, which is of significance in native chemical ligation 
for the synthesis of large proteins. This approach allows the synthesis of peptide thioesters by using 
Fmoc SPPS, which is usually an incompatible method due to the nucleophilic secondary amine 
required for Fmoc removal. Moreover, 2-oxazolidinone was used for the synthesis of various C-
terminally modified peptides which are otherwise unattainable without the use of specialized 
resins, handles, or linkers. By exploring the various applications of the cyclic urethane moiety, this 
thesis work has demonstrated the effectiveness and wide-spread applicability of cyclic urethane 
derived peptidomimetics in the field of synthetic organic chemistry.  
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CHAPTER 1: GENERAL OVERVIEW OF PEPTIDE 
BIOCHEMISTRY AND METHODS FOR CHEMICAL 
SYNTHESIS AND MODIFICATION 
 
1.1 GENERAL INTRODUCTION TO AMINO ACID AND PEPTIDE 
STRUCTURE  
 
Amino acids play a fundamental role in nature as peptide building blocks and as intermediates 
in metabolic processes.1 The twenty naturally occurring amino acids contain a wide array of 
chemical versatility.2 The general structure of amino acids contains terminal amino and carboxyl 
groups which are bound by a central α-carbon. Attached to the α-carbon is a H atom and a side 
chain group designated as R, which serves as the basis of differentiation between one amino acid 
and another (Figure 1.1). This R group is what gives each amino acid its distinct identity and 
unique physical and chemical properties.  
 
Figure 1.1 General amino acid ionic structure. 
Based on the nature of the R group, amino acids can be classified into the following four categories: 
hydrophobic (nonpolar side chains), polar (uncharged residues with hydrophilic character), acidic 
(side chains with a negatively charged carboxyl group), and basic (side chains with a positively 
charged amino group).  Moreover, due to the presence of four different functional groups attached 
2 
 
to the α-carbon, amino acids can exist in the form of two enantiomers, D(R) and L(S). While the 
L-form is predominant in nature, mutations can give rise to some D-amino acids as well. Amino 
acids also have a predominant ionic structure at physiological pH. The neutral zwitterion is formed 
by a balance in charges in between the N-/C-termini and it may also implicate a polar, charged 
amino acids side chain group (Figure 1.1).  The latter can also affect the acid/base properties of 
amino acids which contain ionizable groups that can affect the overall/net charge of the amino 
acids in solution and as a function of changes in pH of the buffer system (Figure 1.2). 
 
Figure 1.2 Venn diagram of amino acid properties. Figure adapted from reference (2). 
Individual amino acids can be further linked together through peptide (amide) bonds to form 
a higher order structure, peptides. The formation of peptides takes place by condensation reactions 
in between the carboxylic group of one amino acid and the amino group of the adjacent amino acid 
thereby releasing a water molecule.1 Peptides are comprised of amino acid linkages encompassing 
50 or less residues; they are essential to the most basic biological processes, including signal 
3 
 
transduction and metabolism. For peptides to have the ability to perform a biologically important 
function, not only do they have to contain a certain amount of amino acids, the residues must also 
be incorporated in a specific order. The primary sequence of amino acids which make up the 
composition of a peptide is critical to its structure-function relationship. Small peptides ranging 
from two to dozens of amino acid residues can have a discernable effect on organism physiology. 
 
Scheme 1.1 Peptide bond formation. Scheme adopted from reference (1). 
Nature carries an extraordinary selection of biologically active peptides which participate in 
crucial roles in human function including hormones, neurotransmitters, and growth factors (Figure 
1.3).3 Furthermore, they serve as regulatory molecules in defense, stress, and reproductive 
processes.4 With the discovery of over 7000 naturally occurring peptides, they are at the core of a 
living organism’s daily operation.3 Some of the most notable peptides include: carnosine (1.1), a 
dipeptide found in muscle tissue; glutathione (1.2), a tripeptide that serves as a scavenger for 
oxidizing agents which have been implicated in cancer; and enkephalins (1.3), two pentapeptides 
that are naturally occurring pain relievers.5 Even more vital to the human body are oxytocin (1.4) 
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and vasopressin (1.5), two notable small peptide hormones with big effects.5 Oxytocin is essential 
to child birth, where it aids in labor induction, contraction of the uterine muscle, and simulation of 
milk flow in a nursing mother. It also stimulates emotions of bonding and affection. Meanwhile, 
vasopressin maintains regular blood pressure level by acting as an antidiuretic in patients with low 
blood pressure. As demonstrated by the abovementioned peptides, naturally occurring peptides 
exhibit inherent properties which act as an inspiration for exploring their therapeutic profile and 
structure-function activity through chemical synthetic routes.  
Figure 1.3 Bioactive peptides found in nature.  
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1.2 PEPTIDE SYNTHESIS OVERVIEW 
During the last 50 years, there has been immense expansion and progress in the field of peptide 
and protein chemistry.  Modern peptide chemistry includes many branches of study including 
synthesis, purification, analysis, structure and conformation investigation, and molecular 
modeling. Advances in biotechnology have facilitated the use of natural peptides as a starting point 
for novel synthetic peptide therapeutics with excellent specificity and efficacy which 
revolutionized peptide-based drug design and discovery. Since 2008, the peptide therapeutic 
market has exceeded the multi-billion-dollar level and over 400 peptides have been entered into 
clinical studies thus far.6 Moreover, chemical synthesis has provided a practical method for 
allowing structural elucidation and synthetic manipulation of biologically relevant peptides that 
can only be isolated in small quantities. Synthetically derived peptides have also been essential in 
studying enzyme substrates, binding properties, and in NMR structural studies.   
 Generally, peptide synthesis can be described as the assembly of amino acid monomers 
stepwise through a continuous cycles of coupling reactions in between adjacent amino acids 
followed by the removal of a reversible protecting group leading to peptide elongation until the 
point of completion. The term peptide was first coined by Fischer and Fourneau who performed 
the first peptide synthesis at the turn of the 20th century.7 Next, benzyloxycarbonyl (Cbz), the first 
reversible amino protecting group, was created which paved the way for further advances in the 
newly discovered field.8 In 1953, Du Vigneaud was able to combine the earlier strategies and bring 
them to sophistication to construct a peptide successfully mimicking the properties of the hormone 
oxytocin.9 However, the true breakthrough came with the introduction of 
dicyclohexylcarbodiimide (DCC), an unprecedented coupling reagent which refined the 
methodology of peptide bond formation and led to the milestone of solid phase peptide synthesis 
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by Merrifield.10 Building on previous discoveries in addition to his own extensive research, 
Merrifield was able to prefect the conditions for the synthesis of peptides on solid support and was 
awarded the Nobel Prize in Chemistry in 1984 for his pioneering contributions to the field of solid 
phase peptide synthesis. 
 While synthetic peptides can be made in solution or on a solid support, the solid support 
method is preferred due to the inherent limitations of solution phase synthesis. In solution, 
chemical synthesis gives rise to side products after each coupling step.  Therefore, the 
intermediates and/or desired products must be purified, isolated, and characterized after each step 
in the deprotection/coupling cycle. Equally important, peptide insolubility in the solvents essential 
for synthesis proves problematic. Although attractive for large scale reactions due to quantitatively 
high yields, the demanding and laborious task of solution phase synthesis in addition to being ill-
suited for synthesis of long peptides detract from its practical use in the advancement of peptide 
chemistry. 
1.3 SOLID PHASE PEPTIDE SYNTHESIS 
The discovery of solid phase peptide synthesis (SPPS) created a paradigm shift in the field of 
peptide synthesis by allowing the assembly of a peptide chain onto an insoluble and filterable 
porous support without the tedious task of purification and characterization after each reaction 
step. Pioneering the concept in the early 1960s, Merrifield proposed the use of a polystyrene-based 
solid support to assemble peptides in a stepwise fashion from the C to N terminus using amino 
terminal protected amino acids.10 He synthesized a tetrapeptide by utilizing Cbz as an Nα protecting 
group, DCC as the coupling reagent, and hydrobromic acid (HBr) or saponification as the cleaving 
agent that releases the peptide from the solid support.10  
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Further advancement of the SPPS technique included the use of t-butyloxycarbonyl (Boc) 
as a terminal amino protecting group which would allow for the use of hydrogen fluoride (HF) as 
the acid medium for peptide release from the resin.11,12 In its initial development stages, the 
methodology was solely based on acidolysis where side chain protecting groups and the linkage 
between the peptide and resin were relatively stable to moderate amounts of acid and labile in the 
presence of strong acidic conditions. Strong acids allow for the simultaneous deprotection of the 
amino acid side chain functionalities and liberation of the peptide from the resin support, thereby 
yielding an unprotected peptide to be purified. While the chemistry of deprotection and coupling 
was subject to variations, the standard procedure of SPPS allowed for the process to be automated, 
unlike solution-based synthesis.  
 
Scheme 1.2 SPPS procedure followed by Merrifield. Scheme adopted from reference (10) with 
permission. 
In the period ranging from the 1960s to 1980s, progress had been made in the refinement 
of classical peptide synthesis methods to facilitate the synthesis of larger and biologically complex 
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peptides. The introduction of 9-fluorenylmethoxycarbonyl (Fmoc) by Carpino for Nα protection 
of amino acids offered a mild alternative to the acid-labile Boc-based synthesis strategies.13,14 By 
utilizing Fmoc as a protecting group, SPPS shifted from a pure acidylosis methodology to an 
orthogonal technique which required a base for deprotection of the terminal Fmoc-protected amino 
group and an acid for the removal of side chain protecting group and peptide cleavage.6 
Advantages of utilizing Fmoc chemistry in comparison to the Boc protecting group include mild 
synthetic conditions, rapid deprotection of the Nα protecting group, and the possibility of 
monitoring coupling and deprotection through ultraviolet-visible spectroscopy (UV-Vis). 
Moreover, some peptides may be susceptible to acid-catalyzed side reactions which will interfere 
with the peptide efficacy and yields.  
The advantages associated with SPPS outweigh the limitations that may be associated with 
the yields related to the synthesis of lengthy peptides. Generally, reagents that are low in molecular 
weight can be used in excess to yield a considerable quantity of product. Moreover, the easy 
filtration of excess reagents eliminates the need for intermediate purification that consumes ample 
amounts of time during solution phase synthesis. Equally important, the mild conditions promoted 
by Fmoc chemistry eliminated the possibility of any side reactions that may have risen from acid 
sensitive peptide components. Amino acid solubility is not an issue during the coupling cycle, 
while the solid support used to anchor the peptide is chemically compatible with the needed 
substrates, solvents, and reagents. The abovementioned benefits lend themselves to the successful 
expansion of SPPS into the billion-dollar industry it is today.  
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Scheme 1.3 General SPPS Protocol. Scheme adopted from: Sigma Aldrich 
1.3.1 SOLID SUPPORT RESINS 
Since the development of SPPS, various resins including those with linkers and spacers 
have been created to be adaptable to various synthetic conditions.15 Since each type of resin has 
unique physical and chemical properties, the choice of solid support often dictates the success of 
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a peptide synthesized via SPPS.  Currently, there are a plethora of commercially available solid 
supports that are compatible with peptide synthesis. Solid support specifications include stability, 
swelling and insolubility properties, and they must allow for filtration of excess reagents. 
Moreover, the resin must be unreactive towards all reagents and solvents that may be used during 
the synthesis process. Even more crucial to the successful chain elongation is extensive swelling 
to allow for reagent penetration into the resin pore and attachment of the first amino acid to the 
resin linker.  
 
Figure 1.4 Solid support for peptide synthesis. 
 Resins are mainly classified into two main categories: polystyrene (PS) and polyethylene 
glycol (PEG). The hydrophobic PS resins can either be lightly or highly cross-linked, where the 
amount of divinylbenzene (DVB) can vary.16 Lightly cross-linked PS resins tend to be gel-type 
and microporous, where space in between crosslinks contains solvent and solutions of polymer 
segments.  Meanwhile, the more polar PEG resins are predominantly composed of ethylene glycol 
spacers. Moreover, they have no preference for swelling solvent since the PEG chain has good 
compatibility with most solvents. Other materials that have also been utilized as solid supports for 
SPPS including: silica, polymethacrylate, and controlled pore glass.16 Another important resin 
property that influences reactivity and kinetics is size distribution. Most commonly, resin beads 
have a diameter of 100-200 mesh and 200-400 mesh which allow for effective swelling and 
coupling.16  
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Since SPPS is traditionally executed in the C to N terminal direction, the linker present in 
the resin pore dictates the functional group that will be present at the C-terminus following 
cleavage of the peptide from the solid support since it serves as the point of connection between 
the first amino acid and resin bead.17 The first resin ever used for SPPS was the non-polar cross-
linked PS with a chloro-methyl group as a linker, which was later named the Merrifield resin. The 
first amino acid is loaded onto the resin by nucleophilic displacement of the chloride by the 
carboxylate group located on the amino acid. Upon HF-mediated cleavage of the peptide from the 
solid support, the carboxylic acid is regenerated at the C-terminus of the peptide. Presently, the 
Wang linker is more commonly used to yield a carboxylic acid at the C-terminus of a peptide; it 
was specifically designed for Fmoc-based synthesis, where the resulting peptide can be cleaved by 
TFA.18 Another resin that can popularly yield a C-terminal carboxylic acid in addition to a peptide 
with protected side chains is 2-chlorotrityl chloride resin. In addition to generating a carboxylic 
acid at the C-terminus of a peptide, a carboxyamide is also another standard choice which is 
obtained by using the Rink linker.19 There are a multitude of readily available resins and linkers 
which ease the synthetic burden and allow flexibility in the choice of C-terminal protecting group 
and loading condition pertaining to the first amino acid.  
1.3.2 COUPLING REAGENTS  
In the process of SPPS, the coupling step consists of the formation of an amide bond 
between two neighboring amino acid residues. The peptide bond is formed through activation of 
the carboxy component of one amino acid and the subsequent attack of the Nα group. While this 
reaction is thermodynamically favorable, the formation of a new amide bond has a high activation 
energy requirement. To aid in the coupling reaction initiation, coupling reagents serve as carboxy 
activators, often forming a more reactive C-terminal ester. In the past fifty years, many reagents 
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have been used to increase the efficiency of amino acid couplings and play a key role in generating 
considerably high yields and purities of the isolated, crude synthetic peptides.  
Carbodiimides such as dicyclohexylcarbodiimide (DCC) and diisopropylcarbodiimide 
(DIC) are considered to be classical in situ coupling reagents.6,20,21 The activation step proceeds 
via nucleophilic attack of the carboxylate oxygen on the carbodiimide carbon. Upon formation of 
a reactive O-acylisourea species, a carboxylic ester with an activated leaving group, nucleophilic 
attack by the N-terminal amino group results in the peptide bond formation. While DCC and DIC 
proceed through similar mechanistic pathways, DIC is the reagent of choice due to its solubility in 
a majority of organic solvents, which also makes the removal of the unwanted urea by-product 
easier to accomplish via solvent filtration.  
 
Scheme 1.4 One pot DIC coupling mechanism. Scheme adopted from reference (20) with 
permission. 
While DIC executes coupling with high efficiency, it can be problematic. This method of 
activation has the potential to promote racemization and dehydration of asparagine (Asn) and 
glutamine (Gln) side chains. Using an additive in combination with DIC eliminateds the 
abovementioned limitations and accelerates carbodiimide-mediate couplings (Figure 1.5). Popular 
additives include 1-hydroxy-benzotriazole (HOBt) [A] and 1-hydroxy-7-aza-benzotiazole (HOAt) 
[B], which are triazoles that attack the O-acylisourea to form an activated ester.20 More recently, 
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ethyl cyanohydroxyiminoacetete (Oxyma) [C] has been developed as an alternative to HOAt and 
HOBt with comparable coupling efficiency.  
 
Scheme 1.5 HOBt and DIC coupling mechanism. Scheme adopted from reference (18) with 
permission. 
While carbodiimide reagents were the standard coupling reagents in peptide synthesis, 
newly developed activators have more commonly been put into practice due to their increased 
coupling kinetics. Examples of newly established coupling reagents in SPPS include: benzotriazol-
1-yl-oxy tris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) [D],  O-benzotriazol-1-yl-
N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) [E], O-(7-azabenzotriazol-1-yl)-
N,N,N'N'-tetramethyluronium hexafluorophosphate (HATU) [F], O-(6-Chlorobenzotriazol-1-yl)-
N, N,N',N'-tetramethyluronium hexafluorophosphate (HCTU) [G], and O-benzotriazol-1-yl-
N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) [H].6 The abovementioned coupling 
reagents also proceed via a similar mechanistic pathway to that of the carbodiimide reagents; the 
main difference in reagents classes is the initial rate of activation which lends itself to rapid 
coupling rates.  
 
14 
 
 
Figure 1.5 Structure of reagents used as additives during peptide coupling.   
1.3.3 MODIFIED AMINO ACIDS  
While peptides have impeccable potential due to their biological and therapeutic abilities, 
they are inherently limited due to their instability towards proteolysis and poor bioavailability.22 
In the past few years peptidomimetics have emerged as a powerful class of compounds which 
overcomes the shortcomings associated with peptides. Modified peptides (peptidomimetics) 
essentially mimic a natural peptide or protein in its chemical composition, structure and its ability 
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to perform a biologically relevant role. In addition to increased stability and bioavailability, 
peptidomimetics can also have increased receptor binding affinity and selectivity, thereby making 
these mimics leading compounds in the field of drug design and discovery.23 By mapping 
structure-activity relationships, key residues that are responsible for a physiological effect can be 
identified while other non-essential amino acids can be manipulated to yield a more potent effect.  
Incorporation of unnatural amino acids or modification of the peptide backbone chain 
provides peptidomimetics several advantages over naturally structured peptides. Unnatural amino 
acids can include β/-amino acids, which respectively contain two and three carbon atoms between 
the amino terminus and carboxyl terminus (Figure 1.6). In the case of β-amino acids, a total of 4 
diastereomers are possible which expands the structural diversity in molecular design.24 Moreover, 
D-amino acids can also be incorporated into a peptide to increase stability and induce a 
conformational change. By including several D-amino acid residues, the propensity for a peptide 
to form a secondary structure can be increased.25 Most recently, modifications to the peptide 
backbone have been introduced to increase the versatility of peptidomimetic applications. Some 
notable examples include: glutamic acid (Glu) side chain cyclization to form a backbone pyro-
glutamyl moiety (Figure 1.6),26 which has been used in the synthesis of a solid support thioester 
precursor and enzyme mimetics; Hoffmann rearrangement of the Asn side chain to form a five-
membered N-acylurea moiety,27 which has been used as an enzyme mimic due to the susceptibility 
of C-N bond proceeding N-acylurea to hydrolysis; and modification of Methionine’s (Met) side 
chain to a homoserine lactone moiety via treatment with cyanogen bromide (CNBr) which has 
long been used in the field of chemical cleavage as well.28,29 Inspired by the versatility of 
applications relevant to the modification of amino acid side chains, this was designated as the topic 
of choice for the purpose of this thesis work.  
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Figure 1.6 Modified amino acids. (A) β-amino acid (B) γ-amino acid (C) pyro-glutamyl moiety 
(D) N-acylurea (E) N-acylurea 
1.4 CYCLIC URETHANE MOIETY 
Amino acid modification to versatile moieties with broad applicability has gained 
considerable attention in the past few years. Motivated by the idea of introducing a multipurpose 
moiety to increase the functionality of peptides, we sought to incorporate the cyclic urethane 
moiety otherwise known as 2-oxazolidinone and explore the plethora of applications that 
accompany this incorporation (Figure 1.7).  
 
Figure 1.7 General structure of cyclic urethane. 
Before its incorporation into peptides, cyclic urethanes gained wide-spread recognition as 
antimicrobial agents and chiral auxiliaries as popularized by Evans. As antimicrobial agents, they 
exhibit activity against multi-drug resistant gram-positive bacteria including Staphylococcus 
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aureus, Staphylococcus epidermis, Streptococcus pneumoniae, and enterococci.30 Factors 
contributing to the successful application of 2-oxazolidinone in the medicinal chemistry field are 
related to its novel mode of action, binding selectivity, and its inhibition at the initiation phase of 
bacterial translation.30 Owing to its unique chemical and biological properties, this moiety has 
promoted the development of derivatives that also exhibit potent activity.  
Meanwhile, the use of chiral auxiliaries including oxazolidinones has been widely used in 
the synthesis of enantiomerically pure compounds since the early 1980s.31Auxiliaries such as 
oxazolidinone are substituted at the 4 and 5 positions to dictate controlled reactions. Through steric 
hinderance, the substituted positions direct the manner by which stereoselective transformations 
take place. Specifically, oxazolidinone chiral auxiliaries have been applied to aldol reactions, 
alkylation reactions, Diels-Alder reactions, and the synthesis of β-amino acids among many other 
synthetic transformations.32-34 Requirements for the efficient use of a chiral auxiliary include a 
strong predisposition for a highly selective enolate reaction, a strong bias for enolate 
diastereofacial selection in new bond formation, and cleavage must occur in mild conditions that 
do not promote racemization of the desired product.34 The abovementioned requirements are easily 
fulfilled through utilizing oxazolidinone as a chiral auxiliary. 
Moreover, cyclic urethane has been incorporated into peptides to serve as a pseudo-proline 
surrogate due to its structural similarity to 5-membered proline (Pro) and its stability towards 
standard Fmoc synthesis, chemical ligation, and convergent synthesis conditions.35 Owing to its 
structure, pseudo-prolines have the ability to introduce a “kink” into the peptide backbone which 
allows for disruptions of β-sheet structures which tend to be problematic during chain elongation 
due to intermolecular aggregation.36,37 Incorporation of cyclic urethane into the peptide chain 
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increases peptide solvation, increases coupling kinetics, and induced a slight turn into the peptide 
backbone. 
Due to their versatile applicability, many synthetic routes have been explored in the 
synthesis of oxazolidinones. Generally, this moiety is synthesized through the reaction of amino 
alcohols with several reagents including phosgene, dialkyl carbonates, urea, carbon dioxide, 
carbon monoxide, and oxygen.38 Several notable methods have also been used for the synthesis 
process such as: the chiral resolution method, iodocyclocarbamation, The Heweh-
Kauffman/Speranza-Peppel Method, and direct catalytic asymmetric amination of aldehydes.30 
Moreover, serine (Ser), threonine (Thr), and cysteine (Cys) have been used as building blocks for 
amino acid derived pseudo-prolines through the reaction of carbonyl containing reagents such as 
aldehydes and ketones.36,37 Building upon this knowledge, we progressed to develop a rational 
design approach for the synthesis of cyclic urethane containing peptides. 
1.4.1 DESIGN OF CYCLIC URETHANE CONTAINING PEPTIDES 
In the process of designing cyclic urethane containing peptides, we sought to peruse an 
approach where the cyclic urethane moiety would be derived from naturally occurring amino acids 
serine, threonine, and/or cysteine.  Moreover, this approach would include modification of the 
amino acid residue(s) within the peptide sequence. Unique to our submonomer approach are a few 
factors: i) the cyclic urethane is to be derived from a natural amino acid, ii) the modification would 
take place within the peptide sequence rather than involving the prerequisite solution-phase 
synthesis of the cyclic urethane modified amino acid building block followed by incorporation into 
the peptide, and iii) modification to the desired moiety does not require a special protecting group 
or yield the dehydrated product as previously reported.39 
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We proceeded to rationalize the reaction mechanism. In this case, Ser was selected as the 
reactive amino acid residue. Based on Ser’s nucleophilic side chain, we sought to activate the 
hydroxymethyl side chain to promote nucleophilic attack on a carbonyl containing compound to 
form an activated intermediate with a good leaving group (Scheme 1.6). Subsequently, 
intramolecular nucleophilic attack of the amide nitrogen of the peptide backbone on the 
intermediate could proceed to produce a five-membered cyclic urethane ring or a six-membered 
ring. Based on proximity of the amidic nitrogen, we hypothesized that the five-membered cyclic 
urethane would be the more kinetically favorable product, which would prove to be more 
resourceful in its variety of application.40 
1.4.2 SYNTHESIS  
Once the rational resign was in place, we proceeded to execute the methodology 
experimentally. The focus of our design was to form the cyclic urethane moiety on a solid support 
post peptide synthesis. First, we screened carbonyl donating agents to determine the most effective 
reagent in the synthesis of cyclic urethane.41  
 
Scheme 1.6 Serine modification mechanism. 
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For activation of serine’s side chain, various electrophilic reagents such as 4-nitrophenyl 
chloroformate, 1,1-carbonyldiimidazole (CDI), and N, N-disuccinimidyl carbonate (DSC) were 
screened and quantitative conversion of Ac-GGSAAG to the cyclic urethane containing version 
was observed by HPLC. Further confirmation of the modification by molar mass was obtained by 
mass spectrometry. With a conversion percentage of approximately 99%, DSC was determined to 
be the reagent of choice for efficient conversion of Ser to cyclic urethane.  
Table 1.1 Reagent screening for the backbone activation of serinea 
 
Table adopted from reference (41) with permission. 
Following reagent screening, formation of the cyclic urethane was further optimized on 
solid support by exploring other reaction conditions including solvent, time, temperature, and 
stoichiometry. A low conversion of 40% was observed in DCM (dichloromethane) due to poor 
solubility of DSC. When a mixture of DCM: DMF (dimethylformamide) (1:1) was screened as a 
solvent, the conversion increased by 20%. Meanwhile, an increased solubility in DMF led to a 
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conversion increase to 99%. Moreover, the role of N-terminal protecting groups was explored in 
the formation of cyclic urethane. Groups such as acetyl, tosyl, and Boc were investigated as to 
determine whether they would influence the efficiency of modification. Contrary to previously 
reported literature, the results indicated that formation of cyclic urethane is independent of the 
nature of the N-terminal protecting group.39  
 
Table 1.2 Optimization of reaction conditions for cyclic urethane formation on solid supporta 
 
aTable adopted from reference (41) with permission. 
Following optimization studies on solid support, varying amounts of DSC were explored 
on Fmoc-GASFAG post-cleavage from the solid support to determine the equivalents of reagent 
required for solution-phase modification.40 Ten equivalents of DSC produced an 80% yield, while 
twenty equivalents yielded 90% modified peptide. 
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Table 1.3 Optimization of reaction conditions for cyclic urethane formation in solutiona 
Entry Equivalents (%) Yieldb 
1 5 75 
2 10 80 
3 20 90 
aReaction conditions: peptide (1 equiv.), DSC (5-20), DIEA (5-20 equiv.) and a crystal of DMAP 
in DMF were stirred overnight at room temperature. Purified by HPLC. bIsolated yield.  
 
1.4.3 NMR CHARACTERIZATION  
Upon optimization of the synthesis conditions, NMR characterization was performed to 
confirm the formation of the five-membered cyclic urethane ring rather than the six-membered 
ring on the sequence Fmoc-GS (Figure 1.8 and 1.9).40  
The key differences in chemical shift that confirm the formation of the five-membered 
cyclic urethane ring include: 1) the methine carbon has a predicted 13C shift of 55.5 ppm for the 
cyclic urethane ring and the observed chemical shift value was 55.4 ppm 2) HMBS correlation 
from both NH2 protons to the neighboring carbonyl carbon indicate that the amino group is free 
and not involved in ring formation 3) the methine carbon would have a 13C shift value of 51.6 ppm 
if the six-membered ring had formed. 
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Figure 1.8 NMR spectra for modified Fmoc-GS. (A) 1H NMR (B) 13C NMR. Figure adopted 
from reference (40) with permission. 
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Figure 1.9 Comparison of NMR chemical shifts for cyclization of Ser to a five-membered ring 
versus a six-membered ring. Figure adopted from reference (40). 
1.5 THESIS OBJECTIVES 
The growing number of applications related to the modification of the amino acid side chains 
in a submonomer approach, i.e. directly within the peptide sequence, served as the framework for 
this thesis work.42,43 Pursuing Ser as the model amino acid for the formation of the reactive cyclic 
urethane moiety results in a labile C-N bond which renders it susceptible to cleavage. Building on 
this principle, we sought to use the susceptibility of this moiety to cleavage and fulfill the following 
objectives: (1) use cyclic urethane as an enzyme mimic, thereby providing a new chemical 
cleavage methodology that is applicable to natural peptide sequences as well as mutated sequences 
that tend to be highly resistant to proteolysis, (2) use the cyclic urethane as a chemical cleavage 
method for cyclic peptides and uniquely structured lasso peptides which cannot be readily 
sequenced by MS/MS due to complex fragmentation patterns, (3) use the cyclic urethane moiety 
as a means for sequencing cyclic peptide libraries (4) use the cyclic urethane to make C-terminally 
modified peptides with various functional groups from the Rink amide resin and (5) use the cyclic 
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urethane to make the challenging peptide thioester precursor obtained from solid support through 
Fmoc synthesis which would lend to important applications in the native chemical ligation of 
synthetic peptides into chemically derived proteins.  
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CHAPTER 2: SITE-SELECTIVE CHEMICAL CLEAVAGE OF 
PEPTIDE BONDS 
 
2.1   ABSTRACT 
The cleavage of peptides and proteins is an essential tool used in bioanalytical, biotherapeutic, 
and bioengineering techniques. While enzymatic digestion is the preferred method of protein 
analysis, sequences which contain mutations and/or modifications deviate from nature’s design for 
a native peptide/protein and tend to be resistant towards proteolysis. Therefore, there is a growing 
need for chemical cleavage methods which can analyze peptidomimetics that are unable to be 
recognized and processed by proteases. More recently, several methods have emerged which allow 
for site-selective cleavage of extremely unreactive bonds, including amides, thereby providing 
invaluable information regarding protein sequence, structure, and function.  For controlled and 
selective cleavage of peptide bonds, chemical cleavage must selectively bind to one or more amino 
acid residues within a peptide chain and selectively cleave the peptide bond. Building on this 
principle, we have developed an approach that utilizes DSC to selectively modify Ser, Thr, Cys, 
and/or Glu, rendering them susceptible to peptide bond fragmentation. Subsequent incubation in 
buffer leads to the hydrolysis of the peptide bond at the N-terminal side of the modified amino 
acid. This methodology lends itself to peptide sequencing applications by exhibiting broad 
substrate scope in the cleavage of various bioactive peptides with post-translational modifications 
(e.g. N-acetylation and N-methylation) and mutations (D- and β- amino acids) which have been 
implicated in age related diseases.  
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2.2  CHAPTER OBJECTIVES 
In this chapter, the development of an artificial chemical peptidase for site-selective cleavage 
of unreactive peptide bonds at serine, threonine, and cysteine residues is discussed. The site-
selective cleavage of a peptide bond is a crucial procedure in protein sequencing and various new 
bioanalytical and bioengineering applications. Peptide bonds, however, are extremely stable 
towards hydrolysis, with a half-life of 500-1000 years at room temperature and pH 4-8. This limits 
the range of appropriate cleavage reagents, especially those that may trigger selective peptide bond 
hydrolysis at specified amino acid residues. Commonly used reagents include proteases, self-
cleaving intein sequences, metals, and chemical agents, such as cyanogen bromide, albeit with 
certain restrictions associated with poor selectivity, efficiency and limited substrate scope, 
especially related to fragmenting modified peptides or peptidomimetics. In order to address these 
limitations, this strategy provides a method that selectively modifies serine, threonine, and cysteine 
residues in any peptide chain and cleaves the peptide chain at the site of modification under neutral 
aqueous buffer conditions. The site-selective cleavage parlays the reaction of an electrophilic 
reagent with the nucleophilic hydroxymethyl group of serine/threonine and/or the thiol of cysteine 
to activate the backbone amide chain. In this chapter, the rationale for site-selective modification 
of these selected residues in a peptide chain, the potential for selective-cleavage under mild 
conditions, and the effectiveness of the methodology for mutated and post-translationally modified 
peptides is described. This artificial chemical peptidase provides a new scissile position, Pro-Ser 
peptide bonds, which are typically resistant to cleavage by most proteolytic enzymes. Site-
selective modification and cleavage of peptides is essential for ongoing efforts to determine the 
structure activity relationship of various biologically relevant peptides/proteins in addition to their 
modified analogs. 
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2.3  GRAPHICAL ABSTRACT 
 
Figure 2.1 Graphical abstract for Site-Selective Cleavage of Peptide Bonds. Figure adopted with 
permission from: Elashal, H.; Raj, M. Chem. Commun. 2016, 52, 6304.1 
 
2.4  INTRODUCTION  
Site-selective cleavage of peptide bonds is an important reaction that has wide spread 
application in the vast field of proteomics, including sequencing, therapeutics, and the 
development of new bioanalytical techniques.2,3 Enzymatic digestion is one of the most prominent 
methods of metabolizing proteins to their basic components in order to facilitate its sequence 
analysis.4 Proteases that are commonly employed in protein hydrolysis include: trypsin which 
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cleaves at charged residues (Arg and Lys), chymotrypsin which cleaves at aromatic residues (Phe, 
Trp, and Tyr) in addition to Leu and Met, and pepsin which cleaves at residues with bulky side 
chains (Leu and Phe). While proteases cleave proteins with high specificity, precision, and fidelity, 
they have several disadvantages. Proteases have been known to contaminate the protein/peptide 
digestion and they require specific ranges of temperature and pH for optimal activity or enzyme 
denaturation can limit performance. Moreover, they lack efficacy when applied to diseased, post-
translationally modified, and unnatural sequences, where their utility is greatly needed to facilitate 
the understanding of the onset of disease and the body’s purpose for modifying proteins from their 
native state.  
 
Figure 2.2 Protease digestion of a protein.  
Owing to this limitation, efficient chemical cleavage methods have been developed as a way 
of offsetting the limitations associated with enzymes. The most commonly utilized chemical 
cleavage method is Edman degradation which gained wide spread popularity due to its broad 
applicability.5 This technique utilizes phenyl isothiocyanate for N-terminal cleavage of peptides 
without disrupting other peptide bonds within the peptide sequence.  The cleavage process 
proceeds under mild alkaline conditions; phenyl isothiocyanate is reacted with an uncharged N-
terminal amino group to form a cyclized phenylthiocarbamyl derivatized moiety (Scheme 2.1).6 
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Upon the addition of acid, this N-terminal moiety is cleaved as a thiazolinone derivative which is 
extracted into organic solvent. Once treated with acid, the stable phenylthiohydantoin can be 
identified by utilizing chromatographic techniques or gel electrophoresis.6 While this process can 
be executed repeatedly to identify the N-terminal residues in the protein chain, the efficiency of 
this methodology diminishes after 30 cycles of cleavage. Moreover, the process of determining 
each amino acid can be tedious and it lacks selectivity. Similar methods for N-terminal amino acid 
determination include Sanger’s method, which has been widely applied in protein sequencing and 
ultimately resulted in the Nobel prize awarded to Frederick Sanger in 1958.7,8  
 
Scheme 2.1 Edman degradation. Scheme adopted from reference (6).  
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More recently, chemical cleavage methodologies have been developed based on amino acid 
side chain modification. These methodologies provide selectivity at the point of cleavage and they 
are uncomplicated in their execution, thereby facilitating the cleavage process and analysis of 
unknown sequences and/or proteolytically resistant sequences. Currently utilized selective 
cleavage methods include: cyanogen bromide for Met (Scheme 2.2),9 2-nitro-5-thio-cyanobenzoic 
acid,10 and dehydroalanine for Cys,11,12 and 2-iodosylbenzoic acid for Trp and Tyr.13 
 
Scheme 2.2 Methionine mediated cleavage of peptide bonds. Scheme adopted with permission 
from: Kaiser, R.; Metzka, L. Anal. Biochem. 1999, 266, 1.14 
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While these techniques have proven complementary to proteases, they are limited by: 
inadequate selectivity, harsh conditions and low yields.15 In the case of cyanogen bromide, the 
methodology uses toxic conditions and has a limited scope due to side reactions in the presence of 
methionyl-serine and methionyl-threonine.14 Most recently, diacetoxyiodobenzene (DIB) was 
reported for asparagine-selective cleavage, yet oxidative modifications were observed at other 
reactive amino acid residues such as Cys and Met (Scheme 2.3).16 Metals have been intensively 
studied for hydrolysis of peptide bonds, but their practical use in structure determination of 
proteins is still in its infancy.17-24 Even with their associated drawbacks, chemical cleavage 
methods are a necessity in the analysis and characterization of proteolytically resistant 
proteins/peptides. Chemical methods aid in cleaving large proteins into smaller fragments which 
may be analyzed by complementary cleavage methods. They provide information regarding the 
presence of a particular amino acid in the protein/peptide sequence, its quantity based on the 
successful execution of cleavage, and they allow for cleavage even in the presence of unnatural 
residues such as D an β amino acids.  
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Scheme 2.3 Asparagine mediated cleavage of peptide bonds. Scheme adopted with permission 
from reference (16). 
Owing to the need for more efficient chemical cleavage methodologies that are applicable to 
a broader variety of amino acids and peptide sequences, we sought to develop a chemical cleavage 
method that utilizes a cyclic urethane.  Chemically modifying the amide backbone chain at Ser to 
include a cyclic urethane moiety renders the neighboring scissile peptide bond weak and 
susceptible to hydrolysis under neutral, aqueous conditions (Scheme 2.4).   
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Scheme 2.4 Rationale for the serine-selective modification and peptide cleavage in neutral 
aqueous solution. Scheme adopted from reference (1) with permission. 
 
2.5  RESULTS AND DISCUSSION 
To achieve the cyclic urethane modification at Ser, reaction conditions were optimized using 
varying amounts of DSC, 4-dimethylaminopyridine (DMAP), and N,N-diisopropylethylamine 
(DIEA) on a model Fmoc-protected hexapeptide Fmoc-Gly-Ala-Ser-Phe-Ala-Gly [retention time 
(Rt)=16.9 min)]. Previous attempts of utilizing DSC to form this cyclic urethane moiety on 
Fmoc/Boc peptides lead to the formation dehydroalanine.25 Using our optimized conditions1, Ser 
cyclization proceeded in 17 hrs as indicated by the sharp peak 2a with a Rt=17.9 min, which was 
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analyzed by mass spectrometry (MS) (Figure 2.3). Following cyclization, the modified peptide 
was incubated in phosphate buffer with a pH of 7.5 for 31 hrs, and the reaction was monitored by 
HPLC. After the incubation period, the peak at 17.9 min disappeared and two new peaks appeared 
which was indicative of peptide cleavage into two fragments. MS analysis of the peaks at 8.9 min 
and 18.6 min proved these peaks to be the products resulting from cleavage at the N-terminal side 
of Ser. The N-terminal fragment 3a eluted at 18.6 min, while the modified C-terminal fragment 4 
eluted at 8.9 min.  
 
Figure 2.3 HPLC charts of the reaction mixture of 1a and DSC (10 equiv.), DIEA (10 equiv.), and 
a crystal of DMAP in DMF at (a) t = 0 h (top), (b) at t = 17 hrs (middle), and (c) after addition of 
0.1 M phosphate buffer (pH 7.5) at t = 48 h(bottom) at 37 ºC. HPLC conditions: 0.1% FA (v/v) in 
water, 0.1% FA in CH3CN, gradient: 0–80% in 25 min, 1.0 mL min_1 flow rate, detected at 254 
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nm. Insets show the LCMS spectrum corresponding to Rt at 16.9 min (1a, top), 17.9 min (2a, 
middle), 18.6 min (3a, bottom) and 8.9 min (4, bottom). Figure adopted from reference (1) with 
permission. 
 
 Following initial cyclization and cleavage of Ser, we sought to determine the effects of side 
chain functionality of the residue preceding Ser on the cyclization and cleavage efficiency of 
peptides. Moreover, we wanted to explore the effect of reaction conditions on unprotected side 
chains to determine if the reaction generated undesired side products. Using the sequence Fmoc-
Gly-Xaa-Ser-Phe-Ala-Gly, various hexapeptides were synthesized to include different residues at 
the Xaa position (Table 2.1).  
Table 2.1 Serine-selective amide bond cleavage of Fmoc-Gly-Xaa-Ser-Phe-Ala-Gly (1a-j)a 
 
Table 2.1 adopted from reference (1) with permission. 
After incubation in buffer (pH=7.5) for 48 hrs, the C-terminal fragment Oxd-Phe-Ala-Gly 
4 was obtained as a product post cleavage of all peptides with varying HPLC conversions ranging 
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from 70 to 99%. Peptides which included Ala 1a, Gly 1b, Met 1c, His 1d, Tyr 1e, Trp 1f, and Asp 
1i substituted at the Xaa position underwent conversion to the cleavage products after 48 hrs in a 
highly efficient manner (entries 1-6 and 9, Table 2.1). This conversion proceeds smoothly in 
contrast to other chemical cleavage methods which result in the over-oxidation of Tyr, Trp, and 
Met containing peptides. Thus, our method is tolerable of many side chain functional groups. 
Meanwhile, the peptide 1g containing Valine adjacent to Ser gave moderate yield after four days 
in phosphate buffer (pH= 7.8) due to the presence of a bulky side chain (entry 7, Table). The 
peptide containing Xaa= Lys 1h proceeded to modify in a unique manner due to the presence of a 
free amine in the Lys side chain (Scheme 2.5). The amine side chain also reacted with DSC; upon 
treatment with buffer, however, the desired Lys-Ser cleavage occurred, and an N-terminal 
carboxylate lysine derivative was generated 3h in addition to Oxd-FAG-NH2. Eventually, the N-
terminal carboxylated lysine derivative underwent decarboxylation of the unstable carbamic acid 
to generate Fmoc-GK-OH (entry 8, Table 2.1) leaving the Lys residue unmodified. The final 
substitution included Proline 1j in the position adjacent to Ser, and the cyclization and cleavage of 
the Pro-Ser bond proceeded with high efficiency. Typically, enzymatic digestion at a location 
neighboring to Pro is nearly unfeasible due to the cis amide bond rotation produced by Pro in the 
peptide backbone which makes the enzyme active site inaccessible.26 However, in the case of 
utilizing our DSC-mediated chemical methodology, peptide-bond cleavage smoothly proceeded 
with a conversion of 98% which illustrated the efficiency of this technique regardless of the 
neighboring amino acid to Ser.  
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Scheme 2.5 Modification scheme of lysine containing peptide. Scheme adopted from reference 
(1) with permission. 
Table 2.2 Substrate scope of site-selective cleavage of peptide bondsa 
 
Table 2.2 adopted from reference (1) with permission. 
The substrate scope of the reaction was further evaluated (Table 2.2). Modification of Thr 
was also feasible as demonstrated by entries 1 and 2 (Table 2.2). After incubation with buffer, 
cleavage was observed at the N-terminal side of Ser and Thr, which is expected due to the similar 
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side chain functionality exhibited by both residues, thereby mimicking enzyme specificity towards 
similar substrates.  However, cyclization of Threonine’s side chain required a higher amount of 
DSC, which may be due to the presence of a methyl group neighboring to the hydroxyl group 
(entry 2, Table 2.2). Peptide Fmoc-GACFRFG-NH2 also underwent modification and cleavage at 
the N-terminus of Cys and generated a thiazolidinone modified C-terminal fragment Thz-FRFG-
NH2 and the N-terminal fragment Fmoc-GA-OH. Peptides with longer lengths as well as multiple 
Ser residues gave comparable results (75-79%) illustrating the utility of this methodology of 
cleaving lengthy peptides into smaller fragments that are more easily analyzed (entries 3 and 4, 
Table 2.2). Meanwhile, peptides that contained D-amino acid residues which are generally 
resistant to enzymatic digestions due to their unnatural confirmation, were successfully cleaved 
under the mild reaction conditions (entries 5 and 6, Table 2.2). Additionally, peptide 11 comprising 
of an intramolecular disulfide bridge afforded the cleavage product without disrupting the disulfide 
bond (entry 7, Table 2.2). Therefore, this methodology allows for the disulfide mapping, which is 
an advantage over other chemical methodologies which tend to break the disulfide bond.27 
 While exploring the substrate scope in a Glu containing peptide 12, surprisingly, cleavage 
occurred both at the N-terminal side of Glu and Ser to generate three fragments under the reaction 
conditions (entry 8, Table 2.2). The activation of Glu by DSC proceeds through the formation of 
a five-membered pyro-glutamyl imide moiety (pGlu) (Scheme 2.6). 
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Scheme 2.6 Modification scheme of glutamic acid to a pyro-glutamyl moiety. Scheme adopted 
from reference (1) with permission. 
 
In the presence of Asp 1i, while also containing a free carboxylic acid side chain, modification 
and cleavage is not observed due to side chain length (Scheme 2.7). 
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Scheme 2.7 Modification of Asp side chain vs. Glu side chain. Scheme adopted from reference 
(1) with permission. 
Next, compatibility with a free main chain carboxylic group was explored by synthesizing Fmoc-
GSGF-OH on Wang resin. Under the reaction conditions, cleavage was observed only at the N-
terminus of Ser and generated an N-terminal Fmoc-Gly fragment and Oxd-Gly-Phe-OH as the C-
terminal fragment (Scheme 2.8). This experiment in addition to the scope studied in Table 2.1 
confirmed that most reactive side chains remain unmodified during the execution of these reaction 
conditions, contrary to other cleavage methods which lead to the oxidation of reactive amino acid 
side chains. Moreover, this method is applicable to peptide bond hydrolysis at Ser, Thr, reduced 
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Cys and Glu residues. The observed rates of reaction indicated that the Ser residue was most 
reactive to the DSC-mediated activation and hydrolysis conditions. Moreover, the multiple 
fragmentation patterns at the selected Ser, Thr, Cys and Glu residues can facilitate peptide 
sequencing of a broad range of naturally occurring peptides.    
 
Scheme 2.8 DSC reaction scheme in the presence of a C-terminal carboxylic acid. Scheme 
adopted from reference (1) with permission. 
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Table 2.3 Site-selective cleavage of mutated and post-translationally modified peptides 
 
Table 2.3 adopted from reference (1) with permission. 
Subsequently, bioactive peptides, Bradykinin 1328 and type I hair keratin fragment 14, were 
cleaved successfully with conversion rates ranging from 77-80% (entries 1 and 2, Table 2.3).  
Furthermore, we extended the scope of the reaction conditions to the scission of bioactive peptides 
with various post-translational modifications such as N-acetylated antimicrobial peptide AP00011 
15, N-acetylated β amino acid containing antimicrobial peptide 16, and N-methylated bioactive 
peptide 17, which serves as a substrate for cAMP-dependent protein kinases29 (entries 3-5, Table 
2.3). The abovementioned modified peptides cleaved selectively at Ser with ease and high 
conversion. Chemical cleavage of these peptides proceeds independently of the presence of 
unnatural amino acid residues which is a great advantage over proteases which are unable to 
selectively recognize and cleave these modified peptides.  
 Moreover, this methodology was successfully applied on an amyloid β peptide, Fmoc-Ile-
β Ala-Gly-Lys-Asn-Ser-Gly-Val-NH2 18, which contained a mutated alanine β-amino acid 
residue, which is a notable mutation responsible for various age-related disease such as cataracts 
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and Alzheimer’s (entry 6, Table 2.3) (Scheme 2.9).30 Finally, the reaction was carried out on a 
fully unprotected peptide, SGISGPLS, a fragment of antimicrobial Bovine β-defensin 13. 
Treatment with DSC followed by hydrolysis generated fragments Oxd-GI, Oxd-GPL, and Oxd. 
 
Scheme 2.9 Application of cleavage methodology on an amyloid β peptide fragment. Scheme 
adopted from reference (1) with permission. 
 CONCLUSIONS 
In this study, a site-selective approach for the cleavage of peptides at the N-terminal of Ser, 
Thr, Cys, and Glu was developed by modification under metal free, mild conditions. The reactive 
side chains of other amino acids remained unmodified under the optimal reaction conditions, 
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which is an advantage over other chemical cleavage methods that yield modified fragments 
resulting from over-oxidation. Moreover, disulfide bonds are stable to the reaction conditions, 
thereby enabling the determination of disulfide positions within a peptide. The method also 
demonstrated broad substrate scope including cleavage of mutated and post-translationally 
modified peptides, which are unsuitable substrates for proteases. Additionally, a Pro-Ser bond was 
successfully cleaved, which is generally a difficult task for proteases due to the conformational 
restraints of Pro residues. Moreover, this method is also applicable to sequencing challenging 
peptides that have a high propensity for aggregation such as the amyloid peptides. The latter may 
be potentially applicable for determining the underlying mutations responsible for various age-
related disorders. These results provided a firm basis for subsequent studies aimed at the 
development of artificial chemical proteases for the cleavage of target proteins. 
2.6  EXPERIMENTAL SECTION 
General: All commercial materials (Aldrich, Fluka, Nova) were used without further purification.   
All solvents were reagent grade or HPLC grade (Fisher). Anhydrous THF, diethyl ether, CH2Cl2, 
and DMF were obtained from a dry solvent system (passed through column of alumina) and used 
without further drying. All reactions were performed under air in round bottom flask. Yields refer 
to chromatographically pure compounds; % conversion were obtained by comparison of HPLC 
peak areas of products and starting material. HPLC was used to monitor reaction progress. 
 
Materials: Fmoc-amino acids were obtained from Nova Biochem is under (EMD Millipore 
Corporation) (Billerica, Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide resin 
was obtained from ChemPep Inc (Wellington, Florida). N,N,N′,N′-Tetramethyl-O 
(1Hbenzotriazol-uronium hexafluorophosphate (HBTU) was obtained from CreoSalus (Louisville, 
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Kentucky). N,N′-Disuccinimidyl carbonate (DSC) was obtained from Nova Biochem, under 
(EMD Millipore Corporation) (Billerica, Massachusetts). 4-Dimethylaminopyridine (DMAP): 
Merck KGaA (Darmstadt, Germany). N,N-Dimethylformamide (DMF): Macron Fine Chemicals 
(Center Valley, Pennsylvania). Dichloroethane (DCE), acetonitrile, N,N-Diisopropylethylamine 
(DIEA), N,N'-diisopropylcarbodiimide (DIC), were purchased from (EMD Millipore 
Corporation)(Billerica, Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill, 
Massachusetts). Trifluoroacetic acid (TFA) was purchased from VWR 100 Matsonford Road 
Radnor, PA. Diethyl Ether: Sigma Aldrich (St. Louis, Missouri). Water was purified using a 
Millipore MilliQ water purification system. 
NMR 
This was done by Ryan Cohen at Merck facilities at Rayway, NJ. 1H NMR spectra were 
recorded on a 600 MHz spectrometer and 13C NMR spectra on a151 MHz, spectrometer at ambient 
temperature. All NMR chemical shifts () are referenced in ppm relative to residual solvent or 
internal tetramethylsilane. 1H NMR chemical shifts referenced to residual DMSO-d6 at 2.50 ppm, 
and 13C NMR chemical shifts referenced to DMSO-d6 at 39.52 ppm. 13C  NMR spectra are proton 
decoupled. NMR spectral data are reported as chemical shift (multiplicity, coupling constants (J), 
integration). Multiplicity is reported as follows: singlet (s), broad singlet (bs), doublet (d), doublet 
of doubles (dd), doublet of triplet (td), triplet (t) and multiplet (m). Coupling constant (J) in Hertz 
(Hz). 
HPLC 
 
Semi-Preparative HPLC: 
Preparative HPLC chromatography (HPLC) was performed on Beckman Coulter equipped with 
System Gold 168 detector and 125P solvent module HPLC with a 10 mm C-18 reversed-phase 
column. All separations involved a mobile phase of 0.1% FA (v/v) in water (solvent A) and 0.1% 
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FA (v/v) in acetonitrile (solvent B). Semi-preparative HPLC method using a linear gradient of 0– 
80% acetonitrile in 0.1% aqueous FA over 30 min at room temperature with a flow rate of 3.0 mL 
min-1. The peptide absorbance was monitored at 220 nm (peptide bond) and 254 nm (aromatics) 
unless otherwise noted. 
 
Analytical HPLC: 
Analytical HPLC chromatography (HPLC) was performed on an Agilent 1200 series HPLC 
equipped with a 4.6x150 mm (5µm) C-18 reversed-phase column. All separations involved mobile 
phase of 0.1% FA (v/v) in water (solvent A) and 0.1% FA (v/v) in acetonitrile (solvent B). Peptide 
compositions were evaluated by analytical reverse phase HPLC using a gradient of 0.1% FA in 
acetonitrile versus 0.1% FA in water. Analytical HPLC method using a linear gradient of 0–80% 
0.1% FA (v/v) acetonitrile in 0.1% aqueous FA over 30 min at room temperature with a flow rate 
of 1.0 mL min-1. The peptide was monitored by absorbance at 254 nm unless otherwise noted. 
 
LCMS: 
Mass spectrometry was performed using ultra high-performance liquid chromatography-mass 
spectrometry using the Agilent 1100 Series ESI LC MSD Spectrometer.  
 
Fmoc Solid-Phase Peptide Synthesis:31  
Peptides were synthesized manually on a 0.25 mmol scale using Rink amide resin. Fmoc–group 
was deprotected using 20% piperidine–DMF for 20 min to obtain a deprotected peptide-resin. 
Fmoc-protected amino acids (1.25 mmol) were sequentially coupled on the resin using a HBTU 
(1.25 mmol) and DIEA (1.25 mmol) for 2 h at room temperature. Peptides were synthesized using 
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standard protocols.31 The peptide was cleaved from the resin using a cocktail of 95:2.5:2.5, 
trifluoroacetic acid (TFA):triisopropylsilane (TIPS):water (H2O) for 2 h. The resin was removed 
by filtration and the resulting solution was concentrated. The oily residue was triturated with 
diethyl ether to obtain a white suspension. The resulting solid was analyzed and purified by RP 
HPLC. 
  
General procedure for cyclization: To a 5-mL round-bottom flask containing peptide (2-20mg 
(1 equiv.) in 0.5-2 mL dimethylformamide (DMF) was added a solution of DSC (5-20 equiv.), 
DIEA (5-20 equiv.) and crystal of DMAP in DMF (0.2-0.5 mL). The mixture was stirred at room 
temperature for 10 h. The reaction was concentrated under vacuum and resulting peptide was 
dissolved in 1:1 mixture of water and acetonitrile and purified by RP HPLC. The purified fractions 
were lyophilized to afford cyclized peptide as a white powder; yield: (60-80 %). 
 
NMR Chemical Shifts for Fmoc-G-Oxd: 
Analysis done by Ryan Cohen utilizing Merck facilities located in Rahway, NJ. 1H NMR 
chemical shifts referenced to residual DMSO-d6 at 2.50 ppm, and 
13C NMR chemical shifts 
referenced to DMSO-d6 at 39.52 ppm. 1 H NMR (600 MHz, DMSO-d6) δ 7.90 (d, J = 7.5 Hz, 2H), 
7.75 (s, 1H), 7.72 (d, J = 7.4 Hz, 2H), 7.64 (t, J = 6.0 Hz, 1H), 7.42 (t, J = 7.5 Hz, 2H), 7.39 (s, 
1H), 7.33 (t, J = 7.4 Hz, 2H), 4.73 (dd, J = 9.1, 3.1 Hz, 1H), 4.60 (t, J = 9.0 Hz, 1H), 4.36 – 4.15 
(m, 6H).  
13C NMR (151 MHz, DMSO-d6) δ 169.9, 169.1, 156.4, 153.5, 143.8, 140.7, 127.6, 127.1, 125.2, 
120.1, 66.8, 65.8, 55.4, 46.6, 44.1. 
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CHAPTER 3: CYLIC AND LASSO PEPTIDES:  STRUCTURE 
DETERMINATION, ROTAXANE FORMATION, AND 
TOPOLOGY ANALYSIS 
 
3.1 ABSTRACT 
  Natural products play a vital role in drug discovery and design as new peptide-based 
therapeutics continue to enter clinical trials. Bioactive peptides produced by non-ribosomal 
pathways such as N-methylated cyclic peptides and lasso peptides contain unique properties such 
as high receptor-binding activity, specificity towards their target, metabolic stability, and 
conformational rigidity. However, due to their distinctively complex topology, the ability to 
effectively determine their sequence and utilize the structure activity relationship in developing 
lead compounds remains limited. These limitations are primarily due to incompatibility with the 
majority of available sequencing methods including enzymatic digestion, chemical methods, and 
tandem mass spectroscopy. To overcome these limitations, we have developed a chemical 
methodology that can modify the backbone peptide chain at Ser to generate the cyclic urethane 
moiety, 2-oxazolidinone, thereby rendering the Ser N-terminal peptide bond susceptible to 
cleavage under hydrolytic conditions. This fragmentation method allowed for easy and rapid 
sequence determination by tandem mass spectroscopy. The methodology was applied to a broad 
substrate scope including the ability to modify peptides containing Thr, Cys, Glu, and unnatural 
amino acids such as homoserine which account for 60% of naturally occurring cyclic peptides.  
Utilizing this methodology, the cleavage and sequencing of stable N-methylated cyclic peptides, 
Polycarponin C and a Somatostatin analogue, has been accomplished. In addition, lasso peptides 
lariatin A, albusnodin, and benenodin-1 have also been structurally validated. Additionally, we 
created a peptide rotaxane by the selective cleavage of benenodin-1. This is the first chemical 
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methodology to be effectively applied for the cleavage of lasso peptides which is a major milestone 
in simplifying sequence determination of lasso peptides, studying the lasso topology, monitoring 
the effect of cleavage on sterically locked residues, and using lasso peptides as scaffolds for 
making rotaxane type interlocked machines. 
3.2 CHAPTER OBJECTIVES 
This study was a collaborative effort between our lab and the Link Lab at Princeton 
University, which specializes in lasso peptides. Chuhan Zong expressed and supplied the lasso 
peptides and helped in lasso data analysis post reaction. Meanwhile, cyclic peptide synthesis, 
purification, modification, and analysis in addition to lasso peptide modification was executed by 
the Raj group.  
This chapter describes a simple and versatile chemical methodology that facilitates 
sequence determination of cyclic and lasso peptides, explores the lasso topology and the effect of 
cleavage on sterically locked residues, and uses lasso peptides as scaffolds for making rotaxane 
type interlocked machines. This methodology is the first chemical methodology to be used for the 
abovementioned applications which is a major milestone in understanding of the importance of 
residue location in maintaining topologically distinct structures and harnessing their unique 
activity. Based on the results described in Chapter 2, this chapter applies our strategy for the ring 
opening of cyclic peptides and/or cleavage of lasso peptides to yield simplified fragments for 
peptide sequencing. The significance of this approach is based on a wide substrate scope and its 
compatibility with highly abundant amino acids which are found in over 60% of naturally 
occurring cyclic and lasso peptides. Moreover, this method is chemo-selective and does not lead 
to side reactions or byproducts in the presence of unprotected amino acid side chains. We have 
developed a general method for the cleavage and sequencing of peptides with unique topologies. 
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As compared to other cleavage methodologies, this method is the first chemical method to be 
applied for the cleavage of N-methylated peptides and lasso peptides which provides a gateway to 
further probe the mechanics of how the lasso structure is threaded and the effectiveness of steric 
locks post cleavage.  We have demonstrated the effectiveness of our method for the cleavage of 
cyclic peptides, N-methylated cyclic peptides, and lasso peptides.   
 
3.3 GRAPHICAL ABSTRACT 
 
Figure 3.1 Graphical abstract for Cyclic and Lasso Peptides: Sequence Determination, Topology 
Analysis, and Rotaxane Formation. Figure adopted with permission from: Elashal, H. E.; Cohen, 
R. D.; Elashal, H. E.; Zong, C.; Link, A.J.; Raj, M. Angew. Chem. 2018, DOI: 
10.1002/anie.201801299.1 
3.4 INTRODUCTION  
The discovery of active natural products has been at the root of modern drug design and 
they continue to play a vital role as ground-breaking peptide based drugs make their way towards 
clinical trials.2  Biologically active peptides produced by non-ribosomal pathways carry unique 
characteristics which allows them to have diverse functionalities.3 Specifically, cyclic peptides are 
of considerable interest since they contain the following key properties: high receptor-binding 
activity, specificity towards their target, metabolic stability, conformational rigidity, and the 
potential to be cell permeable.4 Unique peptides such as Cyclosporine A (an immunosuppressant),5 
peptides rich in N-methylation, microcin J25 (lasso peptide with anti- bacterial activity),6 and 
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Kalata B17,8 (cyclotide with insecticidal activity) are all natural  products with exceptional stability 
and bioactivity. However, the ability to immediately study and harness the structure activity 
relationship of these types of cyclic peptides in order to develop lead compounds is hindered due 
to the difficulty in determining the sequence of cyclic peptides. 
While enzymatic cleavage is one of the most utilized methods for peptide sequencing, lasso 
peptides, cyclic peptides (especially those that are N –methylated), and other uniquely structured 
peptides are resistant to enzymatic cleavage, with slower kinetic rates by 20-300 folds as compared 
to their linear counterparts.9 Mechanistically, the decrease in cleavage rates results from a slower 
rate of cleavage (kcat) and a weaker interaction with proteases (Km).
10 On the other hand, chemical 
methods for peptide bond cleavage can provide an efficient alternative to overcoming the 
abovementioned limitations. However, the existing methods for selective cleavage carry several 
limitations. Since cyclic peptides lack a free N-terminal amine, they cannot be sequenced via 
Edman degradation.11 The most commonly used method for chemical cleavage of cyclic peptides 
utilizes CNBr for the selective modification of methionine;12 however, methionine is the second 
least abundant amino acid in nature,13 therefore its presence in a naturally isolated product is a 
rarity.  Moreover, the cleavage is dependent on the neighboring amino acids; for example if 
methionine is followed by serine or threonine, side reactions convert methionine to homoserine 
without peptide bond cleavage and also leads to the modification of tyrosine’s side chain.14 Due 
to the lack of available chemical methods which can effectively modify abundant amino acid 
residues and afford cleavage of complex cyclic peptides, their feasibility for the sequencing of 
unique biologically active peptides remains limited.  
While many advancements have been made in the field of sequencing technology, their 
practical utility in the sequencing of naturally available cyclic peptides remains problematic.15 
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Typically, tandem mass spectroscopy is the most rapid and efficient method to determine the 
sequence of a peptide. While this holds true for linear peptides, structure and sequence assignment 
becomes more complicated for cyclic peptides. Cyclic peptides undergo ring opening at various 
positions to generate a family of mass degenerate ions which further fragments to generate 
complex mixtures of various short fragments.16-20 The interpretation of the various fragmentation 
patterns becomes difficult and impractical. Moreover, analysis of the MS/MS spectra is also 
hindered by the lack of defined N and C termini. Additionally, many biologically active peptides 
are synthesized through non-ribosomal pathways which increases the likelihood that unnatural 
amino acid residues may be present in the peptide which adds to the complexity of spectroscopic 
analysis. To this end, nuclear magnetic resonance spectroscopy (NMR) remains the only viable 
method for accurately predicting the structure and sequence of cyclic peptides, lasso peptides, and 
other peptides with distinct topologies. Furthermore, wrongful assignment of NOE contacts can 
lead to an inaccurate structure determination.21 For example, a branched- cyclic peptide can be 
mistaken for a lasso structure and the opposite is also true.21 Therefore, careful, lengthy, and 
tedious data interpretation are required in order to yield the correct sequence and structure 
assignment of peptide natural products through NMR.  
In this chapter, a simple and convenient approach for sequence determination of non-
ribosomally produced highly stable lasso peptides and cyclic peptides with unnatural amino acid 
residues and N-methylation is reported. The methodology entails the site-selective amine 
backbone activation at Ser, Thr, Glu, and/or Cys. Upon activation, the amide bond at the N-
terminal side of the residue(s) becomes susceptible to cleavage thereby converting the peptide into 
its linear counterpart which can easily be sequenced by MS/MS. The proposed strategy has a broad 
substrate scope and is compatible with some of the most highly abundant amino acids found in 
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nature.13 To implement this approach, at least one Ser, Thr, Glu, or Cys should be present in the 
desired cyclic peptide, which is of high probability due to the presence of at least one of the 
abovementioned residues in approximately 60% of naturally occurring cyclic peptides and 66% of 
lasso peptides as determined by a survey sample screened through NORINE, 22 a cyclic peptide 
database, and a comprehensive list of all lasso peptides discovered to date.21  Additionally, this 
methodology can also be utilized to modify various unnatural amino acid residues that are readily 
found in numerous bioactive cyclic peptides obtained from nature. Unnatural amino acids with a 
reactive side chain functionality such as a hydroxyl group or an amine and have the ability to form 
a five membered or six membered ring would be compatible with this strategy. For example, 
homoserine, beta-hydroxy-Phe (β-OH-Phe), β-OH-Asn, β-OH-Gln, β-OH-Asp, β-OH-Val, β-OH-
Tyr, and beta homoserine (β-Hse) are amongst the unnatural amino acids which fulfill these 
criteria. Moreover, this method is chemo-selective and does not interfere with any other 
unprotected amino acid side chain; it does not generate byproducts or lead to side reactions. To 
the best of our knowledge, this is the only chemical method available that has a potential of 
sequencing more than 60% of lasso peptides and N-methylated cyclic peptides which is a 
significant advancement as compared to pre-existing techniques. 
3.5 RESULTS AND DISCUSSION 
Due to the difficulties associated with utilizing tandem mass spectroscopy for cyclic 
peptide analysis, we developed a strategy that converts these peptides to their linear counterparts. 
Upon linearization of the cyclic peptide, the previously mentioned obstacles related to the use of 
MS/MS for sequence determination become eliminated thereby simplifying the process of MS/MS 
analysis. The proposed strategy involves the conversion of Ser to an oxazolidinone moiety, thereby 
making the amide bond susceptible to cleavage at the Ser N-terminus under hydrolytic conditions.  
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The modification of Ser encompasses the reaction of its hydroxymethyl group with N,N-
disuccinimidyl carbonate (DSC) to generate an intermediate (Scheme 3.1). Next, nucleophilic 
attack of the amide nitrogen of the peptide backbone produces the desired 2-oxazolidinone moiety. 
Upon formation of 2-oxazolidinone, the C-N bond is easily hydrolyzed under mild conditions to 
generate a ring-opened (linear) peptide. Earlier attempts at the formation of this moiety on 
Fmoc/Boc protected peptides led to the formation of dehydroalanine.23 This methodology is also 
applicable to Thr and Cys which exhibit similar side chain functionalities as serine. Moreover, 
glutamic acid also serves as a substrate for this modification due to its nucleophilic side chain 
which has the ability to form a pyroglutamyl imide moiety. Our group previously reported the 
application of this moiety for the synthesis of thioesters and for the cleavage of linear peptides.24,25 
 
Scheme 3.1 Macrocyclic Peptide Sequencing Strategy. Scheme adopted from reference (1) with 
permission. 
Using previously determined reaction conditions,25 we proceeded to sequence 
Polycarponin C, a mono-methylated cyclic peptide with anti-cancer activity.26 First, we incubated 
the peptide with chymotrypsin27 since it contains a phenylalanine to assess if enzymes can be 
utilized for opening of these N-methylated peptides.  After 48 hours, no detectable cleavage of 
Polycarponin C was noted which confirmed the limitation of using enzymatic degradation in 
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sequencing of these peptides (Figure 3.2a). Next, direct MS/MS analysis was carried out in an 
effort to determine the peptide sequence without any modification (Figure 3.2b). However, the 
spectra generated complex fragmentation patterns that were difficult to assign. Moreover, several 
fragments corresponded to the same mass, which made accurate assignment a challenging task. 
We then proceeded to selectively modify the peptide backbone chain at the N-terminus of Thr by 
using DSC, which is otherwise very stable and has a half-life of 500-1000 years at pH 4-8.28 
Following the treatment with DSC, the peptide was hydrolyzed to its linear counterpart under mild 
aqueous buffer conditions (pH 7.4) at room temperature (Figure 3.2c). Noteworthy, the cleavage 
proceeded smoothly even in the presence of a Pro residue neighboring the site of cleavage which 
highlights a key advantage over enzymatic digestion which cannot proceed in the presence of a 
nearby Pro.29 Upon analysis of the linear counterpart by MS/MS, the spectra clearly showed the 
ring opened peptide with a clear fragmentation pattern that is easier to decipher as compared to the 
MS spectra obtained by direct analysis of the cyclic peptide (Figure 3.2c).  
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Figure 3.2 Sequencing polycarponin C. a) HRMS spectrum after 48 h incubation with 
chymotrypsin showing proteolytic resistance, b) complex MS/MS spectrum of polycarponin C, 
and c) simplified MS/MS spectrum of its ring-opened analogue. Figure adopted from reference (1) 
with permission. 
 
Next, we sought to sequence a stable tri-N-methylated Somatostatin analogue.30 After 
incubation with a mixture of trypsin and chymotrypsin27 for 48 hours, the peptide remained intact, 
with no observable cleavage (Figure 3.3). Direct MS/MS analysis was also troublesome due to the 
complications noted above. Conversely, upon utilizing our method for sequencing, the peptide was 
opened to its linear counterpart following Thr activation and hydrolysis (Figure 3.3). By applying 
our methodology on these two cyclic peptides, we have demonstrated the efficiency of our strategy 
in the sequencing of bioactive cyclic peptides containing multiple methyl groups. 
 
Figure 3.3 Sequencing data for a somatostatin analog. A) HRMS spectrum after protease 
incubation showing no detectable cleavage, b) MS/MS spectrum of cyclized peptide, and c) 
MS/MS spectrum of ring-opened peptide. Figure adopted from reference (1) with permission. 
 
To demonstrate compatibility of our method with unnatural amino acids which are 
abundant in cyclic peptides isolated from nature, we synthesized one such model cyclic peptide 
62 
 
Gly-Tyr-Val-Hse-Phe-Leu-Ala containing homoserine (Hse). Due to hydroxyl side chain of 
homoserine and the side chain proximity to the amidic nitrogen, we hypothesized that homoserine 
can effectively react with DSC to form a six-membered oxazinanone ring making the homoserine 
N-terminal amide bond susceptible to hydrolysis (Figure 3.4). As predicted, homoserine in a cyclic 
peptide underwent modification upon treatment with DSC to a 6-membered ring followed by 
hydrolysis to its linear counterpart under neutral buffer conditions.   
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Figure 3.4 Cleavage data for Homoserine (Hse)-containing macrocyclic peptide. HRMS spectra 
of (a) cyc-Gly-Tyr-Val-Hse-Phe-Leu-Ala, (b) activated six-membered oxazinanone moiety, and 
(c) hydrolytically-cleaved linear peptide, which is amenable for MS/MS sequencing. Figure 
adopted from reference (1) with permission. 
 
We have also applied this approach for sequencing a model cyclic peptide with serine 
residue cyc(Ser-Phe-Arg-Tyr-Ala-Glu) by selective modification of serine to 5-membered 2-
oxazolidinone moiety followed by the cleavage of the backbone chain at the N-terminus of serine 
under hydrolytic conditions (Figure 3.5). The resulting linear peptide was then sequenced by 
tandem mass spectrometry. By displaying applicability to homoserine in addition to Ser, Cys, Thr, 
and Glu, we can effectively apply our method to sequence over 60% of naturally occurring cyclic 
peptides.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Serine activation to cyclic urethane moiety. a) 4: Rt = 9.3 min, b) 5: Rt = 10.8 min, c) 
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6: Rt = 10.3 min. Rt = retention time. Inset shows MS of compounds 4, 5 and 6. Figure adopted 
from reference (1) with permission. 
 
To further assess the scope of our methodology, we explored the applicability of our 
strategy with lasso peptides which are known for their wide range of bioactivity including 
antimicrobial, enzyme inhibitory, and receptor antagonistic in addition to their unique topology 
which contains a ring, loop, and a tail component.21,31 Sequencing of this distinctive class of 
peptides is problematic due to the unique lasso topology which is highly stable toward enzymatic 
cleavage by common digestive enzymes. On the other hand, isopeptidases have been found in 
organisms that express lasso peptides. These isopeptidases have the ability to cleave only the 
isopeptide bond present in the ring to yield a ring opened linear peptide.32-35 However, each 
isopeptidase is specific only to the lasso peptide isolated from the same prokaryote.32-35 Therefore, 
there is a need for chemical cleavage methods since there is no general method that can further 
assist in the sequence determination of the majority of lasso peptides.  
To test the stability of lasso peptides towards enzymes before proceeding with cleavage 
through chemical modifications, we chose lariatin A and albusnodin. Lariatin A is an antimicrobial 
lasso peptide which contains an Arg residue in the ring region,36 while albusnodin, another lasso 
peptide, contains two consecutive Arg residues in the loop region.37 Since Arg is a substrate for 
trypsin, we treated both peptides with trypsin to investigate if cleavage would occur. After 
incubating the peptides with trypsin overnight, no observable cleavage was detected, thereby 
confirming the resistance of lasso peptides to proteolytic degradation. As further proof, we also 
incubated lariatin A with a mixture of trypsin and chymotrypsin since it also contains Trp, a 
substrate for chymotrypsin. After 24 hr, lariatin A remained completely intact. In fact, the lasso 
spectra after treatment with enzymes looks more complicated because these enzymes cleave 
themselves and generate multiple small fragments.  
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Figure 3.6 Sequencing data for lasso peptide, lariatin A. MS/MS spectra of the fully ring-opened 
peptide, C, and cleavage product, A, from reaction at Ser-13, which is present at the steric lock 
region. Figure adopted from reference (1) with permission. 
 
We then proceeded to utilize our methodology for the cleavage of lariatin A and albusnodin 
since both peptides contain Ser within their sequence. Since lariatin A contains two Ser, one in the 
ring and the other in the loop region, we expected that treatment with DSC overnight will modify 
only the Ser which is present in the ring because the serine present in the loop region is threaded 
inside the ring making it less exposed. To our surprise, the major product was modification of Ser-
13, and after hydrolysis, this generated a branched, cyclized peptide (A) and a short, linear peptide 
(B). A small amount of the expected branched, ring-opened product (C) was also observed; 
however, unexpectedly Lys17 was converted into a cycloocta-urea moiety (Figure 3.6). Previously 
on short model peptides, modification of the Lys side chain amino group was observed after 
treatment with DSC to the corresponding carbamic acid that subsequently would regenerate Lys 
under the hydrolytic conditions.25a However, in this case, Lariatin A’s molecular topology may 
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facilitate intramolecular ring formation. Meanwhile, albusnodin has one Ser located in the ring 
region of the peptide which was expected to afford a linear peptide upon hydrolysis.25b Treatment 
with DSC and subsequent hydrolysis efficiently yielded the conversion of albusnodin to a ring 
open peptide. Although albusnodin has two Arg residues, no lasso peptide cleavage was observed 
upon treatment with carboxypeptidase and trypsin which emphasizes the high stability of lasso 
peptides towards enzymes even in the presence of two enzymatic cleavage sites. 
Notably, efficiency of the reaction conditions decreases when applied to lasso peptides due 
to variations in structure such as loop size, ring size, steric locks, and residues threaded through 
the ring making them difficult to access. However, even with lower conversion rates, the cleaved 
product is enough to conduct MS/MS analysis thereby providing insight into lasso sequencing and 
structure determination. 
In addition to exploring our strategy with the above-mentioned lasso peptides, we also 
studied reactivity with benenodin-1, another lasso peptide. Benenodin-1 is unique to our study 
since it contains three possible cleavage sites. It contains Ser, Thr, and Glu in the loop region of 
the peptide.32 It was interesting to monitor if modification and cleavage of Glu would occur since 
it serves as a steric lock.31 Interestingly, we observed the modification and cleavage of only Ser in 
benenodin-1 which resulted in the formation of a rotaxane structure (Figure 3.7). Rotaxanes have 
an interlocked architecture where a dumbbell shaped molecule is threaded through a macrocyclic 
ring which gives them immense potential as molecular machines.38-40 In the case of benenodin-1, 
Glu and Gln serve as steric locks which prevent the un-threading of the linear peptide obtained 
after cleavage at the N-terminus of Ser thereby disconnecting the loop from the ring portion. This 
result showed that our methodology has the potential to utilize lasso peptides as scaffolds for the 
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formation of rotaxanes and various other interlocked peptide based molecular machines which are 
challenging to make through the available synthetic methods.41  
 
Figure 3.7. LC-MS of a rotaxane obtained from the modification/cleavage at Ser-9 of benendonin-
1 ΔC5. Figure adopted from reference (1) with permission. 
 
Other benenodin-1 ΔC5 cleavage products were also observed from Ser, Thr, and Glu residues 
that facilitated sequencing (Scheme 3.2). In these cases, linear peptides were generated from the 
loop region. Cleavage at or near the steric lock unthreads the loop from the ring, while distal site 
cleavage generates the rotaxane structure through conservation of the threaded architecture. 
 
Scheme 3.2 Benenodin-1 ΔC5 Cleavage Products. Figure adopted from reference (1) with 
permission. 
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Overall, our approach simplifies the complicated lasso topology to simple fragments such as 
linear peptides and/or ring-tail peptides which can then be easily sequenced by further enzymatic 
digestion and/or tandem mass spectroscopy. Importantly, this method also has the potential to 
make peptide rotaxanes from lasso scaffolds.  
3.6 CONCLUSIONS 
  We have developed a general method for the cleavage and sequencing of peptides with 
unique topologies. We have demonstrated the effectiveness of our method for the cleavage of 
cyclic peptides, N-methylated cyclic peptides, and lasso peptides. As compared to other cleavage 
methodologies, this method is the first chemical method to be applied for the cleavage of N-
methylated peptides and lasso peptides which provides a gateway to further probe the mechanics 
of how the lasso structure is threaded and the effectiveness of steric locks post cleavage.  Moreover, 
this methodology has a broad substrate scope due to its reactivity with highly abundant residues 
including Ser, Thr, Glu, and Cys as well as it compatibility with several unnatural amino acid 
residues such as homoserine and other beta-hydroxy amino acids. Overall, this methodology 
provides a means with the potential to sequence over 60% of naturally occurring cyclic peptides 
and 66% of all lasso peptides. Adding to its attractiveness, this methodology is selective to the 
abovementioned residues; it does not react with other unprotected amino acid side chains, generate 
byproducts, or lead to any side reactions.  By utilizing this methodology, we are able to sequence 
peptides with unique structures, study the effect of loop size and residue location on lasso peptide 
cleavage, make interlocked structures like rotaxanes from lasso scaffolds, and provide a platform 
for discovering newly isolated biologically active peptides.  
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3.7 EXPERIMENTAL SECTION 
General: All commercial materials (Sigma-Aldrich, Fluka, and Novabiochem) were used without 
further purification. All solvents were reagent or HPLC (Fisher) grade. Diethyl ether, 
dichloromethane, and N,N-dimethylformamide were obtained from a dry solvent system (passed 
through an alumina column) and used without further drying. All reactions were performed under 
air in glass vials. HPLC was used to monitor reaction progress. 
Materials: Fmoc-amino acids were obtained from Novabiochem (EMD Millipore Corporation, 
Billerica, Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide, Wang, and 2-
chlorotrityl (2-ClTrt) resins were obtained from ChemPep Inc. (Wellington, Florida). N,N,N′,N′-
Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) was obtained from 
CreoSalus (Louisville, Kentucky). N,N′-Disuccinimidyl carbonate (DSC) was obtained from 
Novabiochem (EMD Millipore Corporation, Billerica, Massachusetts). 4-Dimethylaminopyridine 
(DMAP) was obtained from Merck KGaA (Darmstadt, Germany). N,N-Dimethylformamide 
(DMF) was obtained from Macron Fine Chemicals (Center Valley, Pennsylvania). Acetonitrile, 
N,N- diisopropylethylamine (DIEA), triisopropylsilane (TIPS), and N,N'-diisopropylcarbodiimide 
(DIC) were purchased from Novabiochem (EMD Millipore Corporation, Billerica, 
Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill, Massachusetts). 
Trifluoroacetic acid (TFA) was purchased from VWR (100 Matsonford Road Radnor, 
Pennsylvania). Diethyl ether, dichloromethane (DCM), methanol (MeOH), phenylsilane, 1-
hydroxy-7-azabenzotriazole (HOAt), tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4], 2-
nitrobenzenesulfonyl chloride (o-NBS-Cl), 2,4,6-trimethylpyridine, triphenylphosphine, 
tetrahydrofuran (THF), diisopropyl azodicarboxylate (DIAD), mercaptoethanol, 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), acetonitrile, toluene, dimethyldichlorosilane, and 
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1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) were obtained from Sigma-Aldrich (St. Louis, 
Missouri). Water was purified using a Millipore Milli-Q water purification system. Lariatin A was 
purchased from Abcam (Cambridge, Massachusetts). 
LC-MS:  
A Portion of analysis was done at Seton Hall University; the other portion was done at Merck 
facilities at Rahway, NJ by Ryan Cohen. Peptide compositions were evaluated by high 
performance liquid chromatography (HPLC) on an Agilent 1100 series HPLC equipped with a 
4.6x150 mm (5µm) C18 column. All separations used mobile phases of 0.1% formic acid (v/v) in 
water (solvent A) and 0.1% formic acid (v/v) in acetonitrile (solvent B). A linear gradient of 0–
80% solvent B in 30 minutes at room temperature with a flow rate of 1.0 mL min-1 was used. The 
eluent was monitored by UV absorbance at 220 nm unless otherwise noted. Mass spectrometry to 
check reaction mixtures was performed on an Agilent 1100 Series HPLC with MSD VL mass 
spectrometer using positive polarity electrospray ionization (+ESI).  
LC-HRMS: 
Analysis was done at Merck facilities at Rahway, NJ by Ryan Cohen. High resolution MS data 
were acquired using an Agilent 1290 UHPLC with a 6520 Q-ToF mass spectrometer under positive 
polarity electrospray ionization (+ESI) with capillary and fragmentor voltages set to 3.5 kV and 
175 V, respectively. The instrument was calibrated prior to data acquisition using Agilent’s 
reference standard solution, which provided accurate masses within 5 ppm. A reversed phase, 
linear gradient separation was performed at a flow rate of 1.0 mL min-1 on a C18 column (Waters 
Acquity UPHLC peptide BEH C18, 1.7 µm particle size, 50 mm x 2.1 mm I.D.) thermostatted at 
45°C and gradient from 95% solvent A (0.1% formic acid in water) to 99% solvent B (0.1% formic 
acid in acetonitrile) in 4 minutes, followed by 1 minute re-equilibration.  
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MS/MS: 
A portion of analysis was done was done at Merck facilities at Rahway, NJ by Ryan Cohen; 
the other portion was done at Princeton University by Chuhan Zong. Tandem MS analyses 
were performed either on an Agilent 1260 HPLC coupled with a 6530 Q-ToF or on an Agilent 
1290 HPLC coupled with a 6520 Q-ToF mass spectrometer.  Both mass spectrometers were 
operated under electrospray ionization in positive polarity (+ESI). Reverse phase C18 gradient 
separation conditions were used (mobile phase A = 0.1% formic acid in water and mobile phase B 
= 0.1% formic acid in acetonitrile). Spectra were acquired in profile mode with collision energies 
ranging from 25-90 V and nitrogen (N2) as collision gas. 
General Procedure for Fmoc Solid-Phase Peptide Synthesis:  
Peptides were synthesized manually using standard protocols42 with either Rink amide resin (0.25-
mmol scale) for Ser-Phe-Arg-Tyr-Ala-Glu or 2-ClTrt resin (0.175-mmol scale) for N-methylated 
peptides. Fmoc-protected amino acids were sequentially coupled on the resin with an excess of 
HBTU and DIEA for 2 hrs at room temperature. Fmoc was deprotected with a 20% v/v piperidine 
in DMF solution for 20 min.  
Macrocyclization of Linear Peptide, Ser-Phe-Arg-Tyr-Ala-Glu, on Solid Support: 
To peptide, Ser-Phe-Arg-Tyr-Ala-Glu, containing O-allyl protected glutamic acid on solid support 
(50 mg, 0.69 mmol/g) was added a 3 mL solution of 20 mg Pd(PPh3)4 and 72 µL phenylsilane in 
DCM. This solution was incubated on a shaker at room temperature for 40 minutes. The resin was 
washed with DCM (3 X 2 min). The above reaction was repeated, and then the resin was washed 
with DCM (3 X 2 min), MeOH (3 X 2 min), and DMF (3 X 2 min). The palladium catalyst was 
removed from the resin by washing with DIEA in DMF (2% v/v)  (2 X 2 min) and then with DMF 
(2 X 2 min). Next, the peptide was treated with 20% piperdine in DMF to remove the Fmoc 
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protection. Macrocyclization was achieved by exposing the resin to DIC, HOAt, and a catalytic 
amount of DMAP in DMF on a shaker for 15 hrs. The solution was drained, and the resin was 
washed with DMF. To confirm complete macrocyclization, the Kaiser test43 was performed, which 
showed yellow bead coloration indicating absence of free amino groups. The peptide was then 
cleaved from the resin by 2 hrs incubation with a solution of TFA:TIPS:water (95/2.5/2.5, v/v/v). 
Resin was removed by filtration, and the resulting solution was evaporated. The peptide was 
purified by reversed-phase semi-preparative chromatography. 
N-Methylation of Linear Peptides on Solid Support: 
N-methylated residues were synthesized on solid support using a reported method involving oNBS 
protection.43 A 155 mg o-NBS-Cl and 230 µL trimethylpyridine solution in 5 mL DMF was added 
to the resin and shaken at room temperature for 30 minutes, which was then filtered and washed 
with DMF.  The protection step was then repeated, followed by 5X washing with DMF. The resin 
was soaked in THF and then dried under vacuum. A solution of 230 mg triphenylphosphine and 
2.5 µL MeOH in 2.5 mL THF was added to the resin and shaken for 5 minutes. The resin was then 
treated with a solution of 175 µL DIAD in 2.4 mL THF (added portion-wise at 500 µL each time 
and shaken for 10 minutes). The resin was then filtered and washed with DMF.  Mitsunobu 
conditions were repeated once more. Finally, oNBS deprotection proceeded by soaking the resin 
in DMF, followed by 10 minute exposure at room temperature while shaking in a 5 mL DMF 
solution containing 122 µL 2-mercaptoethanol and 131 µL DBU, and then filtering and washing 
with DMF.  Deprotection was repeated once.  
Macrocyclization of N-methylated Peptides in Solution: 
Peptides were cleaved from the resin with a 20% v/v HFIP solution in DCM. The DCM was 
evaporated, and linear peptides were purified by chromatography. Cyclization occurred with 20 
73 
 
mg HOAt, 20 µL DIC in dry DMF per 2 mg of peptide. Side chain protecting groups were then 
deprotected by adding a solution of TFA:TIPS:water (95/2.5/2.5, v/v/v) and incubating the solution 
for 2 hrs. N-methylated macrocyclic peptides were then purified by reversed-phase semi-
preparative chromatography. 
 
Albusnodin Expression and Purification: 
This portion of work was done by Chuhan Zong at Princeton University. For a typical 
heterologous production of albusnodin, Streptomyces strains were cultured in GYM medium with 
total volume of 1 L. All strains were cultured in 5 x 1000 mL Erlenmeyer flasks (each flask 
contained 200 mL of GYM medium) that were treated with 1 mL dimethyldichlorosilane in toluene 
to minimize the culture from sticking to the glass wall and a stainless steel spring was placed at 
the bottom of each flask to improve aeration. Starting cultures were inoculated with 2 x 109 spores 
in 150 mL 2YT medium and incubated at 30 °C with orbital shaking (350 rpm) for 8 h. The 
germlings were harvested by centrifugation at 2,000 x g, resuspended in 25 mL of GYM medium, 
dispersed by a quick sonication pulse, and used to inoculate production cultures at a starting OD450 
of 0.005. Production cultures were incubated at 30°C with orbital shaking (250 rpm) for an 
additional 7 days. The cell lysate and supernatant of the samples were separated by centrifugation 
at 8,000 x g at 4 ◦C for 20 minutes. The cells were lysed in methanol.  The insoluble fraction was 
removed by centrifugation at 8,000 x g at 4 ◦C for 10 minutes, and the methanol-soluble fraction 
was dried using rotary evaporation and then resuspended in 500 μL of 50% acetonitrile and 50% 
water solution. The supernatant was extracted using a Strata C8 column (Phenomenex 6 mL size). 
The crude extract was eluted from the column using methanol, and dried using rotary evaporation, 
and then reconstituted in 500 μL of a solution of acetonitrile / water (1:1, v/v).  
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Benenodin-1 ΔC5 Expression and Purification: 
This portion of work was done by Chuhan Zong at Princeton University. Benenodin-1 ΔC5 
was obtained as previously described.32 Briefly, the lasso peptide was expressed using E. coli BL21 
cells with the plasmid, pCZ35, containing the lasso peptide gene cluster. Cultures were grown at 
37°C in 100 µg/mL LB-ampicillin broth. Cells were harvested by centrifugation and then lysed in 
MeOH. The lysate containing the peptide was purified by solid phase extraction followed by 
reversed-phase semi-preparative chromatography.  
General Procedure for Activation of Ser, Thr, Cys, Glu, and Hse Residues within 
Macrocyclic Peptides and Lasso Peptides: 
Per cleavage site in 1 mg of peptide, excess DSC (25 mg), DIEA (20 µl of a 20% vol/vol solution 
in DMF), and a crystal of DMAP were added to macrocyclic or lasso peptides in 450 µl DMF in a 
5 mL round bottom flask. The reaction mixture was agitated using an orbital shaker for 16 hours 
to modify desired cleavage residues. The mixture was then removed and DMF was evaporated.  
General Procedure for Ring-Opening of Macrocyclic and Lasso Peptides:  
0.45 mL of phosphate buffer (pH 7.6) was added to the activated macrocyclic or lasso peptide. 
This mixture was then agitated on an orbital shaker at 37°C for 48 hours and then checked by LC-
MS to ensure complete cleavage.  
Procedure for Protease Incubation. 
Incubation of macrocyclic and lasso peptides with chymotrypsin and/or trypsin were conducted 
using a 50 mM NH4HCO3 digestion buffer. The peptide substrates were treated with 50 μl of 0.1 
μg/μL protease (sequencing grade) in a total volume of 800 μL for each protease alone or 1600 µL 
for both trypsin and chymotrypsin together. Incubation was carried out for 48 hours at 37°C and 
samples were then analyzed by LC-HRMS. 
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CHAPTER 4: OXAZOLIDINONE MEDIATED SEQUENCE 
DETERMINATION OF ONE BEAD ONE COMPOUND CYCLIC 
PEPTIDE LIBRARIES 
 
4.1 ABSTRACT 
Cyclic peptides are attractive therapeutics for drug discovery due to high proteolytic 
stability, permeability, and high binding affinity. The therapeutic ability of cyclic peptides 
prompted the synthesis of cyclic peptide libraries by split and pool methods for High Throughput 
Screening (HTS) against various biological targets. A major obstacle associated with this approach 
is the sequencing difficulty of hit cyclic peptides obtained by HTS using traditional sequencing 
methods such as NMR, MS/MS, and enzymatic digestion. Therefore, we developed a one bead 
one compound (OBOC) dual ring opening/cleavage approach for sequencing of hit cyclic peptides 
by selective modification of a serine residue to an oxazolidinone moiety within the cyclic peptide 
and as a linker to allow for the liberation of the protected linear peptide into solution. Formation 
of the oxazolidinone moiety increases the susceptibility of the amide bond at the N-terminus of 
serine towards hydrolysis and leads to the opening of a cyclic peptide to its linear counterpart and 
simultaneous release of the resulting linear peptide from the solid support. The resulting linear 
peptide in solution was then sequenced in one minute by a liquid chromatography, ion mobility 
spectrometry, tandem mass spectrometry (LC-IMS-MS/MS) method, which provided faster 
sequencing of the ring opened peptides due to its inherently high peak capacity. To extend this 
approach, libraries of cyclic peptides (4-10 amino acids) containing different combinations of 
amino acids were successfully synthesized and sequenced with 98% overall accuracy, 
demonstrating the robustness and versatility of this methodology. 
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4.2 CHAPTER OBJECTIVES 
In this chapter, a simple and versatile one bead one compound approach for determining 
the sequence of libraries of cyclic peptides on solid support is described. A methodology based on 
the selective-activation of the backbone amine chain of cyclic peptide libraries was developed, 
which will facilitate the sequencing of HIT peptides post biological screening. This technique can 
be revolutionary in decreasing the amount of time spent in determining HIT sequences, thereby 
paving the way for rapid development of lead compounds into therapeutic drugs. 
The strategy entails the selective activation of the amide backbone chain at serine, 
threonine, and/or cysteine residues for the ring opening and sequencing of HIT cyclic peptides. 
The significance of this approach is that encoding tags or toxic reagents are not required for 
determining the sequence, which makes it distinct from the currently used methods. Moreover, 
this method is compatible with free amino acid side chains and does not lead to any side reactions. 
Another major advantage of this approach is that disulfide bonds remain stable under the reaction 
conditions, thus it has a potential to be applicable for the sequencing of cyclic peptides rich in 
disulfide bonds. In addition, the IMS-MS technique was used in an unprecedented manner for the 
rapid sequencing of cyclic peptides from the crude mixture; this portion of the study was done by 
Ryan Cohen. The use of IMS-MS reduces the time for sequencing of one cyclic peptide by 20-fold 
as compared to traditional MS/MS methods. 
 
 
 
4.3 GRAPHICAL ABSTRACT 
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Figure 4.1 Graphical abstract for Oxazolidinone Mediated Sequence Determination of One Bead 
One Compound Cyclic Peptide Libraries. Figure adopted with permission from: Elashal, H. E.; 
Cohen, R. D.; Elashal, H. E.; Raj, M. Org. Lett. 2018, 20 (8), 2374.1 
 
4.4 INTRODUCTION 
Cyclic peptides are of considerable interest due to their powerful potential as therapeutic 
agents.2-5 Compared to their linear counterparts, cyclic peptides exhibit high receptor-binding 
affinity, specificity, and stability due to their high conformational rigidity.6 Owing to their unique 
character, cyclic peptides are suitable tools for drug discovery. The therapeutic ability of cyclic 
peptides has prompted the synthesis of cyclic peptide libraries by split and pool methods7 followed 
by high-throughput screening against biological targets to determine “hit” peptides.8 However, 
their utility is hindered by the challenges that accompany the sequencing of the cyclic peptides. 
While enzymatic cleavage is one of the most utilized methods for peptide sequencing, it is 
incompatible with cyclic peptides; cyclic peptides are resistant to enzymatic cleavage by 20-300 
folds as compared to their linear conterparts.9 Mechanistically, the decrease in cleavage results 
from both a lower rate of cleavage (kcat) and a weaker interaction with proteases (Km).
10 Since 
cyclic peptides lack a free N-terminal amine, they cannot be sequenced via Edman’s degradation.11 
Meanwhile, tandem mass spectroscopy (MS/MS), another widely employed sequencing method, 
affords complex fragmentation patterns, which are difficult to interpret.12-16 Many attempts have 
been made in developing methods to overcome the challenges associated with sequencing hit 
macrocyclic peptides. The first utilized method in sequencing of hit cyclic peptides consisted of 
one-bead one-compound (OBOC) libraries that employed genetic encoding tags to record 
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synthesis history (Scheme 4.1).17-19 Nonetheless, OBOC is mainly compatible with natural amino 
acid containing peptides therefore its use in sequencing of cyclic peptides is of limited practicality. 
Meanwhile, the ladder synthesis involves capping small amounts of the peptide after each coupling 
before the final macrocyclization of the peptide to track the cyclic peptide sequence (Scheme 4.1). 
However, this approach is limited by interference from the small linear peptides (encoding tags) 
during the screening process.20  
To combat the abovementioned limitations, Pei and co-workers developed a one-bead two-
compound (OBTC) method consisting of segregated bilayer beads allowing each bead to constitute 
two elements.21,22 A cyclic peptide is exposed on the surface for screening, while the inside 
contains its linear counterpart for sequencing (Scheme 4.1). The disadvantage of this approach is 
that the cyclization step cannot be monitored due to the presence of the linear peptide tag.21 
Another major limitation associated with this method is that it cannot be used for sequencing cyclic 
peptides obtained from nature. More recently, strategies based on opening the macrocyclic ring 
post screening have been developed as an alternative to bead-based assays.23 These methods rely 
on incorporation of specific moieties into the cyclic peptide that can be chemically cleaved, 
resulting in the linear form which allows sequencing of hit cyclic peptides via MS/MS.   
In this manner, Lim and co-workers introduced an alkylthioaryl bridge into cyclic peptides, 
which is cleavable upon oxidation of the thioether by mCPBA to generate the linear peptide.24 
However, the oxidation reaction is not specific to the thioether, consequently, other functional 
groups such as guanidines and primary amines are also oxidized during the ring-opening reaction 
leading to complicated MS/MS fragmentation. Moreover, this method utilizes toxic cyanogen 
bromide (CNBr) for the cleavage of cyclic peptides.  
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Scheme 4.1 Literature methods for sequencing of cyclic peptides. A) One-bead-one-compound 
method (Adopted from reference [22] with permission) B) Ladder synthesis method (Adopted 
from reference [20] with permission) C) One-bead-two-compound method (Adopted from 
reference [21] with permission) D) Alkylthioaryl bridge method (Adopted from reference [24] 
with permission) 
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Recently, the Kodadek25 and Biron26 groups reported the use of a methionine residue for 
linearization and cleavage of cyclic peptides/peptoids from the solid support which is appealing in 
the sense that a natural amino acid is incorporated into different sequences for ring opening 
(Scheme 4.2). Nonetheless, complicated inverse peptide synthesis, side reactions, long cleavage 
times, and the use of toxic CNBr for cleavage detract from the attractiveness of this method.  
Most reported methods require aggressive chemical reagents or post-screening reactions 
that could lead to side-chain modifications. Conversely, Biron and coworkers have reported the 
utilization of a photo-cleavable moiety, β-amino acid 3-amino-3-(2-nitrophenyl)propionic acid 
(ANP), for the ring opening and release of the peptide from the resin (Scheme 4.2).27 Although 
this approach is reagent free and utilizes UV radiation for the opening of the cyclic ring, it remains 
limited by the formation of a mixture of various linear peptide side products, leading to 
complicated HPLC and MS/MS data interpretation. Another major limitation is that this method 
leads to the oxidation of the Met and Trp side chains. In addition, the synthesis and screening of 
these cyclic peptides must be done in the dark to prevent opening of the macrocycle or cleavage 
from the resin.27 Due to the sensitivity of the ANP moiety towards light, the cyclic peptides 
containing the ANP unit cannot be stored for long term use. A major advantage of the ring-opening 
strategy is that the same chemical entity is displayed inside and on the surface of the bead thus 
eliminating the risk of interference by coding tags during the screening, which is in contrast to the 
OBTC and ladder synthesis methods. Moreover, the cyclization step can be easily monitored to 
ensure a complete conversion to the cyclic peptide. Based on these strategies, our research goal 
was related to the development of an efficient and single-step ring-opening approach that would 
be compatible with free amino acid side chains and would not require the use of harsh chemical 
reagents. 
84 
 
 
Scheme 4.2 Literature methods for cleavage of cyclic peptides. A) Kodadek’s CNBr method 
(Adopted from reference [25] with permission) B) Biron’s CNBr method (Adopted from reference 
[26] with permission) C) ANP method (Adopted from reference [27] with permission) 
This chapter reports a simple and convenient approach for fast sequence determination of 
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cyclic peptides from OBOC libraries that overcome the challenges associated with existing 
methods. The methodology entails the selective activation of the amide backbone chain at the 
serine residue for the cleavage and sequencing of hit cyclic peptides. The significance of this 
approach is that encoding tags or toxic reagents are not required for determining the sequence, 
which makes it distinct from the currently used methods.  Moreover, this method is compatible 
with free amino acid side chains and does not lead to any side reactions.  
 
Scheme 4.3 Rationale for the sequencing of cyclic peptides by ring-opening/cleavage strategy. 
Reagents: (a) standard Fmoc/HBTU chemistry; (b) Pd(PPh3)4, phenylsilane; 20% piperdine (c) 
HOAt, DIC; (d) TFA (25%); (e) DSC, DIEA, DMAP; and (f) H2O: ACN (1:1), DIEA. Scheme 
adopted from reference (1) with permission. 
 
4.5 RESULTS AND DISCUSSION 
This approach utilizes two serine residues, one as part of the linker and one within the 
macrocycle (Scheme 4.3). The strategy involves the conversion of Ser to an oxazolidinone moiety, 
thereby making the amide bond susceptible to cleavage at the Ser N-terminus under hydrolytic 
conditions. Earlier attempts at the formation of this moiety on Fmoc/Boc protected peptides led to 
the formation of dehydroalanine.28 Our group recently reported the application of this moiety in 
the synthesis of thioesters.29 This methodology simultaneously converts cyclic peptides into their 
linear counterparts and releases them from the solid support. The linear peptides obtained from 
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solid support could then be easily sequenced by mass spectrometry. Scheme 4.3 illustrates the 
ring-opening/cleavage reaction for sequencing of cyclic peptides. Notably, only those resin-bound 
peptides that complete both the activation and displacement steps would be released. Thus, the 
released linear peptides should exhibit high purity, eliminating the need for extensive purification.  
To implement this strategy, a serine (trt) trityl residue with a selectively removable side-
chain protecting group (pg) as a linker was anchored onto the solid support. To this linker, a linear 
peptide with another serine (trt) residue, with a selectively removable side-chain pg, was 
synthesized on solid support by standard Fmoc chemistry.29 After removal of the allyl21 and Fmoc 
protecting groups, the peptides were cyclized on resin by using HOAt and DIC.30 The Kaiser test 
was used to monitor the macrocyclization reaction qualitatively.31 After macrocyclization, the (trt) 
groups from both the serine residues were selectively removed with TFA/DCM (1:3).32  
Initially, we assessed the efficiency of the activation of serine residues within a 
macrocyclic peptide and as a linker. The serine residues were activated with N,N’-disuccinimidyl 
carbonate (DSC) to generate two five-membered oxazolidinone rings on a model cyclic peptide 
cyc(GFSFAE)-S 1a (Table 4.1). To optimize the formation of two oxazolidinone moieties on the 
model cyclic peptide cyc(GFSFAE)-S on solid support, various reaction conditions such as time, 
temperature, and equivalents of DSC were explored (entries 1-6, Table 4.1). A mixture of mono 
oxazolidinone moiety-containing cyclic peptide 2a’ and desired bis oxazolidinone moieties-
containing cyclic peptide cyc(GF-Oxd-FAE)-Oxd 2a was obtained by using 10-15 equiv. of DSC 
at room temperature in 15 hrs (entries 1-2, Table 4.1). 
 
Table 4.1 Optimization of the activation of cyclic peptide cyc(Gly-Phe-Ser-Phe-Ala-Glu)-Ser-
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Rink 1a on solid support.a 
 
Entry DSC (equiv.) Temp. (oC) Time (h) Conversion (%)b 
2a 2a’ 
1 10 RT 15 50 50 
2 15 RT 15 75 25 
3 20 RT 15 >99 - 
4 20 RT 6 90 10 
5 20 65 6 ND ND 
6 20 65 15 ND ND 
aCyclic peptide 1a (50 mg) was reacted with DSC (10-20 equiv.), DIEA (10-20 equiv.) and a 
crystal of DMAP in DMF for (3-15 hrs). bConversion to desired two oxazolidinone-containing 
cyclic peptide cyc(GF-Oxd-FAE)-Oxd 2a and one oxazolidinone-containing cyclic peptide 2a’ 
was calculated from the absorbance at 220 nm using HPLC after release from solid support ND = 
not detected. Table adopted from reference (1) with permission. 
When 20 equiv. of DSC was used at room temperature, the conversion to 2a was 90% in 6 
h, whereas when the reaction was run for 15 hrs, the conversion increased to 99% (entries 3-4, 
Table 4.1). Similar reactions at high temperature (65 oC) gave a mixture of various unidentified 
side-products (entries 5-6, Table 4.1). To confirm the absence of the unmodified cyclic peptide, a 
small amount of the resin was cleaved and analyzed by HPLC and MS (Figure 4.2). 
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Figure 4.2 HPLC and MS of cyc(GF-Oxd-FAE)-Oxd 2a. Figure adopted from reference (1) with 
permission. 
Subsequently, serine activation was explored on solid support with various cyclic peptides 
of different sequences and different ring sizes (4-9 membered) (1b-1f, entries 1-5, Table 2). It is 
noteworthy that formation of the activated oxazolidinone moiety is independent of the nature of 
the amino acid preceding serine, and high conversion to the oxazolidinone moiety was obtained 
with cyclic peptides of various sizes. Moreover, the results in Table 2 showed that activation of 
serine does not depend on its position in the cyclic peptide. This is in contrast to the methionine-
based ring cleavage method where a C-terminal Met lead to formation of two homoserine lactone 
residues after ring opening, resulting in difficult sequencing of the linearized peptide, while an N-
terminal Met led to moderate cyclization efficiency.  
Table 4.2 Substrate scope of the activation of cyclic peptides 1b-1i on solid support to 2b-2i.a 
 
Entry Cyclic Peptides 1 Conversion (%)b 
1 cyc(SFFAE)-S 1b 85 
2 cyc(SGVFAE)-S 1c 89 
3 cyc(GSFAE)-S 1d 92 
4 cyc(GFKSYGLE)-S 1e 90 
5 cyc(AFSIGFE)-S 1f 88 
6 cyc(AFSFE)-T 1g 95 
7 cyc(GFCE)-C 1h 92 
8 cyc(AMPFISFPE)-C 1i 85 
aCyclic peptide 1b-1i (50 mg) was reacted with DSC (20 equiv.), DIEA (20 equiv.) and a crystal 
of DMAP in DMF for (15 hrs) at RT. bConversion to desired two oxazolidinone-containing cyclic 
peptide 2b-2i  was calculated from the absorbance at 220 nm using HPLC after release from solid 
support. Table adopted from reference (1) with permission. 
Next, the peptide backbone activation on cyclic peptides was investigated with threonine 
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cyc(AFSFE)-T 1g, whose side chain functionality exhibits strong similarity to serine. As expected, 
threonine underwent smooth cyclization under the optimized reaction conditions and generated a 
methylated oxazolidinone moiety cyc(AF-Oxd-FE)-MeOxd 2g  (entry 6, Table 4.2). In a similar 
manner, cysteine-containing cyclic peptides cyc(GFCE)-C 1h and cyc(AMPFISFPE)-C 1i 
generated thiazolidinone-activated cyclic peptides cyc(GF-Thz-E)-Thz 2h and cyc(AMPFI-Oxd-
FPE)-Thz 2i under the reaction conditions (entries 7 and 8, Table 4.2).  
The stability of the oxazolidinone moiety on the resin-bound macrocyclic peptide was also 
evaluated. The resin-bound oxazolidinone moiety containing cyclic peptide was found to be stable 
in a desiccator for longer than a month, which is in contrast to the previously reported photo-
cleavable ANP method.27 
Nucleophilic displacement of the oxazolidinone moieties under basic hydrolytic conditions 
simultaneously opened the cyclic peptide to its linear variant and released the resulting linear 
peptide acid from the solid support. Initially, the reaction was performed at room temperature in 
water:ACN (1:1, v/v) without base (entry 1, Table 4.3). This resulted in release of 10% linear 
peptide acid 3a from the resin after 15 hrs at room temperature.  
To optimize the cleavage of the activated cyclic model peptide cyc(GF-Oxd-FAE)-Oxd 2a to its 
linear counterpart and simultaneous release of the resulting linear peptide Oxd-FAEGF 3a into 
solution, various reaction conditions, such as base and temperature, were investigated (entries 2-
6, Table 4.3 and Figure 4.3). Hydrolytic cleavage under neutral conditions indicates that 
macrocyclic ring opening occurs more rapidly than peptide release from the resin (entries 1-2, 
Table 4.3). This was confirmed by acidic cleavage of the peptide from the resin after treatment 
with hydrolytic conditions for brief amount of time. Another advantage of this approach is that 
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only the serine activated peptide chain is released from the resin, thus delivering a highly pure 
linear peptide into the solution. The resin was then filtered, and the solvent was evaporated to 
obtain linear peptide Oxd-FAEGF 3a, which was then analyzed by HPLC and MS/MS (Figure 
4.3). 
Table 4.3 Optimization of the reaction conditions for dual ring-opening/cleavage of cyclic peptide 
2a to its linear counterpart 3a on solid support.a 
 
Entry Base Temp. (oC) Time (h) Conv.(%)b 
1 - RT 15 10 
2 DIEA RT 4 70 
3 DIEA RT 8 97 
4 DIEA RT 15 99 
5 DIEA 65 4 >99 
6 DIEA 65 2 99 
aActivated cyclic peptide 2a (50 mg) was treated with water:ACN (1:1) 1 mL and DIEA (40 µL). 
bConversion and release of resulting linear peptide Oxd-FAEGF 3a into the solution was calculated 
from the absorbance at 220 nm using HPLC. Table adopted from reference (1) with permission. 
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Figure 4.3 a) HPLC and MS of linear peptide Oxd-FAEGF 3a, b) MS/MS spectra of peptide Oxd-
FAEGF 3a. Figure adopted from reference (1) with permission. 
Next, various cyclic peptides with different amino acids and sizes were evaluated for the 
ring-opening and release strategy on solid support (Table 4.4).  
Table 4.4 Substrate scope of the ring-open/cleavage strategy on activated cyclic peptides 2b-2i.a 
 
Entry Activated Cyclic Peptides 2 Conversion (%)b 
1 cyc(OxdFFAE)-Oxd 2b 85 
2 cyc(Oxd-GVFAE)-Oxd 2c 89 
92 
 
3 cyc(G-Oxd-FAE)-Oxd 2d 92 
4 cyc(GFK-Oxd-YGLE)-Oxd 2e 90 
5 cyc(AF-Oxd-IGFE)-Oxd 2f 88 
6 cyc(AF-Oxd-FE)- MeOxd 2g 95 
7 cyc(GF-Thz-E)-Thz 2h 92 
8 cyc(AMPFI-Oxd-FPE)-Thz 2i 85 
aActivated cyclic peptide 2b-2i (50 mg) was treated with water:ACN (1:1) 1 mL and DIEA (40 
µL). bConversion and release of resulting linear peptide 3b-3i into the solution was calculated from 
the absorbance at 220 nm using HPLC. Table adopted from reference (1) with permission. 
It was noted that opening of the oxazolidinone activated cyclic peptides 2 on solid support 
to their linear counterparts 3 is independent of the nature of the amino acid residues preceding 
serine. For example, cyclic peptides with bulky amino acid residues next to serine such as 
Tyr(tBu), Phe, Lys(Boc), and a cyclic peptide with β-branched residues such as Ile generated linear 
peptides cleanly in high yields (entries 4-8, Table 4.4). Noteworthy, backbone activation is also 
possible at Thr and Cys due to similar side chain functionality exhibited by these resides. The 
possibility of modification at Ser, Cys, and/or Thr residues provides an additional advantage to the 
utility of this method affording multiple cleavage sites to aid in the sequencing process. Moreover, 
possible activation at any of the abovementioned residues allows variation in the generation of 
OBOC libraries generated; the peptide library is not limited to include only Ser residues. In the 
presence of Thr or Cys, sequencing post screening becomes feasible as demonstrated in peptides 
2g, 2h, and 2i which contain methylated oxazolidinone and thiazolidinone (entries 6-8, Table 4.4) 
By demonstrating an expanded substrate scope, oxazolidinone formation efficiently mimics 
enzyme function by providing multiple cleavage sites under mild conditions. 
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After the ring-opening/cleavage of a cyclic peptide, one oxazolidinone residue remained 
attached to the N-terminus of the linear peptide chain. Since only the activated serine residue can 
be released from the solid support after hydrolysis, the result is release of a highly pure linear 
peptide into solution. In contrast to other methods, we did not observe any oxidation of the 
unprotected side chain residues after dual ring opening/cleavage of cyclic peptides from the solid 
support.   
 
Figure 4.4 a) LC-MS separation of Oxd-YIGE, b) 2D separation – ion mobility drift time versus 
total ion chromatogram, c) MS/MS spectrum without quadrupole selection of parent ion 
(interfering signals marked with green asterisks), and d) MS/MS spectrum including ion mobility 
filtering to remove chemical interference. Figure adopted from reference (1) with permission. 
Sequencing was then accomplished by tandem mass spectrometry on a quadrupole time-
of-flight (Q-ToF) instrument incorporating a two-dimensional liquid chromatography, ion 
mobility spectrometry separation (LC-IMS-MS/MS) (Figure 4.3).33 Peak capacity can be 
significantly increased by pairing IMS with ultra-high-pressure liquid chromatography; thereby, 
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allowing for a ballistic reversed gradient to be employed. The overall separation time was just one 
minute, which would enable the analysis of large combinatorial cyclic peptide libraries. Both 
HRMS identification of the precursor ion and MS/MS were performed in a single run by passing 
all ions through the quadrupole to the collision cell for collision induced dissociation (CID). For 
traditional LC-MS/MS instrument setups, this would result in significant interference from 
impurities and system contaminants; however, here IMS filtering in this method allows for the 
production of a clean MS/MS spectra (Figure 4.3).34 Spectra were then interpreted either manually 
or in most cases via de novo sequencing software (viz., PEAKS Studio). 
To demonstrate the compatibility of our strategy with OBOC libraries, a small cyclic 
peptide library of varying amino acid composition and ring sizes ranging from 4 to 10 amino acids 
was prepared on Tenta Gel resin with Glu(OAll) as the first amino acid on the solid support. The 
library was prepared by split-and-pool synthesis using standard Fmoc/tBu solid-phase peptide 
chemistry. Following Glu(OAll), the next positions within the peptide library were filled by a 
random combination of 20 L-amino acids. Serine was added randomly within varying positions 
within the peptide sequence, and the peptide was cyclized after selective deprotection of Fmoc and 
OAllyl groups as described above. This was followed by Ser activation using DSC. After removal 
of the side-chain protecting groups, 34 beads were randomly selected and individually hydrolyzed 
under basic conditions at 65 oC on a heated shaker for 4 hrs. The resulting crude linear peptides 
were then sequenced by the LC-IMS-MS/MS method (Figure 4.4, Table 4.5).35-37 These results 
demonstrated the wide scope of the ring-opening OBOC strategy in sequencing of cyclic peptides 
of varying size and composition. 
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Table 4.5 High throughput screening of various cyclic peptides with varying ring sizes and composition on beads.  
Entry 
Cyclic Peptide  
Sequence 
MS/MS Sequence Coveragea 
Calculatedb 
[M+H]+ 
Observedb 
[M+H]+ 
Conversion 
(%)c 
1 SMRE  547.2293 547.2303 >99 
2 SAFE  478.1932 478.1918 >99 
3 STFVE  607.2722 607.2716 >99 
4 SFRVE  662.3257 662.3265 >99 
5 SYFAE  641.2566 641.2561 >99 
6 SNYAE  608.2311 608.2335 >99 
7 SYIGE  593.2566 593.2584 99 
8 SFNTE  622.2467 622.2461 >99 
9 SVRFAE  733.3628 733.3651 >99 
10 SFRYAE  797.3577 797.3595 >99 
11 SNYAAE  679.2682 679.2676 >99 
12 SYIGAE  664.2937 664.2947 99 
13 SYFVGE  726.3093 726.3115 99 
14 SKIFEG  705.3566 705.3576 >99 
15 SHVDEF  758.3104 758.3105 >99 
16 STLDEF  736.3148 736.3156 >99 
17 SRQFEA  762.3529 762.3531 99 
18 SKIFAGE  776.3937 776.3944 99 
19 SAHDVGE  739.3006 739.2987 99 
20 STYDAFE  857.3312 857.3307 >99 
21 STFKRVE  891.4683 891.4704 >99 
22 SIGFEAF  795.3672 795.3683 >99 
23 SRVDYGAE  921.4061 921.4053 >99 
24 SAVFMNAE  893.3822 893.3811 >99 
25 SKVRNYAE  496.2514
d 496.2513d 99 
26 SRYQVANE  496.2332
d 496.2330d 99 
27 SKARFGVE  459.7432
d 459.7430d 99 
28 SAQVFRFTE  1109.5374 1109.5393 99 
29 SYTFNDKLE  1141.5160 1141.5174 >99 
30 SRVKNGFEA  1032.5221 1032.5232 99 
31 SYLFDWREK  1268.6058 1268.6067 >99 
32 SGYVKDFRAE  1196.5695 1196.5672 99 
33 SAYKFGPSAE  541.2511
d 541.2519d 99 
34 SATKFESRVE  589.7937
d 589.7917d >99 
aMS/MS sequence coverage indicates observed y and b ions as right (red) and left (blue) cleavages, respectively 
bCalculated and observed [M+H]+ are for ring-opened peptides 
cReaction conditions: Conversion was determined by cleavage of the pre-treated resin under TFA cleavage 
conditions 
dDoubly charged ions, [M+2H]2    Table adopted from reference (1) with permission. 
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Another unique feature of this approach is that peptides with glutamic acid residues can also be 
selectively modified to a pyro-glutamyl amide moiety with the backbone peptide chain leading to 
the ring opening of the cyclic peptide at the N-terminus of Glu under hydrolytic conditions 
(Scheme 4.4). We synthesized and sequenced a potent p53 cyclic peptide analogue which is 
implicated in the p53/MDM2 interaction38 and contains two glutamic acid residues.  
 
 
Scheme 4.4 Rationale for the sequencing of cyclic peptides containing glutamic acid by the 
formation of pyro-glutamyl amide moiety. Reagents: DSC, DIEA, DMAP; followed by H2O: ACN 
(1:1), DIEA. Scheme adopted from reference (1) with permission. 
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4.6 CONCLUSIONS 
We developed a general one bead one compound (OBOC) method for sequencing cyclic 
peptides obtained from combinatorial libraries. Our method is compatible with both on-bead and 
solution-phase library screening. As compared to encoding tag methods, one bead two compound 
(OBTC) approaches or other one bead one compound (OBTC) methods, the major advantage of 
this method is that it is direct, without the need to tag each bead, which makes the synthesis of 
libraries of cyclic peptides easier. By excluding the encoding tag component, chances of 
interferences during the screening process are greatly reduced, if not abolished. Our method has 
high substrate scope and ring opening of cyclic peptides can be achieved at serine, threonine, 
cysteine, and glutamic acid residues, which is a significant advantage over the current OBOC 
approaches that rely either on a methionine residue or an unnatural entity. This method is 
compatible with free amino acid side chains due to the fact that they remain unmodified under 
reaction conditions.39 Furthermore, our method does not require any special residues and is stable 
to light and air thus eliminating the requirement of special handling conditions. The activated 
peptides can be stored in a desiccator for a month without any degradation. Therefore, this 
methodology can be readily applied in any chemical or biochemical laboratory.  
In addition, we utilized the higher separation power of ion mobility spectrometry paired 
with ultra-high-pressure liquid chromatography to develop a high throughput tandem MS 
sequencing method. Precursor ion selection was found to be unnecessary as interfering signals 
could be removed via ion mobility filtering, and this allowed for compound libraries to be analyzed 
in a single run. Using this method, over 1000 cyclic peptides can be sequenced in one day. 
Moreover, interpretation of the data has the capability of being automated as the spectra were 
found to be compatible with de novo sequencing software. The main attributes of our method are 
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its simplicity, facile synthesis without major side product formation, high substrate scope, and 
high-throughput capability. This robust method will better enable the search for cyclic peptides as 
novel therapeutics. 
4.7 EXPERIMENTAL SECTION 
General: All commercial materials (Sigma-Aldrich, Fluka, and Novabiochem) were used without 
further purification. All solvents were reagent or HPLC (Fisher) grade. Diethyl ether, CH2Cl2, and 
DMF were obtained from a dry solvent system (passed through column of alumina) and used 
without further drying. Conversions were obtained by comparison of HPLC peak areas of products 
and starting materials. HPLC was used to monitor reaction progress. 
Materials: Fmoc-amino acids were obtained from Novabiochem (EMD Millipore Corporation, 
Billerica, Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide resin was obtained 
from ChemPep Inc (Wellington, Florida). N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-
yl)uronium hexafluorophosphate (HBTU) was obtained from CreoSalus (Louisville, Kentucky). 
N,N′-Disuccinimidyl carbonate (DSC) was obtained from Novabiochem (EMD Millipore 
Corporation, Billerica, Massachusetts). 4-Dimethylaminopyridine (DMAP) was obtained from 
Merck KGaA (Darmstadt, Germany). N,N-Dimethylformamide (DMF) was obtained from Macron 
Fine Chemicals (Center Valley, Pennsylvania). Acetonitrile, N,N- Diisopropylethylamine (DIEA), 
and N,N'-diisopropylcarbodiimide (DIC) were purchased from Novabiochem (EMD Millipore 
Corporation, Billerica, Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill, 
Massachusetts). Trifluoroacetic acid (TFA) was purchased from VWR (100 Matsonford Road 
Radnor, Pennsylvania). Diethyl ether was obtained from Sigma-Aldrich (St. Louis, Missouri). 
Water was purified using a Millipore Milli-Q water purification system. 
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Purification: Semi-preparative chromatography was performed using a Beckman Coulter 
equipped with a System Gold 168 detector, a 125P solvent module, and a 10 mm C-18 reversed-
phase column. All separations involved a mobile phase of 0.1% formic acid (v/v) in water (solvent 
A) and 0.1% formic acid (v/v) in acetonitrile (solvent B). The semi-preparative HPLC method 
employed a linear gradient of 0–80% solvent B over 30 minutes at ambient temperature with a 
flow rate of 3.0 mL min-1. The separation was monitored by UV absorbance at both 220 and 254 
nm unless otherwise noted. 
HPLC:  
Peptide compositions were evaluated by high performance liquid chromatography (HPLC) on an 
Agilent 1200 series HPLC equipped with a 4.6x150mm (5µm) C-18 reversed-phase column. All 
separations used mobile phases of 0.1% formic acid (v/v) in water (solvent A) and 0.1% formic 
acid (v/v) in acetonitrile (solvent B). A linear gradient of 0–80% solvent B in 30 minutes at room 
temperature with a flow rate of 1.0 mL min-1 was used. The eluent was monitored by UV 
absorbance at 220 nm unless otherwise noted.  
LC-MS: 
Mass spectrometry to check reaction mixtures was performed using an Agilent 1100 Series HPLC 
with MSD VL mass spectrometer using positive polarity electrospray ionization (+ESI).  
HRMS: 
Analysis was conducted by Ryan Cohen at Merck facilities in Rahway, NJ. HRMS data were 
recorded on an Agilent 1290 UHPLC with 6560 ion mobility Q-ToF mass spectrometer using 
positive polarity electrospray ionization (+ESI). 
LC-IMS-MS/MS for sequencing peptides:  
Analysis was conducted by Ryan Cohen at Merck facilities in Rahway, NJ. An Agilent 1290 
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UHPLC and 6560 ion mobility Q-ToF mass spectrometer using positive polarity electrospray 
ionization (+ESI) were used to sequence peptides. LC-IMS-MS conditions are provided in Table 
4.6. Collision induced dissociation (CID) was used to generate MS/MS spectra using N2 as 
collision gas and energies ramped from 20 to 60 V. 
 
Table 4.6.  LC-IMS-MS conditions 
Parameter Condition 
Column Waters Acquity CSH C18, 1.7 m particle size, 50 mm x 2.1 mm I.D. 
Column temperature 50°C 
Mobile phase A 0.1% formic acid in water 
Mobile phase B Acetonitrile 
Gradient 
time (min) % A % B 
0.00 95 5 
0.65 1 99 
0.75 1 99 
0.76 95 5 
1.00 95 5 
 
Injection volume 1.0 L 
Flow rate 1.0 mL/min 
Ionization (+)ESI using Agilent’s jet stream source 
Voltages capillary = 3.5 kV, fragmentor = 175 V, nozzle = 1100 V 
Drying gas N2, 300°C, 10 L/min 
Nebulizer 45 psig 
Sheath gas N2, 275°C, 12 L/min 
Mass range m/z 150 to 3200 
IM trap fill time = 40,000 s, release time = 150 s 
Acquisition rate frames = 1/s, IM transients = 19/frame, max drift time = 50 ms 
 
Fmoc Solid-Phase Peptide Synthesis:40 Peptides were synthesized manually on a 0.25 mmol 
scale using Rink amide, Wang, Chem Matrix and TentaGel resins. Fmoc was deprotected using 
20% piperidine–DMF for 20 min to obtain a deprotected peptide-resin. Fmoc-protected amino 
acids (0.75 mmol) were sequentially coupled on the resin using HBTU (0.75 mmol) and DIEA 
(0.75 mmol) for 2 hrs at room temperature. Peptides were synthesized using standard protocols.1 
Peptides were cleaved from the resin using a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl 
silane:water for 2 hrs. The resin was removed by filtration and the resulting solution was 
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concentrated. The oily residue was triturated with diethyl ether to obtain a white suspension. The 
resulting solid was purified by semi-preparative chromatography. 
General Procedure for Cyclization of Linear Peptides on Solid Support: To a peptide 
containing Glu(Oallyl)OH amino acid on the solid support (50 mg, 0.69 mm/g) was added a 
solution of tetrakis(triphenylphosphine)palladium(0), Pd(PPh3)4 (20 mg), phenylsilane (72 µL) in 
DCM (3 mL), and the peptide was left on the shaker for 40 minutes. The resin was washed with 
10 mL DCM (3 X 2 min). The above reaction was repeated, and then the resin was washed with 
10 mL DCM (3 X 2 min), 10 mL MeOH (3 X 2 min), and 10 mL DMF (3 X 2 min). The palladium 
catalyst was removed from the resin by washing it with 10 mL DIEA (2 X 2 min), followed by 
washing with 10 mL DMF (2 X 2 min). Next, the peptide was treated with 20% piperdine/DMF to 
remove the Fmoc protecting group. Macrocyclization was achieved by exposing the resin to 50µL 
DIC, 50 mg HOAt, and a catalytic amount of DMAP in DMF per 50mg of resin on a shaker for 
15 hrs. The solution was drained, and the resin was washed with DMF. To confirm the complete 
macrocyclization, the Kaiser test was performed. Yellow bead coloration indicated absence of free 
amines, while blue coloration indicated incomplete macrocyclization. To further confirm 
formation of cyclic peptides, the resin was cleaved using a cocktail of 95:2.5:2.5 trifluoroacetic 
acid:triisopropyl silane:water (v/v/v) for 2 hrs. The resin was then removed by filtration, and the 
resulting solution was evaporated. Cyclic peptides were purified by semi-preparative 
chromatography and analyzed by MS. 
General Procedure for Serine Activation to Cyclic Urethane Moiety within Cyclic Peptides 
on Solid Support: The trityl protecting groups on serine residues were selectively removed by 
exposing the peptide on solid support to a 30% TFA in DCM 10 mL solution (3 X 5 min). Both 
serine groups (one as a linker and the other within the macrocycle) were activated on solid support 
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(25-100 mg, 0.25-0.69 mm/g) using a solution of DSC (25 equiv.), DIEA (25 equiv.), and a 
catalytic amount of DMAP in DMF on shaker for 17 hrs. The solution was drained, and the resin 
was washed with DMF, followed by peptide cleavage using a cocktail of 95:2.5:2.5 trifluoroacetic 
acid:triisopropyl silane:water (v/v/v) for 2 hrs. The resin was removed by filtration, and the 
resulting solution was concentrated.  The oily residue was triturated with diethyl ether to obtain a 
white suspension. The resulting solid was purified by semi-preparative chromatography for MS 
analysis. 
General Procedure for Dual Ring-Opening/Cleavage of Cyclic Peptides on Solid Support for 
MS/MS Sequencing: A solution of 1 mL H2O:ACN (1:1, v/v) and 40 µL of DIEA was added to 
the resin containing the activated cyclic urethane-containing macrocyclic peptide. This reaction 
was left on a heated shaker at 65 °C for 4 hrs. The resin was then filtered, followed by solvent 
removal under vacuum. The resulting ring-opened peptide acid was then sequenced by LC-IMS-
MS/MS.  
General procedure for macrocyclization in solution phase. Peptide was cleaved from the resin 
with a 20% v/v HFIP solution in DCM. The DCM was evaporated, and the linear peptide was 
purified by chromatography. Cyclization occurred with 20 mg HOAt, 20 µL DIC in dry DMF per 
2 mg of peptide.  Side chain protecting groups were then deprotected by adding a solution of 
TFA:TIPS:water (95/2.5/2.5, v/v/v) and incubating the solution for 2 hrs. The macrocyclic peptide 
was then purified by reversed-phase analytical chromatography. 
General Procedure for the activation of glutamic acid in cyclic peptide in solution phase. To 
a 5-mL round-bottom flask containing peptide 2-20mg (1 equiv.) in 0.5-2 mL dimethylformamide 
(DMF) was added a solution of DSC (15 equiv.), DIEA (15 equiv.) and crystal of DMAP in DMF 
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(0.2-0.5 mL). The mixture was stirred at room temperature for 10 hrs. The reaction was 
concentrated under vacuum and resulting peptide was dissolved in 1:1 mixture of water and 
acetonitrile and purified by HPLC.  
General Procedure for ring-opening of cyclic peptide in solution phase. To an activated cyclic 
peptide, 1 mL phosphate buffer (pH 7.4) was added. The reaction was stirred at 25 °C and 
monitored by analytical HPLC at regular intervals. The reaction mixture was lyophilized, purified 
by HPLC and isolated.  
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CHAPTER 5: FMOC SOLID PHASE SYNTHESIS OF 
PROTECTED C-TERMINAL MODIFIED PEPTIDES BY 
FORMATION OF A BACKBONE CYCLIC URETHANE MOIETY  
 
5.1 ABSTRACT 
C-terminally modified peptides are of high significance due to the therapeutic properties 
that accompany various C-terminal functional groups and the ability to manipulate them for further 
applications. In this chapter, a universal solid phase strategy for the synthesis of various C-terminal 
modified peptides is reported. The method is independent of the type of resins, linkers, and 
unnatural moieties typically needed for C-terminal modifications. The technique proceeds by the 
modification of a C-terminal serine to a cyclic urethane moiety which results in the activation of 
the backbone amide chain for the nucleophilic displacement by various nucleophiles to generate 
C-terminally modified acids, esters, N-alkyl amides, alcohols, and hydrazides. This cyclic urethane 
technique (CUT) also provides a general strategy for synthesis of C-terminal protected peptides 
which can be used for convergent synthesis of large peptides. The C-terminal protecting groups 
can be cleaved by hydrolysis to release the free peptide. 
5.2 CHAPTER OBJECTIVES 
This chapter describes a universal method for the solid phase synthesis of various C-
terminal modified peptides which is independent of the nature of resins, linkers, and unnatural 
moieties typically needed for C-terminal modifications. This strategy is highly versatile and 
generates peptides with various C-terminal end groups such as acids, esters, alcohols, hydrazides, 
and N-alkyl amides. Another unique feature of this methodology is that it provides a semi-
permanent protecting group at the C-terminus which allows for various modifications in solution; 
hydrolysis can be performed to remove the protecting group and release the free peptide post-
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modification if desired. 
C-terminal modified peptides are of high significance because of the therapeutic properties 
that accompany various C-terminal functional groups.  As a result, there is a necessity for an 
effective solid-phase synthesis approach for the preparation of peptides with various C-terminal 
functional groups. Currently, these modifications are generally attainable by using special resins 
that are appropriately designed to allow the anchoring of the peptide’s C-terminus and generate a 
specific end group at the C-terminus upon cleavage. Other methods include: use of unnatural 
linkers or handles, side-chain or backbone amide anchoring, and inverse solid-phase peptide 
synthesis. Despite their obvious attractiveness, all these methodologies have specific 
disadvantages that need to be addressed. This strategy provides a universal method that relies on 
a natural amino acid (e.g., serine), which is modified to provide a cyclic urethane moiety that 
undergoes nucleophilic displacement with various nucleophiles to generate peptides with the 
desired C-terminal end group.  
In this chapter, we describe the Cyclic Urethane Technique (CUT) that relies on the 
modification of C-terminal serine to the cyclic urethane moiety on solid support and its potential 
for detachability by various nucleophiles under mild conditions to generate C-terminal modified 
protected peptides. 
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5.3 GRAPHICAL ABSTRACT 
 
Figure 5.1 Graphical abstract for Fmoc Solid-Phase Synthesis of Protected C-terminal Modified 
Peptides by Formation of Backbone Cyclic Urethane Moiety. Figure adopted with permission 
from: Elashal, H. E.; Cohen, R. D.; Raj, M. Chem. Commun. 2016, 52, 9699.1 
5.4 INTRODUCTION 
C-terminal modified peptides such as acids and amides have been extensively used in 
chemical synthesis of proteins, semi-synthesis, catalysis, and in various therapeutic applications.2 
Other C-terminal peptide modifications of potential interest in therapeutics include esters, N-alkyl 
amides, and alcohols. These C-terminally modified peptides exhibit a wide range of biological 
activities; for instance, N-alkyl amides enhance metabolic stability and biological activity.3,4 Key 
processes of cell growth and differentiation embody ester groups at their C- terminus.5 Moreover, 
peptide alcohols, such as peptaibols are well known antibiotics and exhibit a wide range of 
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biological activities.6  
In general, C-terminal modified peptides are synthesized in solution after cleavage of 
peptides from solid support.7 For subsequent biological investigations, however, a series of peptide 
derivatives are often required, which calls for the development of flexible solid phase synthesis 
techniques. Modifications at the N-terminus of peptides can be easily achieved on a solid support 
because synthesis of peptides takes place from the C to the N terminus. On the other hand, 
modification at the C-terminus is a challenge due to its direct attachment to the solid support. 
Therefore these modifications are generally attainable by using special resins that are appropriately 
designed to allow the anchoring of the peptide’s C-terminus and generate a specific end group at 
the C-terminus upon cleavage.8 Due to the therapeutic potential of C-terminally modified peptides, 
a growing number of studies reported alternative methods such as the use of (i) special linkers 
between the peptide chain and a solid support which rely on unique oxidative conditions to activate 
the linker for attack by various nucleophiles.9 However, this approach is limited due to the 
undesirable oxidation of sensitive residues such as Cys, Met, and Trp. Other methods include (ii) 
side-chain or backbone amide anchoring approach, whereby the C-terminal carboxyl group is not 
involved as an attachment point to the resin.10 And (iii) inverse solid-phase peptide synthesis (viz., 
from N to C-terminus).11 One major drawback of this approach is potential epimerization at all 
coupling stages due to repeated resin-bound carboxyl activation. Another method is (iv) internal 
resin-capture technique which also involves the use of special linkers or handles.12-14 All of the 
reported methods require special resins, unnatural linkers, or handles for the synthesis of C-
terminally modified peptides.  
This chapter describes the discovery of a novel general strategy that circumvents the use 
of special resins, linkers, or handles and affords peptides with various types of C-terminal 
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modifications such as acids, esters, N-alkyl amides, and alcohols. Another advantage of this 
approach is that it provides a semi-permanent protection at the C-terminus of peptides after 
cleavage of the peptide from the insoluble polymer resin. The semi-permanent protecting group at 
the C-terminus of a peptide is highly desirable for further manipulation in solution, such as for the 
synthesis of large peptides.15  
5.5 RESULTS AND DISCUSSION 
This method is based on the activation of the peptide backbone amide bond. We reasoned 
that the activation of a peptide backbone amide bond by increasing its nucleofugality could render 
the C-N bond susceptible to nucleophilic attack and provide peptides with various C-terminal 
modifications depending upon the nucleophile. The backbone amide chain is activated by the 
formation of a backbone cyclic urethane moiety, which, after nucleophilic displacement, provides 
the C-terminally modified peptide (Scheme 5.1A and 5.1B). Another application of the cyclic 
urethane technique (CUT) is to generate a peptide with semi-permanent protection at the C-
terminus. Peptides with a C-terminal protecting group can potentially be used for further 
modifications in solution, followed by the removal of a protecting group under basic hydrolysis 
conditions (Scheme 5.1C).  
Synthesis of C-terminally modified peptides by this strategy entails anchoring of a C-
terminal serine residue with a selectively removable side-chain protecting group to a solid support 
(Scheme 5.1A). Upon peptide chain assembly, the serine side-chain is selectively deprotected. In 
the first key step, strong activation of the serine’s hydroxymethyl group results in the formation of 
the cyclic urethane moiety on-resin (Scheme 5.1A). Earlier attempts at the formation of the cyclic 
urethane moiety on Fmoc/Boc peptides were unsuccessful and led to the formation of 
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dehydroalanine.16 Our group recently reported the solution phase synthesis of such cyclic urethane 
moiety between the side chain of serine and the amidic nitrogen of the backbone peptide chain.17 
In the second key step, nucleophilic displacement of the cyclic urethane moiety by treatment with 
various nucleophiles releases the protected C-terminal modified peptides from the solid support, 
which are subsequently deprotected in solution (Scheme 5.1B). 
 
 
Scheme 5.1 Rationale for the development of cyclic urethane technique (CUT). (a) Methodology 
for the synthesis of cyclic urethane moiety on solid support. (b) Synthesis of C-terminally modified 
peptides by nucleophilic displacement of cyclic urethane moiety. (c) Synthesis of protected C-
terminal peptides using (CUT) and synthesis of large peptides via convergent approach followed 
by nucleophilic displacement.  Scheme adopted from reference (1) with permission. 
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This cyclic urethane moiety also acts as a semi-permanent protecting group (pg) for the C-
terminus upon cleavage of the peptide from the solid support (Scheme 5.1C). Such protection is 
of significance due to the potential use of the C-terminally protected peptides for the formation of 
large peptides via convergent synthesis approach. Finally, the protecting group (pg) at the C-
terminus can be easily removed by mild, hydrolysis conditions (Scheme 5.1C). It is noteworthy 
that special linkers or handles are not required for CUT, which is in contrast to current methods 
for synthesis of C-terminally protected peptides.15   
To implement this strategy for the synthesis of a C-terminally modified protected peptide, 
a model hexamer peptide, Ac-GPMLAS-Rink was synthesized on Rink Amide resin using the 
SPPS approach with serine(trt) as the C-terminal residue. The trityl (trt) group from serine was 
selectively removed with TFA/DCM (1:3) to generate peptide A (Scheme 5.2). This was followed 
by activation of serine’s hydroxymethyl group with N,N’-disuccinimidyl carbonate (DSC) to 
generate activated intermediate B.17  
 
Scheme 5.2 Synthesis of peptide acid by using CUT. Scheme adopted from reference (1) with 
permission. 
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Next, intramolecular nucleophilic attack of the amidic nitrogen of the peptide backbone on 
the activated intermediate B generated a five-membered cyclic urethane ring Ac-GPMLAOxd 1a 
(Scheme 5.2). After formation of the cyclic urethane moiety 1a, nucleophilic release of the 
protected peptide acid 2a from the solid support was achieved by carrying out hydrolysis under 
basic conditions (Scheme 5.2). The solvent was then removed, and the protected peptide acid 2a 
was analyzed by HPLC and LCMS (Scheme 5.2). Initially, hydrolysis was carried out at ambient 
temperature but longer reaction time (> 24hrs) was required to fully release peptide acid 2a from 
the resin (entry 1, Table 5.1). To achieve maximum conversion, reaction conditions such as time, 
solvent, and temperature were optimized (Table 5.1). For the complete liberation of peptide acid 
2a from the solid support, DMF was used as a co-solvent with water due to beneficial resin 
swelling in DMF (entries 3-5, Table 5.1).  
Table 5.1 Optimization of Reaction Conditions for Synthesis of Protected Peptide Acids.a 
 
Entry pg Solvent Temp 
(°C) 
Time        
(h) 
Conv    
(%)b 
1 Ac H2O RT 15 30 
2 Ac H2O 50 15 45 
3 Ac H2O: DMF 
(4:1) 
50 15 77 
4 Ac H2O: DMF 
(1:1) 
50 15 99 
5 Ac H2O: DMF 
(1:1) 
65 4 59 
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6 Ac H2O: ACN 
(1:1) 
65 2 99 
7 NH2 H2O: ACN 
(1:1) 
65 2 99 
8c Fmoc H2O: ACN 
(1:1) 
65 2 99 
aReaction conditions: Peptide (25 mg, 0.7 mm/g) on solid support was reacted with DSC (100 mg), 
DIEA (70 uL) and a crystal of DMAP in DMF at room temperature followed by hydrolysis. 
bConversion to 2a was calculated from the absorbance at 220 nm using HPLC. The entry in bold 
represents the optimized reaction conditions for hydrolysis. cMixture of completely protected 
peptide and Fmoc deprotected peptide was observed. DIEA = Diisopylethylamine, DMAP = 4-
(N,N-dimethylamino)- pyridine. Table adopted from reference (1) with permission. 
To decrease the release time of peptide acid 2a, hydrolysis was performed on a heated 
shaker at temperatures ranging from RT to 65 ºC (entries 1-5, Table 5.1). Since it is difficult to 
remove DMF from the cleaved peptide, a more volatile solvent such as acetonitrile was preferred 
(entries 6-8, Table 5.1). 
The extent of epimerization from formation of the cyclic urethane moiety and nucleophilic 
displacement was investigated. Diastereomer, Ac-GPML-(D)-A-OH (D2a), was synthesized using 
the optimized conditions (entry 6, Table 5.1), and peptide acids 2a and D2a’ were subsequently 
analyzed by HPLC (Figure 5.2). No detectable levels of epimerization were observed. 
To evaluate the compatibility of all the amino acids and various protecting groups towards 
serine’s activation as a cyclic urethane moiety and its nucleophilic displacement, various peptides 
with different sequences and protecting groups were synthesized and screened under the reaction 
conditions (Table 5.2). 
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Figure 5.2 (a) HPLC trace of purified peptide acid 2a Ac-GPML-(L)-A-OH (b) HPLC trace of 
purified peptide acid diastereoisomer D2a’ Ac-GPML-(D)-A-OH  (c) HPLC trace of mixture 
containing both diastereoisomers 2a and D2a’. Figure adopted from reference (1) with permission. 
The results indicate that all the peptides underwent smooth activation to generate activated 
peptides 1b-1k followed by hydrolysis to corresponding protected peptide acids 2b-2k with 
varying HPLC conversions ranging from 70% to greater than 99% (entries 1-8, Table 5.2). To 
determine the effect of the bulky neighboring residue on serine’s activation and nucleophilic 
peptide release, the hexapeptides, FESQIS-Rink (1e), and TCDVS-Rink (1k) were synthesized. 
The results indicate that the activated peptides 1e and 1k with bulky amino acids (Ile and Val) 
adjacent to serine underwent complete conversion to peptide acids 2e and 2k (entries 4 and 10, 
Table 5.2). The reaction with peptide, FESQIS-Rink 1e, also showed that the technique was 
applicable to peptides with multiple serine residues by selective activation and displacement of 
serine at the C-terminus (entry 4, Table 5.2). 
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Table 5.2 Substrate scope of CUT in synthesis of peptide acids.a 
 
Entry Substrate Peptide 
 
PG 
 
Conv (%)b 
1 1b LFK(Boc)N(Trt)A Ac 95 
2 1c LFK(Boc)N(Trt)A NH2 95 
3c 1d LFK(Boc)N(Trt)A Fmoc 80 
4 1e FE(tBu)S(tBu)Q(Trt)I NH2 90 
5 1f R(Pbf)D(tBu)PMLG Ac 95 
6 1g R(Pbf)D(tBu)PMLG NH2 90 
7 1h Y(tBu)LFK(Boc)N(Trt)A Ac 95 
8 1i Y(tBu)LFK(Boc)N(Trt)A NH2 90 
9 1j VWR(Pbf)A Ac 90 
10 1k T(tBu)C(tBu)D(tBu)V Ac 90 
aReaction conditions: Peptide 1 (25 mg, 0.7 mmol/g) on solid support was reacted with DSC (100 
mg), DIEA (70 uL) and a crystal of DMAP in DMF at room temperature followed by hydrolysis 
with H2O:ACN in DIEA (20 uL) at 65 °C for 2-4 hrs. 
bConversion to peptide acid  was calculated 
from the absorbance at 220 nm using HPLC. cMixture of completely protected peptide and Fmoc 
deprotected peptide was observed. Table adopted from reference (1) with permission. 
 
Next, to demonstrate that the cyclic urethane technique (CUT) is resin independent, model 
pentapeptide, WVRAS was synthesized on Rink Amide, Wang, Chem Matrix, and Tentagel resins. 
The results indicate that both the activation of serine and nucleophilic displacement gave high 
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yields of the protected peptide acid independent of the type of resin, which is in contrast to other 
methods.8  
Protected peptide acids have been extensively useful for the synthesis of macrocyclic 
peptides of therapeutic importance.18 To demonstrate the application of CUT in the synthesis of 
macrocyclic peptides, AKDPYRGS-Rink AM was synthesized on solid support, followed by 
serine selective deprotection, activation 3a, and cleavage with water to obtain the protected linear 
peptide acid AK(Boc)D(tBu)PY(tBu)R(Pbf)G-OH 3b (Scheme 5.3). Next, the protected peptide 
acid 3b was subjected to coupling reagents to obtain the desired head to tail macrocyclized 
protected peptide cyc(AK(Boc)D(tBu)PY(tBu)R(Pbf)G) 3c. This was followed by removal of the 
side-chain protecting groups of the macrocyclic peptide using the TFA cocktail to generate the 
deprotected macrocyclic peptide cyc(AKDPYRG) 3d which was analyzed by NMR, HPLC, and 
MS (Scheme 5.3). In comparison, peptide acid AKDPYRG-OH generated by using Wang resin19 
gave an undesired double cyclized product. Double cyclization can arise from side-chain to head 
or side-chain to side-chain reactions (Scheme 5.4). 
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Scheme 5.3 Application of CUT in synthesis of macrocyclic peptide 3d. Pg = protecting group. 
Scheme adopted from reference (1) with permission. 
 
Scheme 5.4 Various possibilities for macrocyclization using an unprotected peptide. Scheme 
adopted from reference (1) with permission. 
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Next, we applied CUT for the synthesis of protected peptides with various C-terminal 
modifications such as esters, amides and alcohols (Scheme 5.5). To obtain the desired C-terminally 
modified peptide, the corresponding nucleophile was added to a solid support with the cyclic 
urethane moiety at the C-terminus (Scheme 5.5). The cyclic urethane moiety underwent 
nucleophilic displacement and generated the C-terminally modified protected peptide in solution. 
The peptide methyl ester, AVGPPGVA-OMe 5 was obtained by treatment of activated peptide 4 
with methanol in the presence of a base (a, Scheme 5.5). These peptide methyl esters play a 
significant role in key processes of cell growth and differentiation.5 This technique was also 
utilized for the synthesis of peptide methyl ester PFFFOMe 5’ (Scheme 5.6). Synthesis of these 
peptide methyl esters has previously been reported in solution-phase, which is a tedious process 
and requires purification at each step with the constant risk of epimerization.20 It has been shown 
that the presence of a methyl ester group is critical for the catalytic activity of the peptide 5’.20  
 
Scheme 5.5 CUT for synthesis of peptide amides, esters and alcohols. peptide = X-AVGPPGVA-
Oxd, 4. X = NH2 or Ac. Scheme adopted from reference (1) with permission. 
Next, benzylamine was used as a nucleophile on the cyclic urethane moiety to obtain 
peptide an N-alkyl amide peptide 6, an important class of biologically active peptides (b, Scheme 
5.4). The presence of an alkyl amine group at the C-terminus enhances its biological activity, 
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metabolic stability, and hydrophobicity.3,4 This technique was also applied for synthesis of 
peptides with a C-terminal alcohol functionality. Such peptides occur in nature among these, 
peptaibols are well-known antibiotic peptides that exhibit a wide range of biological activity.6 To 
obtain an alcohol group at the C-terminus 7, the cyclic urethane containing activated peptide 4 was 
treated with a solution of sodium borohydride in THF (c, Scheme 5.4). 
 
Scheme 5.6 Application of CUT in synthesis of a catalyst 5’ for aldol reaction. Scheme adopted 
from reference (1) with permission.  
           Moreover, this methodology was implemented in the synthesis of hydrazides. The critical 
importance of a peptide hydrazide is to synthesize complex proteins and bioconjugates; therefore, 
it is an added advantage that the cyclic urethane moiety is capable of providing long peptide 
hydrazides with diverse functional groups that can be utilized directly in NCL. A multi-serine 
containing bioactive peptide hydrazide S(tBu)GIS(tBu)GPLS(tBu)-CONHNH2 3k, a fragment of 
antimicrobial bovine β-defensin 13, was successfully synthesized from the corresponding cyclic 
urethane activated peptide S(tBu)GIS(tBu)GPLS(tBu)-Oxd 2k  by treatment of the peptide with 
hydrazine monohydrate under basic conditions using a heated shaker at 65 °C for 2 h in acetonitrile 
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as a solvent for optimal release (Figure 5.3). 
 
Figure 5.3 Activated serine for the synthesis of the fragment of antimicrobial bovine β-defensin 
13 bioactive peptide hydrazide 3k. (a) HPLC trace of pure bioactive peptide hydrazide 
S(tBu)GIS(tBu)GPLS(tBu)-CONHNH2 3k and inset shows MS of protected peptide hydrazide 3k. 
  
           Given the importance of peptide hydrazides in protein chemical synthesis, we envisioned 
the application of this methodology in an efficient one-pot strategy, comprising solid-phase 
synthesis, hydrazinolysis, and the direct ligation of crude peptide hydrazides to cysteine-containing 
peptide (Figure 5.4). Peptide hydrazide Ac-GPMLA-CONHNH2 3l was cleanly released from Ac-
GPMLA-Oxd 2l by treatment with hydrazine monohydrate and DIEA in acetonitrile at 65 °C for 
2 h and ligated with a cysteine containing peptide CRFAS-NH2. 
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Figure 5.4 Native Chemical Ligation of peptide hydrazide Ac-GPMLA-CONHNH2 3l with N-
terminal cysteine peptide CRFAS-NH2. HPLC/MS traces of peptide hydrazide 3l and ligated 
product 4.  
The main advantage of the described approach is that the elongation of the peptide chain 
can be carried out by means of standard techniques after attachment of the first amino acid as 
serine. Another significant advantage of this approach is that only those resin-bound peptides that 
complete both activation and displacement steps are released. Thus, the released C-terminally 
modified peptides exhibit high purity, eliminating the need for extensive purification. 
Next, we demonstrated the application of CUT for synthesis of peptides with a semi-
permanent protecting group (pg) at the C-terminus (Scheme 5.7). This is of significance because 
C-terminally protected peptides can be used for various manipulations in solution. This technique 
is in contrast to the current methods that require reprotection of the C-terminal carboxyl group in 
solution, with a consequent risk of racemization and low yields.21 Another method for synthesis of 
peptides with a semi-permanent protecting group at the C-terminus utilizes click chemistry based 
handles but is limited by the use of special linkers and the requirement of harsh deprotection 
conditions.21 Our method does not require any special linkers or handles and it employs mild 
deprotection conditions for removal of pg at the C-terminus. 
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For the synthesis of peptides with a semi-permanent C-terminus pg, activated peptide 
Fmoc-AR(Pbf)FPPFR(Pbf)AOxd 4 on a solid support was cleaved from the resin by using the 
TFA cleavage cocktail to generate peptide Fmoc-ARFPPFRAOxd 8 with protection at the C-
terminus (Scheme 5.7). The C-terminally protected peptide Fmoc-ARFPPFRAOxd 8 can be used 
for the synthesis of large peptides by a convergent approach. Subsequently, the protecting group 
at the C-terminus of the resulting large peptide can be easily removed under basic hydrolysis 
conditions as shown above. 
 
 
 
 
Scheme 5.7 (a) CUT technique for synthesis of protected C-terminus peptide 8. (b) HPLC and MS 
chromatogram of C-terminal protected peptide Fmoc-ARFPPFRA-Oxd, 8. peptide = Fmoc-
ARFPPFRA. Scheme adopted from reference (1) with permission. 
5.6 CONCLUSIONS 
A backbone amide activation approach has been developed for the synthesis of C-
terminally modified peptides of therapeutic importance such as acids, amides, esters, N-alkyl 
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amides, alcohols, and hydrazides. This approach is resin and linker independent thus 
circumventing limitations associated with earlier methods. The main advantage of the described 
approach is that the elongation of the peptide chain can be carried out by means of standard 
methodologies after attachment of the first amino acid residue as serine. After construction of the 
peptide, the backbone chain is activated as a cyclic urethane moiety and cleavage is carried out 
under mild nucleophilic displacement conditions that allow easy formation of the desired C-
terminally modified peptide. The target peptides are released from the resin without racemization. 
This cyclic urethane technique (CUT) has also been applied to the synthesis of peptides with the 
protected C-terminus, which can undergo various modifications in solution after release from solid 
support (e.g., large peptides synthesis by a convergent strategy). Moreover, the C-terminal 
protecting group can be easily removed under mild basic hydrolytic conditions. A universal solid 
phase strategy has been effectively developed and applied for the synthesis of various C-terminal 
modified peptides, which are of therapeutic importance due to biological properties that 
accompany the attachment of various C-terminal functional groups. 
5.7 EXPERIMENTAL SECTION 
General: All commercial materials (Aldrich, Fluka, Nova) were used without further purification. 
All solvents were reagent grade or HPLC grade (Fisher). Anhydrous THF, diethyl ether, CH2Cl2, 
and DMF were obtained from a dry solvent system (passed through column of alumina) and used 
without further drying. Conversion were obtained by comparison of HPLC peak areas of products 
and starting material.  
Materials: Fmoc-amino acids were obtained from Nova Biochem (EMD Millipore Corporation) 
(Billerica, Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide resin was obtained 
from ChemPep Inc (Wellington, Florida). N,N,N′,N′-Tetramethyl-O (1H benzotriazol-1-
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yl)uronium hexafluorophosphate (HBTU) was obtained from CreoSalus (Louisville, Kentucky). 
N,N-Disuccinimidyl carbonate (DSC) was obtained from Nova Biochem, under (EMD Millipore 
Corporation) (Billerica, Massachusetts). 4-Dimethylaminopyridine (DMAP): Merck KGaA 
(Darmstadt, Germany). N,N-Dimethylformamide (DMF): Macron Fine Chemicals (Center Valley, 
Pennsylvania). Dichloroethane (DCE), acetonitrile, N,N- Diisopropylethylamine (DIEA), N,N' 
diisopropylcarbodiimide (DIC), were purchased from (EMD Millipore Corporation)(Billerica, 
Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill, Massachusetts). 
Trifluoroacetic acid (TFA) was purchased from VWR 100 Matsonford Road Radnor, PA. Diethyl 
Ether: Sigma Aldrich (St. Louis, Missouri). Water was purified using a Millipore MilliQ water 
purification system. 
 
NMR: 
This was done by Ryan Cohen at Merck facilities at Rayway, NJ. NMR spectra were recorded 
on a 600 MHz spectrometer and carbon NMR spectra on a 151 MHz, spectrometer at ambient 
temperature. All NMR chemical shifts () are referenced in ppm relative to residual solvent or 
internal tetramethylsilane. 1H NMR chemical shifts referenced to residual DMSO-d5 at 2.50 ppm, 
and 13C NMR chemical shifts referenced to DMSO-d6 at 39.52ppm. Carbon NMR spectra are 
proton decoupled. NMR spectral data are reported as chemical shift (multiplicity, coupling 
constants (J), integration). Multiplicity is reported as follows: singlet (s), broad singlet (bs), 
doublet (d), doublet of doubles (dd), doublet of triplet (td), triplet (t) and multiplet (m). Coupling 
constant (J) in Hertz (Hz). 
HPLC 
Semi-Preparative HPLC: 
Preparative HPLC chromatography (HPLC) was performed on Beckman Coulter equipped with 
System Gold 168 detector and 125P solvent module HPLC with a 10 mm C-18 reversed-phase 
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column. All separations involved a mobile phase of 0.1% FA (v/v) in water (solvent A) and 0.1% 
FA (v/v) in acetonitrile (solvent B). Semi-preparative HPLC method using a linear gradient of 0– 
80% acetonitrile in 0.1% aqueous FA over 30 min at room temperature with a flow rate of 3.0 
mL min-1. The eluent was monitored by absorbance at 220 nm and 254 nm unless otherwise 
noted. 
Analytical HPLC: 
Analytical HPLC chromatography (HPLC) was performed on an Agilent 1200 series HPLC 
equipped with a 4.6x 150 mm (5µm) C-18 reversed-phase column. All separations involved mobile 
phase of 0.1% FA (v/v) in water (solvent A) and 0.1% FA (v/v) in acetonitrile (solvent B). Peptide 
compositions were evaluated by analytical reverse phase HPLC using a gradient of 0.1% FA in 
acetonitrile versus 0.1% FA in water. Analytical HPLC method using a linear gradient of 0–80% 
0.1% FA (v/v) acetonitrile in 0.1% aqueous FA over 30 min at room temperature with a flow rate 
of 1.0 mL min-1. The eluent was monitored by absorbance at 254 nm unless otherwise noted. 
LCMS: 
Mass spectrometry was performed using ultra high-performance liquid chromatography-mass 
spectrometry using the Agilent 1100 Series LCMSD VL MS Spectrometer. 
 
HRMS: 
This was done by Ryan Cohen at Merck facilities at Rayway, NJ. HRMS data were recorded 
on an Agilent 6520 Q-ToF mass spectrometer using positive polarity 
electrospray ionization (+ESI). 
 
Fmoc Solid-Phase Peptide Synthesis.22 Peptides were synthesized manually on a 0.25 mmol 
scale using Rink amide, Wang, Chem Matrix and TentaGel resins. Fmoc–group was deprotected 
using 20% piperidine–DMF for 20 min to obtain a deprotected peptide-resin. Fmoc-protected 
amino acids (1.25 mmol) were sequentially coupled on the resin using a HBTU (1.25 mmol) and 
DIEA (1.25 mmol) for 2 hrs at room temperature. Peptides were synthesized using standard 
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protocols.22 The peptide was cleaved from the resin using a cocktail of 95:2.5:2.5, trifluoroacetic 
acid:triisopropyl silane:water for 2 hrs. The resin was removed by filtration and the resulting 
solution was concentrated. The oily residue was triturated with diethyl ether to obtain a white 
suspension. The resulting solid was purified by HPLC. 
General procedure for the activation of serine to cyclic urethane moiety on solid support: 
To a peptide on the solid support (25-100 mg (0.25-0.69 mmol/g) was added a solution of DSC 
(15 equiv.), DIEA (15 equiv.) and catalytic amount of DMAP in dimethylformamide (DMF). The 
resin was left on shaker for 17 hrs. The solution was drained and resin was washed with DMF 
followed by cleavage using a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl silane:water 
for 2 hrs. The resin was removed by filtration and the resulting solution was concentrated. The 
oily residue was triturated with diethyl ether to obtain a white suspension. The resulting solid 
was purified by HPLC for analysis by MS and NMR. 
General procedure for the synthesis of peptide acids from solid support: To an activated 
peptide as cyclic urethane moiety on the solid support, 1 mL H2O:ACN (1:1) and 20 µL of DIEA 
was added and resin was left on the heated shaker at 65 °C for 2 hrs. The resin was filtered which 
is followed by the removal of solvent under high vacuum. The resulting peptide acid was 
analyzed by MS and purified by HPLC to obtain white solid. HPLC: 0.1% FA (v/v) in water 
(solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-80 %, 0.1% FA (v/v) acetonitrile 
in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 nm. 
 
General procedure for the synthesis of peptide esters from solid support: To an activated 
peptide as cyclic urethane moiety on the solid support, 1 mL MeOH and 100 µL of DIEA was 
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added and resin was left on the heated shaker at 65 °C for 4 hrs. The resin was filtered which is 
followed by the removal of solvent under high vacuum. The resulting peptide ester was analyzed 
by MS and purified by HPLC to obtain white solid. HPLC: 0.1% FA (v/v) in water (solvent A): 
0.1% FA (v/v) acetonitrile (solvent B); gradient 0-80 %, 0.1% FA (v/v) acetonitrile in 25 min, 
flow rate = 1.0 mL/min, detection wavelength 220 nm. 
 
General procedure for the synthesis of peptide N-aryl amide from solid support: To an 
activated peptide as cyclic urethane moiety on the solid support, 1 mL ACN and 100 µL of 
benzyl amine was added and resin was left on the heated shaker at 65 °C for 4 hrs. The resin was 
filtered which is followed by the removal of solvent under high vacuum. The resulting peptide 
N-aryl amide was analyzed by MS and purified by HPLC to obtain white solid. HPLC: 0.1% FA 
(v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-80 %, 0.1% FA 
(v/v) acetonitrile in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 nm. 
 
General procedure for the synthesis of peptide alcohol from solid support: To an activated 
peptide as a cyclic urethane moiety on the solid support, 100 mg sodium borohydride in 1 mL THF 
was added and resin was left on the shaker overnight at room temperature. The resin was filtered 
which is followed by the removal of solvent under high vacuum. The resulting peptide alcohol was 
analyzed by MS and purified by HPLC to obtain white solid. HPLC: 0.1% FA (v/v) in water 
(solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-80 %, 0.1% FA (v/v) acetonitrile 
in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 nm. 
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General procedure for the synthesis of peptide hydrazides from solid support: To an activated 
peptide as a cyclic urethane moiety on the solid support, 20 µL hydrazine monohydrate in 1mL 
acetonitrile was added to 25 mg of resin and left on the shaker for 2 hrs at 65ºC. The resin was 
filtered which is followed by the removal of solvent under high vacuum. The resulting peptide 
hydrazide was analyzed by MS and purified by HPLC to obtain white solid. HPLC: 0.1% FA (v/v) 
in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-80 %, 0.1% FA (v/v) 
acetonitrile in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 nm. 
Deprotection of protecting groups from C-terminal modified peptides: C-terminally modified 
peptides were deprotected by using a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl 
silane:water for 2 hrs in solution and the resulting solution was concentrated. The oily residue was 
triturated with diethyl ether to obtain a white suspension. The resulting solid was purified by HPLC 
and analyzed by MS. 
General procedure for the synthesis of protected C-terminal peptides: To an activated peptide 
as cyclic urethane moiety on the solid support, cleavage cocktail of 95:2.5:2.5, trifluoroacetic 
acid:triisopropyl silane:water was added and left on shaker for 2 hrs. Resulting solution was 
concentrated and oily residue was triturated with diethyl ether to obtain a white suspension. The 
resulting protected C-terminal peptide was purified by HPLC and analyzed by MS. HPLC: 0.1% 
FA (v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-80 %, 0.1% FA 
(v/v) acetonitrile in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 nm. 
 
Procedure for Native Chemical Ligation: Peptide hydrazide Ac-GPMLA-CONHNH2 was 
cleanly released from Ac-GPMLA-Oxd by treatment with hydrazine monohydrate and DIEA in 
acetonitrile at 65 °C for 2 hrs. After the filtration of the resin and removal of acetonitrile by a 
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stream of nitrogen, an aqueous phosphate (0.2 M) buffer containing 6.0 M guanidinum chloride 
followed by addition of cysteine containing peptide CRFAS-NH2 was added (final peptide 
concentration of 1.5 and 2.0 mM, respectively). At low pH (3.0) and temperature (−10 °C), an 
aqueous NaNO2 solution was added to the ligation mixture. After 20 min, 4-mercaptophenylacetic 
acid (MPAA) was added, the pH value was adjusted to 7.0, and the reaction was left at room 
temperature for 16 hrs. The formation of the ligation product Ac-GPMLACRFAS-NH2 was 
analyzed by injecting the sample in the HPLC and MS after regular intervals of time. 
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 CHAPTER 6: SERINE PROMOTED SYNTHESIS OF PEPTIDE 
THIOESTER-PRECURSOR ON SOLID SUPPORT FOR NATIVE 
CHEMICAL LIGATION 
 
6.1 ABSTRACT 
Fmoc solid phase peptide synthesis of thioesters for the chemical synthesis of proteins via 
native chemical ligation is a challenge. We have developed a versatile approach for the direct 
synthesis of peptide thioesters from a solid support utilizing Fmoc chemistry. Peptide thioester 
synthesis is performed by the formation of a cyclic urethane moiety via a selective reaction of the 
backbone amide chain with the side group of serine. The activated cyclic urethane moiety 
undergoes displacement by a thiol to generate the thioester directly from the solid support. 
Importantly, the method activates the serine residue for the synthesis of peptide thioesters; it is 
fully automated and free of the types of resins, linkers, handles, and unnatural amino acids typically 
needed for the synthesis of peptide thioesters using Fmoc chemistry. The resulting thioester is free 
of epimerization and is successfully applied for the synthesis of longer peptides using NCL. 
6.2 CHAPTER OBJECTIVES 
This chapter describes a simple and versatile approach for the Fmoc solid phase synthesis 
of peptide thioesters for chemical synthesis of proteins by native chemical ligation (NCL). A novel 
methodology for the activation of serine to generate peptide thioesters from solid support was 
developed and resulting peptide thioesters can be directly used in NCL to yield the desired protein 
without further modifications.  
Fmoc SPPS of peptide thioesters are of high significance because they are precursors for 
convergent synthesis of proteins via NCL.  As a result, there is a great necessity for an effective 
Fmoc solid-phase approach for the preparation of peptide thioesters. Currently, peptide thioesters 
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are synthesized by the use of sulfonamide safety catch linkers, O/N to S acyl shift methods, an 
activated N-acylurea linker, a backbone pyro-glutamyl imide linker, and peptide hydrazides. 
Despite these significant advances, current approaches for the synthesis of peptide thioesters are 
limited by a ‘slow rate’ of ligation, the requirement of acidic conditions, formation of various side 
products, and the need for unnatural linkers at the C-terminus. Our strategy provides a novel way 
for the modification of serine on a solid support which acts as a thioester surrogate. The modified 
serine as a thioester surrogate undergoes nucleophilic displacement with a thiol to generate a 
peptide thioester directly from the solid support.  The technique relies on reactivity of the side 
chain of serine for the acylation of backbone amide chain to generate the cyclic urethane moiety 
on solid support. The cyclic urethane moiety has a potential to act as a thioester surrogate to 
generate peptide thioesters directly from a solid support and post synthetic steps prior to NCL are 
not required.  
6.3 GRAPHICAL ABSTRACT 
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Figure 6.1 Graphical abstract for Serine Promoted Synthesis of Peptide Thioester-Precursor on 
Solid Support for Native Chemical Ligation. Figure adopted with permission from: Elashal, H.; 
Sim, Y. E.; Raj, M. Chem. Sci. 2017, 8, 117.1 
 
6.4 INTRODUCTION 
Total chemical synthesis of proteins provides easy access to various modified proteins with 
high stability and improved biological activity which can be key in understanding the importance 
of various post translational modifications.2,3 Native Chemical Ligation (NCL) has revolutionized 
the field of chemical synthesis of proteins and relies on the reaction of a peptide thioester with a 
cysteinyl peptide.4 Thus, considerable effort has been applied for synthesis of peptide thioesters 
using Fmoc or Boc solid- phase peptide synthesis (SPPS) approach.  
The common method for generation of peptide thioesters by Boc-based SPPS utilizes 
special thioester linkers but Boc chemistry is limited by the use of harsh cleavage conditions, 
usually hydrofluoric acid (HF), thus is not suitable for synthesis of post-translationally modified 
peptides such as glyco- or phospho-peptides.5 Fmoc SPPS is not applicable on thioester resins 
because of the instability of the peptide thioesters towards the piperidine treatment used for the 
deprotection of Fmoc group. Substantial efforts have been utilized for the synthesis of peptide 
thioesters by Fmoc SPPS approach such as use of less basic Fmoc deprotection protocol,6 use of 
sulfonamide safety catch linkers,7 activation of protected peptides in solution,8 O/N to S acyl shift 
methods,9-15 and peptide hydrazides.16-18 Activation of protected peptides in solution for synthesis 
of thioesters is limited by the susceptibility of the C-terminal residue to racemization. Despite the 
significant advances of O/N to S acyl shift methods, they are limited by slow ligation kinetics,14 
and peptide hydrazides require acidic conditions,14 which is unsuitable for synthesis of acid 
sensitive post translationally modified peptides. 
135 
 
Another significant approach for the formation of a thioester is the activation of a relatively 
inert backbone amide bond followed by subsequent thiolysis. Examples include, an activated N-
acylurea linker,19,20 a backbone pyro-glutamyl imide linker.21 An activated N-acylurea approach 
has been extensively used for synthesis of variety of proteins19,20 but is limited by the use of an 
unnatural amino acid, formation of various side products,22,23 and requirement of additional steps 
for the synthesis of N-methylated unnatural amino acid. Whereas, a backbone pyro-glutamyl imide 
linker is limited by the instability of the resin.21 Thus, an efficient and versatile route to peptide 
thioesters via Fmoc-SPPS is highly desirable.  
This chapter describes an approach for the Fmoc synthesis of peptide thioesters for use in 
NCL that is based on the activation of the amide backbone chain at a serine residue.  The 
significance of this approach is that it utilizes a natural serine residue that can be automatically 
assembled onto the solid support and does not require special unnatural amino acids and loading 
procedures, which makes it distinct from the currently used methods.19,20 We believe that this 
accessible and robust Fmoc-based thioesterication technique provides a significant advance to 
chemical protein synthesis due to its uncomplicated nature, therefore eliminating special 
precautions and additional steps typically needed for the synthesis of peptide thioesters.19,20 
This approach relies on the site-selective activation of a backbone amide bond at the C-
terminal serine residue for the generation of a cyclic urethane moiety on the solid support. 
Synthesis of peptide thioesters by this strategy entails anchoring of a C-terminal serine residue 
with a selectively removable side-chain protecting group to a solid support (Scheme 6.1). Next, 
the side-chain of serine is selectively deprotected and activated by an electrophile that results in 
the formation of a cyclic urethane moiety on resin (Scheme 6.1). Next, nucleophilic displacement 
of the cyclic urethane moiety by treatment with a thiol releases the peptide thioester from the solid 
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support, which can then be deprotected in the solution (Scheme 6.1). It is noteworthy that this 
approach utilizes a natural serine during chain assembly followed by acylation of the backbone 
amide chain and is compatible with various amino acids and protecting groups commonly utilized 
in Fmoc solid phase peptide synthesis. Moreover, the thioester is directly obtained from the solid 
support thus reduces the need for extra steps before proceeding with NCL. 
 
Scheme 6.1 Rationale for the development of cyclic urethane technique (CUT) for the synthesis 
of peptide thioesters and its application in native chemical ligation for chemical synthesis of 
proteins. Scheme adopted from reference (1) with permission. 
6.5 RESULTS AND DISCUSSION 
To test the proposed methodology for the synthesis of thioesters, the first step was the 
synthesis of the cyclic urethane moiety from a serine residue on the solid support. The serine 
activation reaction was explored on a solid support with the peptide Fmoc-Gly-Xaa-Ser-Phe-Ala-
Gly, where various amino acids were substituted in the Xaa position.(Table 6.1) It is noteworthy 
that the formation of the activated cyclic urethane moiety is independent of the nature of the amino 
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acid preceding serine and a high conversion to cyclic urethane moiety was obtained even with 
bulky amino acid residues next to serine such as Tyr, Trp, and Val  (Table 6.1, substrates 1e’-1g’). 
Moreover, activation of serine does not depend upon the relative position of serine and the resin. 
Table 6.1 Substrate scope of Ser Cyclization on Fmoc-Gly-Xaa-Ser-Phe-Ala-Gly 
 
Table 6.1 adopted from reference (1) with permission. 
The stability of the cyclic urethane moiety on the resin bound peptide was evaluated. The 
resin bound cyclic urethane moiety is very stable in a desiccator for longer than a month, which is 
in contrast to previously reported pyroglutamyl imide precursor method.21 Moreover, formation of 
the cyclo-urethane moiety on the peptide Fmoc-GFA(L)Oxd (2f) and the corresponding 
diastereoisomer Fmoc-GFA(D)Oxd (2f’) showed no sign of epimerization when analyzed by 
HPLC (Figure 6.2). 
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Figure 6.2 HPLC traces of (a) purified peptide with cyclic urethane moiety 2f Fmoc-GFA(L)-Oxd 
(b) purified peptide diastereoisomer 2f’ Fmoc-GFA(D)-Oxd and (c) mixture containing both 
diastereoisomers of cyclic urethane activated peptides 2f and 2f’, demonstrating lack of detectable 
epimerization. Figure adopted from reference (1) with permission. 
After activating the peptide backbone as a cyclic urethane moiety on model peptide Ac-
GPMLA-Oxd-Rink AM (2g) on solid support, the thiolysis reaction was performed (Table 6.2). 
The resin was treated with varying amounts of thiol/base mixtures and solvents at different 
temperatures, in order to release the peptide into solution as a peptide thioester Ac-GPMLA-COSR 
3g. The resin was then filtered and solvent was evaporated to obtain peptide thioester 3g which 
was analyzed by HPLC, MS and NMR. 
Table 6.2 Synthesis of peptide thioester 3g/3G from activated peptide Ac-GPMLA-Oxd-Rink AM 
2g on solid support.a 
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Entry Base  (equiv.) Solvent 
Temp. 
(°C) 
Time 
(h) 
Conv. (%)b       
3g        3G 
1 - DMF RT 20 10 15 
2 
DBU                   
(5 equiv.) 
DMF RT 20 40 c 60 
3 
DIEA                
(20 equiv.) 
DMF RT 20 60 c 65 
4 
PhSNa           
(0.5 equiv.) 
DMF RT 20 85 c 99 
5 
PhSNa            
(0.5 equiv.) 
ACN RT 20 10 c 20 
6 
PhSNa            
(0.5 equiv.) 
DMF RT 5 30 35 
7 
PhSNa            
(0.5 equiv.) 
DMF HS, 60 °C 20 10 c 70 c 
8 
PhSNa            
(0.5 equiv.) 
DMF HS, 60 °C 5 30 c 99 
9 
PhSNa            
(0.5 equiv.) 
DMF HS, 60 °C 3 50 c 99 
aReaction conditions: Cyclic urethane activated peptide  Ac-GPMLA-Oxd, 2g (25 mg, 0.7 mmol/g) 
on solid support was reacted with thiol (100 µL), and base (0.5-20 equiv.), in DMF (1 mL). 
bConversion to peptide thioester Ac-GPMLA-COSR 3g or Ac-GPMLA-COSR 3G was calculated 
from the absorbance at 220 nm using HPLC. cActivated peptide was completely released from the 
resin but hydrolysis product was observed along with the thioester 3g. RSH = SH-(CH2)2-OH or 
R’SH = SH-(CH2)2-COOC2H5, HS = heated shaker, RT = room temperature, Entries in bold: 
optimized conditions. Thioesterification at HS leads to 5-10% epimerization. Table adopted from 
reference (1) with permission. 
Initially, the reaction was performed at room temperature using DMF as a solvent in the 
presence of a thiol without use of any base (entry 1, Table 6.2). This resulted in the release of 10% 
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peptide thioester 3g from the resin after treatment for 20 h. To increase the conversion to peptide 
thioester 3g, various bases such as DIEA, DBU and sodium thiolate were investigated (entries 2-
4, Table 2.3). Addition of a catalytic amount of sodium thiolate as a base significantly increased 
the yield of peptide thioester 3g released from the resin (80%; entry 4, Table 6.2). Since it is 
difficult to remove DMF from the reaction mixture, a less volatile solvent such as ACN was 
explored, but resulted in very low conversion to a peptide thioester 3g (20 %; entry 5, Table 6.2). 
The final yields in ACN were low due to the poor solubility of sodium thiolate in ACN. 
Temperatures higher than 60 °C resulted in the significant hydrolysis of peptide thioester 3g into 
the corresponding acid (entries 7-9, Table 6.2). The formation of the hydrolyzed product was 
circumvented by the use of ethyl-3-mercaptopropionate, which gave stable peptide thioesters 3G 
that are less susceptible to hydrolysis. All reactions were clean at room temperature irrespective 
of the nature of thiol used and did not show significant amounts of hydrolysis.  
Potential epimerization during the thioesterification process was rigorously examined by 
synthesizing a peptide thioester Ac-GPMLA(L)-COS(CH2)2OH 3g under optimized reaction 
conditions and epimer Ac-GPMLA(D)-COS(CH2)2OH 3g’. No detectable levels of epimerization 
were observed as analyzed by HPLC (Figure 6.3). Next, we investigated epimerization studies on 
peptide thioester Ac-GVALF(L)-(CH2)2-COOC2H5 3j with bulky Phe residue at the C-terminus 
by analyzing it with epimer Ac-GVALF(D)-(CH2)2-COOC2H5
 3j’. Less than 1 % of epimerization 
was observed as analyzed by HPLC. Indeed, Phe is known as an amino acid relatively prone to 
epimerization, and thus these results indicate that our new methodology did not afford substantial 
epimerization.  
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Figure 6.3 HPLC traces of (a) purified peptide thioester Ac-GPMLA(L)-COS(CH2)2OH 3g (b) 
purified peptide thioester diastereoisomer Ac-GPMLA(D)-COS(CH2)2OH 3g’and (c) mixture 
containing both diastereoisomers of peptide thioesters 3g and 3g’, demonstrating lack of detectable 
epimerization. RSH = HS(CH2)2OH. Figure adopted from reference (1) with permission. 
Various peptides with different amino acids and protecting groups were evaluated for the 
synthesis of peptide thioesters (Table 6.3). Protecting groups from peptide thioesters were removed 
by using a TFA cleavage cocktail in solution. It was noted that the formation of peptide thioesters 
is independent of nature of amino acid residues preceding serine. For example, peptides with a 
bulky amino acid residue next to serine such as Val, Phe, Glu(tBu), and Ser(tBu) generated the 
protected peptide thioesters in a clean manner and with high yields (entries 2-5, Table 6.3). From 
these studies, we conclude that the cyclic urethane (Oxd) peptide will be a versatile precursor for 
synthesis of peptidyl thioesters.  
Table 6.3 Fmoc SPPS synthesis of peptide thioesters via activated serine.a 
 
142 
 
 
Entry Substrate Peptide 
Conv 
(%)b 
1 2h Ac-AVGPPGVA-Oxd 95 
2 2i 
Ac-
R(Pbf)AFK(Boc)Y(tBu)GLE(tBu)
-Oxd 
95 
3 2j Ac-GVALF-Oxd 95 
4 2k Ac-Y(tBu)FD(tBu)IR(Pbf)AV-Oxd 90 
5 2l 
Ac-S(tBu)GIS(tBu)GPLS(tBu)-
Oxd 
95 
6 2m Ac-GPMLA-MeOxd 90 
7 2n Ac-GPMLA-Thz 95 
aReaction conditions: Activated peptide, 2 (25 mg, 0.7 mm/g) on solid support was reacted with 
ethyl-3-mercaptopropionate (100 µL), and catalytic amount of sodium thiolate (0.5 equiv.), in 
DMF (1 mL). bConversion to peptide thioester 3 was calculated from the absorbance at 220 nm 
using HPLC. SR = S-(CH2)2-COOC2H5. Table adopted from reference (1) with permission. 
Next, the peptide backbone activation was investigated with threonine, because of its side 
chain functional group which exhibits similarity with serine. As expected, threonine underwent 
smooth cyclization under the optimized reaction conditions and generated MeOxd activated 
intermediate (entry 6, Table 6.3). In a similar manner, cysteine generated cyclic thiozolidinone 
(Thz) intermediate under the reaction conditions (entry 7, Table 6.3). The activated intermediates; 
MeOxd and Thz on thiolysis generated peptide thioester 3G. 
Importantly, our method was successfully applied for the synthesis of a multi-serine 
containing bioactive peptide thioester Ac-SGISGPLS-S(CH2)2CO2C2H5 3L, a fragment of 
antimicrobial bovine beta-defensin 13,24 from cyclic urethane activated peptide 
S(tBu)GIS(tBu)GPLS(tBu)-Oxd 2l (Figure 6.4). This result and table 6.3 demonstrated the 
versatility of cyclic urethane technique in the synthesis of peptide thioesters.  
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Figure 6.4 Cyclic urethane technique for the synthesis of the fragment of antimicrobial bovine 
beta-defensin 13 bioactive peptide thioester 3L RSH = SH-(CH2)2-COOC2H5. (a) HPLC trace of 
pure bioactive peptide thioester 3L and inset shows MS of peptide thioester 3L. Figure adopted 
from reference (1) with permission. 
Next, we utilized peptide thioesters Ac-GPMLA-COS-(CH2)2-COOC2H5 3G and Ac-
AVGPPGVA-COS-(CH2)2-COOC2H5 3h generated by the cyclic urethane technique in Native 
Chemical Ligation (NCL) with an N-terminal cysteine containing peptide Ac-SFARC (Figures 6.5 
and 6.6).  
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Figure 6.5 Native chemical Ligation of peptide thioester Ac-GPMLA-COSR 3G with N-
terminal cysteine peptide Ac-SFARC. RSH = HS-(CH2)2-COOC2H5. Figure adopted from 
reference (1) with permission. 
Relatively dilute conditions were used for the peptide reactants (1.2 mM) as well as low 
concentrations of the 4-mercaptophenylacetic acid catalyst (25 mM). The ligation was completed 
after 24 hrs at 37 °C, demonstrating the utility of cyclic urethane technique in the synthesis of 
peptide thioesters for the formation of large peptides using NCL.  
 
 
 
 
 
 
 
 
 
 
Figure 6.6 Native Chemical Ligation of peptide thioester Ac-AVGPPGVA-COSR 3h with 
N-terminal cysteine peptide Ac-SFARC. RSH = SH-(CH2)2-COOC2H5. Figure adopted 
from reference (1) with permission. 
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6.6 CONCLUSIONS 
We have developed a cyclic urethane activation technique for the rapid synthesis of peptide 
thioesters directly from solid support. The cyclic urethane technique carries out the acylation of 
the peptide backbone with Ser’s side chain undergoing nucleophilic displacement by a thiol to 
release a corresponding thioester into the solution. The significant advantage of this technique is 
that unnatural handles or linkers are not required, and peptide synthesis is carried out by Fmoc-
SPPS without a need for any special reaction conditions and can be fully automated, thus 
constituting a major advance in the field. It is noteworthy that only those peptides that undergo 
complete activation are displaced by the thiol into the solution thus delivering very pure thioesters 
in the solution. Moreover, activation of serine to the cyclic urethane moiety is compatible with 
both unhindered Ala and bulky Phe/Val amino acids next to serine and is resistant to epimerization. 
The results suggest that the cyclic urethane activation technique will be utilized in organic 
synthesis, including peptide and protein chemistry. Moreover, the cyclic urethane ring is stable 
and can be stored in the desiccator for long periods of time without any disintegration. 
Applicability of the strategy was demonstrated by the synthesis of long peptides using NCL. As a 
result, access to C-terminally activated cyclic urethane peptides will be applicable for the synthesis 
of complex post-translationally modified peptides and other biomolecules.  
6.7 EXPERIMENTAL SECTION 
General: All commercial materials (Aldrich, Fluka, Nova) were used without further purification. 
All solvents were reagent grade or HPLC grade (Fisher). Anhydrous THF, diethyl ether, CH2Cl2, 
and DMF were obtained from a dry solvent system (passed through column of alumina) and used 
without further drying. Conversion % were obtained by comparison of HPLC peak areas of 
products and starting material. HPLC was used to monitor the reaction progress. Materials. Fmoc-
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amino acids were obtained from Nova Biochem (EMD Millipore Corporation)(Billerica, 
Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide resin was obtained from 
ChemPep Inc (Wellington, Florida). N,N,N′,N′-Tetramethyl-O-(1Hbenzotriazol-1-yl)uronium 
hexafluorophosphate (HBTU) was obtained from CreoSalus (Louisville, Kentucky). N,N′-
Disuccinimidyl carbonate (DSC) was obtained from Nova Biochem, under (EMD Millipore 
Corporation) (Billerica, Massachusetts). 4-Dimethylaminopyridine (DMAP): Merck KGaA 
(Darmstadt, Germany). N,N-Dimethylformamide (DMF): Macron Fine Chemicals (Center Valley, 
Pennsylvania). Dichloromethane (DCM), acetonitrile, N,N- Diisopropylethylamine (DIEA), N,N'- 
diisopropylcarbodiimide (DIC), Triethylsilane (TES), were purchased from (EMD Millipore 
Corporation)(Billerica, Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill, 
Massachusetts). Trifluoroacetic acid (TFA) was purchased from VWR 100 Matsonford Road 
Radnor, PA. Diethyl Ether, 4-mercaptophenylacetic acid (MPAA), sodium thiophenolate (NaSPh), 
and Tris(2-carboxyethyl)phosphine hydrochloride TCEP.HCl : Sigma Aldrich (St. Louis, 
Missouri). Water was purified using a Millipore MilliQ water purification system. 
 NMR: Analysis done by Ryan Cohen at Merck facilities located at Rahway, NJ. Proton NMR 
spectra were recorded on a 600 MHz spectrometer and carbon NMR spectra on a 151 MHz, 
spectrometer at ambient temperature. All NMR chemical shifts (δ) are referenced in ppm relative 
to residual solvent or internal tetramethylsilane. 1H NMR chemical shifts referenced to residual 
DMSO-d5 at 2.50 ppm, and 
13C NMR chemical shifts referenced to DMSO-d6 at 39.52 ppm. 
Carbon NMR spectra are proton decoupled. NMR spectral data are reported as chemical shift 
(multiplicity, coupling constants (J), integration). Multiplicity is reported as follows: singlet (s), 
broad singlet (bs), doublet (d), doublet of doubles (dd), doublet of triplet (td), triplet (t) and 
multiplet (m). Coupling constant (J) in Hertz (Hz).  
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Semi-Preparative HPLC: Preparative HPLC chromatography (HPLC) was performed on 
Beckman Coulter equipped with System Gold 168 detector and 125P solvent module HPLC with 
C-18 reversed-phase column. All separations involved a mobile phase of 0.1% FA (v/v) in water 
(solvent A) and 0.1% FA (v/v) in acetonitrile (solvent B). Semi-preparative HPLC method using 
a linear gradient of 0– 80% acetonitrile in 0.1% aqueous FA over 30 min at room temperature with 
a flow rate of 3.0 mL min-1 . The eluent was monitored by absorbance at 220 nm unless otherwise 
noted.  
Analytical HPLC: Analytical HPLC chromatography (HPLC) was performed on an Agilent 1100 
series HPLC equipped with a 4.6x150 mm (5µm) C-18 reversed-phase column. All separations 
involved mobile phase of 0.1% FA (v/v) in water (solvent A) and 0.1% FA (v/v) in acetonitrile 
(solvent B). Peptide compositions were evaluated by analytical reverse phase HPLC using a 
gradient of 0.1% FA in acetonitrile versus 0.1% FA in water. HPLC method using a linear gradient 
of 0–80% 0.1% FA (v/v) acetonitrile in 0.1% aqueous FA over 30 min at room temperature with 
a flow rate of 1.0 mL min-1 . The eluent was monitored by absorbance at 220 nm unless otherwise 
noted.  
LCMS: Mass spectrometry was performed using ultra high-performance liquid chromatography-
mass spectrometry using the Agilent 1100 Series LCMSD VL MS Spectrometer.  
Fmoc Solid-Phase Peptide Synthesis:25 Peptides were synthesized manually on a 0.25 mmol 
scale using Rink amide resin. The Fmoc–group was deprotected using 20% piperidine–DMF for 
20 min to obtain a deprotected peptide-resin. Fmoc-protected amino acids (1.25 mmol) were 
sequentially coupled on the resin using a HBTU (1.25 mmol) and DIEA (1.25 mmol) for 2 hrs at 
room temperature. Peptides were synthesized using standard protocols.1 The peptide was cleaved 
from the resin using a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl silane:water for 2 hrs. 
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The resin was removed by filtration and the resulting solution was concentrated. The oily residue 
was triturated with diethyl ether to obtain a white suspension. The resulting solid was purified by 
HPLC. 
General procedure for the native chemical ligation for synthesis of large peptides: 900 μL of 
ligation buffer pH 7.1 (0.2 M sodium phosphate buffer and 6 M guanidine hydrochloride) was 
added to 1.0 mg of the peptide thioester 3G/3h (final concentration 1.3 mM) and 1.3 mg of peptide 
CRAFS (final concentration 2 mM) under argon. The mixture was treated with MPAA (3.8 mg, 
20 mM) and TCEP.HCl (5.5 mg, 17 mM) and pH of solution was adjusted to 7.0 by using 2N 
NaOH solution. The ligation was carried out at 37°C and monitored by RP HPLC. After 
completion of reaction, TCEP.HCl (30 mM in water) was added into the reaction mixture and it 
was left for stirring at room temperature for 1 hr followed by purification of ligated peptide using 
RP-HPLC. 
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CHAPTER 7: CONCLUSIONS AND CONTRIBUTIONS TO 
KNOWLEDGE  
7.1 CONCLUSIONS AND CONTRIBUTIONS TO KNOWLEDGE MADE IN 
THIS THESIS 
7.1.1 SITE-SELECTIVE CHEMICAL CLEAVAGE OF PEPTIDE BONDS 
 The second chapter of this thesis focuses on the development of an artificial protease mimic 
by site-selective modification of Ser, Thr, Cys, and Glu residues. In this study, we optimized 
formation of the cyclic urethane-derived moieties and applied them to site-selective cleavage of 
peptide bonds. The substrate scope was explored to determine the effect of neighboring residues 
on the effectiveness of cleavage. Generally, neighboring residues had no effect; however, bulky 
residues such as Val required longer incubation times in buffer to yield the cleavage product. 
Notably, cleavage proceeded even in the presence of Pro which is of significance due to the 
resistance of amide bonds neighboring Pro to enzymatic cleavage. Furthermore, the methodology 
was successfully applied to peptides containing modifications such as D, β, and N-methylated 
residues which are known to hinder enzymatic cleavage in native sequences. Finally, the scope of 
the reaction was extended to the scission of bioactive peptides including an amyloid beta peptide 
and a fragment of antimicrobial Bovine β-defensin 13. The significance of this research lies in the 
ability to cleave peptide bonds even in the presence of post-translational modifications and 
mutations which is vital in probing age-related disease and the function of these modifications. 
This study was recognized by a publication in Chemical Communications, and it set the foundation 
for further exploration of oxazolidinone mediated peptide bond cleavage and its various 
applications.  
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7.1.2 SEQUENCING OF PROMINENT NATURAL PRODUCTS 
 The third chapter of this thesis focuses on expanding the application of cyclic urethane-
mediated cleavage of peptide bonds to sequencing of cyclic peptides and lasso peptides which are 
natural products with unique therapeutic and structural properties. This study was accomplished 
in collaboration with the Link group at Princeton University, which facilitated expanding the scope 
of the study to lasso peptides. By modifying Ser to a cyclic urethane moiety, linearization of these 
unique peptides became a feasible task. The methodology was applied to a broad substrate scope 
including the ability to modify peptides containing Thr, Cys, Glu, and unnatural amino acids such 
as homoserine which account for 60% of naturally occurring cyclic peptides.  Utilizing this 
methodology, the cleavage and sequencing of stable N-methylated cyclic peptides, Polycarponin 
C, and a Somatostatin analogue in addition to lasso peptides lariatin A, albusnodin, and benenodin-
1 have also been validated. Additionally, we created a peptide rotaxane by the selective cleavage 
of benenodin-1. The impact of this work lies in application of a chemical cleavage methodology 
for the first time to effectively cleave lasso peptides which is a major milestone in simplifying 
sequence determination of lasso peptides, studying the lasso topology, monitoring the effect of 
cleavage on sterically locked residues, using lasso peptides as scaffolds for making rotaxane type 
interlocked machines, and providing a platform for discovering newly isolated biologically active 
peptides. This work was reported in a publication in Angewandte Chemie.  
7.1.3 SEQUENCING OF ONE-BEAD-ONE-COMPOUND LIBRARIES 
 In chapter four, oxazolidinone mediated cleavage of peptide bond is explored on solid 
support to facilitate sequencing of HIT peptides post high throughput screening against biological 
targets. Since cyclic peptides are attractive therapeutics for drug discovery due to high proteolytic 
stability, permeability, and high binding affinity, simplifying the sequencing process is of utmost 
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importance in developing lead compounds.  Toward this end, we developed a one bead one 
compound (OBOC) dual ring opening/cleavage approach for sequencing of hit cyclic peptides by 
selective modification of a serine residue to an oxazolidinone moiety within the cyclic peptide and 
as a linker to allow for the liberation of the protected linear peptide into solution. The major 
advantage of this method is that it is direct, without the need to tag each bead, which makes the 
synthesis of libraries of cyclic peptides easier. In addition, our method has high substrate scope 
and ring opening of cyclic peptides can be achieved at serine, threonine, cysteine, and glutamic 
acid residues, which is a significant advantage over the current OBOC approaches that rely either 
on a methionine residue or an unnatural entity. This work was published in Organic Letters. 
7.1.4 SYNTHESIS OF C-TERMINALLY MODIFIED PEPTIDES 
  In this chapter, a universal solid phase strategy for the synthesis of various C-terminal 
modified peptides is reported; the method is independent of the type of resins, linkers, and 
unnatural moieties typically needed for C-terminal modifications. The technique proceeds by the 
modification of C-terminal serine to a cyclic urethane moiety which results in the activation of the 
backbone amide chain for the nucleophilic displacement by various nucleophiles to generate C-
terminally modified acids, esters, N-alkyl amides, alcohols, and hydrazides. This cyclic urethane 
technique (CUT) also provides a general strategy for synthesis of C-terminal protected peptides 
which can be used for convergent synthesis of large peptides. A universal solid phase strategy has 
been effectively developed and applied for the synthesis of various C-terminal modified peptides, 
which are of therapeutic importance due to biological properties that accompany the attachment 
of various C-terminal functional groups. This cyclic urethane application has been reported in a 
publication in Chemical Communications.  
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7.1.5 SYNTHESIS OF THIOESTERS DERIVED FROM FMOC SPPS 
 In chapter six, we developed a versatile approach for direct synthesis of peptide thioesters 
from a solid support utilizing Fmoc chemistry. Fmoc SPPS of peptide thioesters are of high 
significance because they are precursors for convergent synthesis of proteins via NCL.  As a result, 
there is a great necessity for an effective Fmoc solid-phase approach for the preparation of peptide 
thioesters. To this end, the modified serine acts as a thioester surrogate and undergoes nucleophilic 
displacement with a thiol to generate peptide thioesters directly from the solid support.  
Applicability of the strategy was demonstrated by the synthesis of long peptides using NCL. As a 
result, access to C-terminally activated cyclic urethane peptides will be applicable for the synthesis 
of complex post-translationally modified peptides and other biomolecules. The significance of this 
work was recognized by a publication in Chemical Science. 
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CHAPTER 2 SUPPLEMENTAL MATERIAL 
All of the following figures have been reproduced with permission from: Elashal, H. E.; Raj, M. 
Chem. Commun. 2016, 52, 6304. 
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Figure A1 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Gly-Ala-Ser-Phe-Ala-Gly-NH2 (1a). LCMS: m/z 730.20 (calcd [M+H]+ = 730.01), Purity: 
>95% (HPLC analysis at 254 nm). Retention time: 17.85 min.  
Fmoc-Gly-Ala-Oxd-Phe-Ala-Gly-NH2 (2a). LCMS: m/z 756.40 (calcd [M+H]+ = 756.10), 778.5 
(calcd [M+Na]+ = 778.0). Purity: >95% (HPLC analysis at 254 nm). Retention time: 17.9 min. 
 Fmoc-Gly-Ala-OH (3a). LCMS: m/z 369.20 (calcd [M+H]+ = 369.13). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 18.6 min.  
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.20 (calcd [M+H]+ = 406.0), 428.2 (calcd [M+Na]+ 
= 428.3). Purity: >95% (HPLC analysis at 254 nm). Retention time: 8.9 min.  
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Figure A2 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Gly-Gly-Oxd-Phe-Ala-Gly-NH2 (2b). LCMS: m/z 742.40 (calcd [M+H]+ = 742.50), 371.9 
(calcd [(M+2/)2] + = 371.75). Purity: >95% (HPLC analysis at 254 nm). Retention time: 20.1 min.  
Fmoc-Gly-Gly-OH (3b). LCMS : m/z 355.20 (calcd [M+H]+ = 355.1). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 13.8 min. 
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ = 
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 6.9 min. 
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Figure A3 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Gly-Met-Oxd-Phe-Ala-Gly-NH2 (2c). LCMS: m/z 816.0 (calcd [M+H]+ = 816.20), 408.2 
(calcd [(M+2/)2] + = 408.8). Purity: >95% (HPLC analysis at 254 nm). Retention time: 21.8 min.  
Fmoc-Gly-Met-OH (3c). LCMS : m/z 429.60 (calcd [M+H]+ = 429.2). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 21.6 min.  
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.1 (calcd [M+Na]+ = 
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 9.8 min. 
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Figure A4 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
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Fmoc-Gly-His-Oxd-Phe-Ala-Gly-NH2 (2d). LCMS: m/z 822.10 (calcd [M+H]+ = 822.60), 411.2 
(calcd [(M+2/)2] + = 411.79). Purity: >95% (HPLC analysis at 254 nm). Retention time: 16.9 min. 
 Fmoc-Gly-His-OH (3d). LCMS : m/z 435.0 (calcd [M+H]+ = 435.19). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 15.8 min.  
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.3 (calcd [M+Na]+ = 
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 9.8 min. 
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Figure A5 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Gly-Tyr-Oxd-Phe-Ala-Gly-NH2 (2e). LCMS: m/z 848.20 (calcd [M+H]+ = 848.62), 424.1 
(calcd [(M+2/)2] + = 424.81). Purity: >95% (HPLC analysis at 254 nm). Retention time: 21.1 min.  
Fmoc-Gly-Tyr-OH (3e). LCMS : m/z 461.1 (calcd [M+H]+ = 461.22). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 20.9 min.  
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ = 
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 9.8 min. 
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Figure A6 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Gly-Trp-Oxd-Phe-Ala-Gly-NH2 (2f). LCMS: m/z 871.20 (calcd [M+H]+ = 871.6), 436.0 
(calcd [(M+2/)2] + = 436.33). Purity: >95% (HPLC analysis at 254 nm). Retention time: 19.8 min.  
Fmoc-Gly-Trp-OH (3f). LCMS : m/z 484.1 (calcd [M+H]+ = 484.26). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 16.7 min. 
 Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ = 
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 6.8 min. 
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Figure A7 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Gly-Val-Oxd-Phe-Ala-Gly-NH2 (2g). LCMS: m/z 784.60 (calcd [M+H]+ = 784.58), 
392.5 (calcd [(M+2/)2] + = 392.79). Purity: >95% (HPLC analysis at 254 nm). Retention time: 
16.6 min.  
Fmoc-Gly-Val-OH (3g). LCMS : m/z 397.1 (calcd [M+H]+ = 397.18). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 15.6 min.  
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ = 
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 6.8 min. 
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Figure A8 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Gly-(N-hydroxysuccinimide-Lys)-Oxd-Phe-Ala-Gly-NH2 (2h). LCMS: m/z 928.10 (calcd 
[M+H]+ = 928.62), 464.2 (calcd [(M+2/)2] + = 464.81). Purity: >95% (HPLC analysis at 254 nm). 
Retention time: 17.1 min.  
Fmoc-Gly-N-carboxy-Lys-OH (3h). LCMS : m/z 470.1 (calcd [M+H]+ = 470.2). Purity: >95% 
(HPLC analysis at 254 nm). Retention time: 15.6 min.  
Fmoc-Gly-Lys-OH (3h’). LCMS : m/z 426.1 (calcd [M+H]+ = 426.2). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 14.7 min.  
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ = 
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 9.8 min. 
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Figure A9 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Gly-Asp(cyc)-Oxd-Phe-Ala-Gly-NH2 (2i). LCMS: m/z 782.10 (calcd [M+H]+ = 782.53), 
391.1 (calcd [(M+2/)2] + = 391.76). Purity: >95% (HPLC analysis at 254 nm). Retention time: 
19.8 min. 
 Fmoc-Gly-Asp-OH (3i). LCMS : m/z 413.1 (calcd [M+H]+ = 413.14). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 18.8 min.  
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ = 
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 9.8 min. 
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Figure A10 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
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Fmoc-Gly-Pro-Oxd-Phe-Ala-Gly-NH2 (2j). LCMS: m/z 782.20 (calcd [M+H]+ = 782.56), 391.5 
(calcd [(M+2/)2] + = 391.78). Purity: >95% (HPLC analysis at 254 nm). Retention time: 19.55 
min.  
Fmoc-Gly-Pro-OH (3j). LCMS : m/z 395.1 (calcd [M+H]+ = 395.16). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 18.54 min.  
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ = 
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 8.9 min. 
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Figure A11 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Gly-Ala-Oxd-Phe-Arg-Phe-Gly-NH2 (5a). LCMS: m/z 1003.0 (calcd [M+H]+ = 1003.2), 
502.0 (calcd [(M+2/)2] + = 501.91). Purity: >95% (HPLC analysis at 254 nm). Retention time: 
19.6 min.  
Fmoc-Gly-Ala-OH (5b). LCMS : m/z 369.2 (calcd [M+H]+ = 369.13). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 19.89 min.  
Oxd-Phe-Arg-Phe-Gly-NH2 (5c). LCMS: m/z 652.3 (calcd [M+H]+ = 652.71), 674.2 (calcd 
[M+Na]+ = 674.71). Purity: >95% (HPLC analysis at 254 nm). Retention time: 13.3 min. 
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Figure A12 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Ala-Oxd-Phe-Val-Gly-Ala-(Oxd)-Phe-Arg-Phe-Gly-NH2 (6a). LCMS: m/z 1433.2 (calcd 
[M+H]+ = 1433.3), 717.1 (calcd [(M+2/)2] + = 717.15). Purity: >95% (HPLC analysis at 254 nm). 
Retention time: 13.04 min.  
Fmoc-Ala-OH (6b). LCMS : m/z 312.0 (calcd [M+H]+ = 312.07). Purity: >95% (HPLC analysis 
at 254 nm). Retention time: 12.9 min.  
Oxd-Phe-Val-Gly-Ala-OH (6c). LCMS: m/z 506.3 (calcd [M+H]+ = 506.51), 528.2 (calcd 
[M+Na]+ = 528.51). Purity: >95% (HPLC analysis at 254 nm). Retention time: 5.06 min.  
Oxd-Phe-Arg-Phe-Gly-NH2 (6d). LCMS: m/z 653.1 (calcd [M+H]+ = 653.71), 675.2 (calcd 
[M+Na]+ = 675.71). Purity: >95% (HPLC analysis at 254 nm). Retention time: 9.12 min. 
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Figure A13 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Ala-Val-Arg-Oxd-Phe-Oxd-Ala-Arg-Gly-Phe-Gly-NH2 (7a). LCMS: m/z 1428.1 (calcd 
[M+H]+ = 1428.29), 714.3 (calcd [(M+2/)2] + = 714.64). Purity: >95% (HPLC analysis at 254 
nm). Retention time: 18.2 min.  
Fmoc-Ala-Val-Arg-OH (7b). LCMS : m/z 567.2 (calcd [M+H]+ = 567.39). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 17.3 min. 
 Oxd-Phe-OH (7c). LCMS: m/z 279.1 (calcd [M+H]+ = 279.25), 301.1 (calcd [M+Na]+ = 301.25). 
Purity: >95% (HPLC analysis at 254 nm). Retention time: 8.8 min.  
Oxd-Ala-Arg-Gly-Phe-Gly-NH2 (7d). LCMS: m/z 619.5 (calcd [M+H]+ = 619.63), 641.4 (calcd 
[M+Na]+ = 641.63). Purity: >95% (HPLC analysis at 254 nm). Retention time: 11.87 min. 
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Figure A14 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Arg-Ala-Gly-Ala-Ser-Val-Arg-Phe-Ala-Ser-Phe-Gly-OH (8a). LCMS: m/z 1499.1 (calcd 
[M+H]+ = 1499.36), 750.0 (calcd [(M+2/)2] + = 750.18). Purity: >95% (HPLC analysis at 254 
nm). Retention time: 16.8 min. 
 Fmoc-Arg-Ala-Gly-Ala-OH (8b). LCMS : m/z 596.2 (calcd [M+H]+ = 596.39). Purity: >95% 
(HPLC analysis at 254 nm). Retention time: 12.9 min.  
Oxd-Val-Arg-Phe-Ala-OH (8c). LCMS: m/z 605.3 (calcd [M+H]+ = 605.65), 627.4 (calcd 
[M+Na]+ = 627.65). Purity: >95% (HPLC analysis at 254 nm). Retention time: 8.71 min.  
Oxd-Phe-Gly-OH (8d). LCMS: m/z 335.09 (calcd [M+H]+ = 335.32), 357.1 (calcd [M+Na]+ = 
357.32). Purity: >95% (HPLC analysis at 254 nm). Retention time: 6.8 min. 
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Figure A15 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-D-Val-D-Arg-D-Lys-D-Ala-D-Oxd-D-Arg-D-Ala- D-Ala-NH2 (9a). LCMS: m/z 1106.0 
(calcd [M+H]+ = 1106.02), 553.1 (calcd [(M+2/)2] + = 553.5). Purity: >95% (HPLC analysis at 
254 nm). Retention time: 16.9 min.  
Fmoc-D-Val-D-Arg-D-Lys-D-Ala-OH (9b). LCMS : m/z 695.3 (calcd [M+H]+ = 695.55). Purity: 
>95% (HPLC analysis at 254 nm). Retention time: 19.2 min.  
D-Oxd-D-Arg-D-Ala-D-Ala-NH2 (9c). LCMS: m/z 429.3 (calcd [M+H]+ = 429.43), 451.3 (calcd 
[M+Na]+ = 451.43), Purity: >95% (HPLC analysis at 254 nm). Retention time: 5.2 min. 
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Figure A16 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-D-Val-D-Arg- D-Lys-D-Ala-L-Oxd-D-Arg-D-Ala- D-Ala-NH2 (10a). LCMS: m/z 1106.1 
(calcd [M+H]+ = 1106.02), 553.0 (calcd [(M+2/)2] + = 553.5). Purity: >95% (HPLC analysis at 
254 nm). Retention time: 16.89 min.  
Fmoc-D-Val- D-Arg- D-Lys-D-Ala-OH (10b). LCMS : m/z 695.1 (calcd [M+H]+ = 695.55). 
Purity: >95% (HPLC analysis at 254 nm). Retention time: 19.18 min. 
 L-Oxd-D-Arg-D-Ala-D-Ala-NH2 (10c). LCMS: m/z 429.3 (calcd [M+H]+ = 429.43), 451.7 
(calcd [M+Na]+ = 451.43.Purity: >95% (HPLC analysis at 254 nm). Retention time: 4.7 min. 
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Figure A17 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Cys-Gly-Arg-Arg-Ala-Cys-Gly-Oxd-Phe-Ala-Gly-NH2, disulfide bond (11a). LCMS: m/z 
1330.1 (calcd [M+H]+ = 1330.24), 665.5 (calcd [(M+2/)2] + = 665.62). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 13.1 min. 
 Fmoc-Cys-Gly-Arg-Arg-Ala-Cys-Gly-OH, disulfide bond (11b). LCMS : m/z 942.5 (calcd 
[M+H]+ = 942.84), 471.7 (calcd [(M+2/)2] + = 471.92). Purity: >95% (HPLC analysis at 254 nm). 
Retention time: 12.2 min.  
Oxd-Phe-Ala-Gly-NH2 (11c). LCMS: m/z 406.2 (calcd [M+H]+ = 406.39), Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 5.8 min. 
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Figure A18 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
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Fmoc-Arg-Ala-Pyr-Ala-Gly-Oxd-Gly-Phe-NH2 (12a). LCMS: m/z 1023.4 (calcd [M+H]+ = 
1023.83), 512.1 (calcd [(M+2/)2] + = 512.41). Purity: >95% (HPLC analysis at 254 nm). Retention 
time: 13.9 min. 
 Fmoc-Arg-Ala-OH (12b). LCMS : m/z 468.09 (calcd [M+H]+ = 468.26). Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 12.5 min.  
Pyr-Ala-Gly-OH (12c). LCMS: m/z 258.14 (calcd [M+H]+ = 258.24), 280.0 (calcd [M+Na]+ = 
280.24). Purity: >95% (HPLC analysis at 254 nm). Retention time: 4.98 min.  
Oxd-Gly-Phe-NH2 (12d). LCMS: m/z 335.2 (calcd [M+H]+ = 335.32), 357.4 (calcd [M+Na]+ = 
357.32). Purity: >95% (HPLC analysis at 254 nm). Retention time: 8.98 min. 
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Figure A19 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Arg-Pro-Pro-Gly-Phe-Oxd-Pro-Phe-Arg-NH2 (13a). LCMS: m/z 1308.3 (calcd [M+H]+ = 
1308.22), 654.3 (calcd [(M+2/)2] + = 654.61). Purity: >95% (HPLC analysis at 254 nm). Retention 
time: 16.2 min.  
Fmoc-Arg-Pro-Pro-Gly-Phe-OH (13b). LCMS : m/z 795.3 (calcd [M+H]+ = 795.64). Purity: 
>95% (HPLC analysis at 254 nm). Retention time: 14.9 min.  
Oxd-Pro-Phe-Arg-NH2 (13c). LCMS: m/z 531.3 (calcd [M+H]+ = 531.57), Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 7.28 min. 
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Figure A20 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Leu-Asn-Asp-Arg-Leu-Ala-Oxd-Tyr-Leu-NH2 (14a). LCMS: m/z 1312.0 (calcd [M+H]+ 
= 1312.2), 656.1 (calcd [(M+2/)2] + = 656.6). Purity: >95% (HPLC analysis at 254 nm). Retention 
time: 21.18 min.  
Fmoc-Leu-Asn-Asp-Arg-Leu-Ala-OH (14b). LCMS : m/z 923.4 (calcd [M+H]+ = 923.77). Purity: 
>95% (HPLC analysis at 254 nm). Retention time: 15.1 min.  
Oxd-Tyr-Leu-NH2 (14c). LCMS: m/z 407.2 (calcd [M+H]+ = 407.42), 429.3 (calcd [M+Na]+ = 
429.42). Purity: >95% (HPLC analysis at 254 nm). Retention time: 7.9 min. 
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Figure A21 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
OAc-Ala-Val-Ala-Pro-Ala-Ala-Oxd-Ile-Val-Ala-NH2 (15a). LCMS: m/z 937.1 (calcd [M+H]+ 
= 937.02), Purity: >95% (HPLC analysis at 254 nm). Retention time: 10.9 min.  
OAc-Ala-Val-Ala-Pro-Ala-Ala-OH (15b). LCMS : m/z 541.4 (calcd [M+H]+ = 541.56). Purity: 
>95% (HPLC analysis at 254 nm). Retention time: 8.2 min. 
 Oxd-Ile-Val-Ala-NH2 (15c). LCMS: m/z 414.3 (calcd [M+H]+ = 414.46), Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 6.1 min. 
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Figure A22 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
OAc-Ala-Val-Ala-Pro-βAla-Ala-Oxd-Ile-Val-Ala-NH2 (16a). LCMS: m/z 937.1 (calcd [M+H]+ 
= 937.02), 975.1 (calcd [M+K] + = 975.02). Purity: >95% (HPLC analysis at 254 nm). Retention 
time: 10.6 min.  
OAc-Ala-Val-Ala-Pro-βAla-Ala-OH (16b). LCMS : m/z 541.4 (calcd [M+H]+ = 541.56). Purity: 
>95% (HPLC analysis at 254 nm). Retention time: 7.6 min.  
Oxd-Ile-Val-Ala-NH2 (15c). LCMS: m/z 414.3 (calcd [M+H]+ = 414.46), Purity: >95% (HPLC 
analysis at 254 nm). Retention time: 5.9 min. 
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Figure A23 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in buffer solution; the product peak is labeled. 
Fmoc-Leu-Arg-Arg-Ala-Oxd-(N-methyl)Leu-Gly-NH2 (17a). LCMS: m/z 1033.5 (calcd [M+H]+ 
= 1033.91), 517.3 (calcd [(M+2/)2] + = 517.45). Purity: >95% (HPLC analysis at 254 nm). 
Retention time: 11.9 min.  
Fmoc-Leu-Arg-Arg-Ala-OH (17b). LCMS : m/z 737.4 (calcd [M+H]+ = 737.61), 369.1 (calcd 
[(M+2/)2] + = 369.3)Purity: >95% (HPLC analysis at 254 nm). Retention time: 11.51 min.  
Oxd-(N-methyl)Leu-Gly-NH2 (17c). LCMS: m/z 315.2 (calcd [M+H]+ = 315.3), 337.1 (calcd 
[M+Na]+ = 337.3) Purity: >95% (HPLC analysis at 254 nm). Retention time: 8.88 min. 
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CHAPTER 3 SUPPLEMENTAL MATERIAL 
All of the following figures have been reproduced with permission from: Elashal, H. E.; Cohen, 
R. D.; Elashal, H. E.; Zong, C.; Link, A. J.; Raj, M. Angew. Chem. 2018, DOI: 
10.1002/anie.201801299.     
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A24  MS/MS data for a) cyc(SFRYAE) 4, b) activated oxazolidinone (Oxd)-containing 
macrocyclic peptide, cyc(Oxd-FRYAE) 5, and c) Oxd-FRYAE 6 showing that MS/MS of ring-
opened peptide is much simpler to interpret. 
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Figure A25 Total ion chromatograms and HRMS spectra for lariatin A (1a/b) incubated with 
trypsin (2a/b) and both trypsin and chymotrypsin (3a/b) for 48 h. Some protease degradation was 
observed due to self-cleavage. Peak intensities and ion abundances were similar for each sample 
indicating that lariatin A is stable to protealytic cleavage. 
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Figure A26 Deconvoluted mass spectra for albusnodin (below) and chemical cleavage product 
(above) at Ser-7.  
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CHAPTER 4 SUPPLEMENTAL MATERIAL 
All of the following figures have been reproduced with permission from: Elashal, H. E.; Cohen, 
R. D.; Elashal, H. E.; Raj, M. Org. Lett. 2018, 20 (8), 2374. 
 
 
Figure A27 Macrocyclic ring-opening and resin-cleavage of peptide 1a, cyc(GFSFAE)-S-Rink 
cyc(Gly-Phe-Ser-Phe-Ala-Glu)-Ser-CONH2 (1a). LC-MS: m/z 724.8 (calcd [M+H]+ = 725.3), 
m/z 746.8 (calcd [M+Na]+ = 747.3), Purity: >95% (HPLC analysis at 220 nm). Retention time: 
10.19 min 
cyc(Gly-Phe-Oxd-Phe-Ala-Glu)-Oxd-CONH2 (2a). LC-MS: m/z 776.7 (calcd [M+H]+ = 777.2), 
m/z 798.7 (calcd [M+Na]+ = 799.2), 1552.2 (calcd [2M+H]+ = 1554.4), 1574.3 (calcd [2M+Na]+ 
= 1576.4),  Purity: >95% (HPLC analysis at 220 nm). Retention time: 13.5 min 
Oxd-Phe-Ala-Glu-Gly-Phe (3a). LC-MS: m/z 682.7 (calcd [M+H]+ = 683.2), m/z 704.8 (calcd 
[M+Na]+ = 705.2),  Purity: >95% (HPLC analysis at 220 nm). Retention time: 11.3 min 
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Figure A28 HPLC trace and mass spectrum of peptide 1a, cyc(GFSFAE)-S-CONH2 after resin 
cleavage 
 
 
 
Figure A29 HPLC trace and mass spectrum of peptide 2a, Cyc(GF-Oxd-FAE)-Oxd-CONH2 after 
resin cleavage 
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Figure A30  HPLC trace and mass spectrum of peptide 3a, Oxd-FAEGF-OH 
 
 
 
Figure A31 LC-IM-MS/MS data for linear peptide 3a, Oxd-FAEGF-OH. a) extracted MS spectrum, and 
b) filtered MS/MS spectrum based on product peak drift time. Calcd [M+H]+ = 683.2671, 
Found [M+H]+ = 683.2670 
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Figure A32 Macrocyclic ring-opening and resin-cleavage of peptide 1b, cyc(SFFAE)-S-Rink 
cyc(Ser-Phe-Phe-Ala-Glu)-Ser-CONH2 (1b). LCMS: m/z 668.0 (calcd [M+H]+ = 668.3), m/z 
690.3 (calcd [M+Na]+ = 690.3), Purity: >95% (HPLC analysis at 220 nm). Retention time: 13.96 
Oxd-Phe-Phe-Ala-Glu (3b). LCMS: m/z 625.8 (calcd [M+H]+ = 626.24), m/z 647.5 (calcd 
[M+Na]+ = 648.24), Purity: >95% (HPLC analysis at 220 nm). Retention time: 11.71 min 
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Figure A33 HPLC trace and mass spectrum of peptide 1b, cyc(SFFAE)-S-CONH2 after resin 
cleavage 
 
 
 
Figure A34  HPLC trace and mass spectrum of peptide 3b, Oxd-SFFAE-OH 
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Figure A35  LC-IM-MS/MS data for linear peptide 3b, Oxd-FFAE-OH. a) extracted MS spectrum, and 
b) filtered MS/MS spectrum based on product peak drift time 
 Calcd [M+H]+ = 626.2457, Found [M+H]+ = 626.2450 
 
219 
 
 
Figure A36  Macrocyclic ring-opening and resin-cleavage of peptide 1c, cyc(SGVFAE)-S-Rink 
cyc(Ser-Gly-Val-Phe-Ala-Glu)-Ser-CONH2 (1c). LCMS: m/z 676.70 (calcd [M+H]+ = 677.3), 
Purity: >95% (HPLC analysis at 220 nm). Retention time: 9.5 min 
Oxd-Gly-Val-Phe-Ala-Glu (3c). LCMS: m/z 635.0 (calcd [M+H]+ = 635.6), Purity: >95% (HPLC 
analysis at 220 nm). Retention time: 7.9 min 
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Figure A37 HPLC trace and mass spectrum of peptide 1c, cyc(SGVFAE)-S-CONH2 after resin 
cleavage 
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Figure A38  HPLC trace of peptide 3c, Oxd-GVFAE-OH 
 
 
Figure A39  Macrocyclic ring-opening and resin-cleavage of peptide 1d, cyc(GSFAE)-S-Rink 
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cyc(Gly-Ser-Phe-Ala-Glu)-Ser-CONH2 (1d). LCMS: m/z 578.0 (calcd [M+H]+ = 578.2), Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 9.68 min 
Oxd-Phe-Ala-Glu-Gly (3d). LCMS: m/z 536.0 (calcd [M+H]+ = 536.1), Purity: >95% (HPLC 
analysis at 220 nm). Retention time: 9.55 min 
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Figure A40 HPLC trace and mass spectrum of peptide 1d, cyc(GSFAE)-S-CONH2 after resin 
cleavage 
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Figure A41 HPLC trace of peptide 3d, Oxd-FAEG-NH2 
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Figure A42  Macrocyclic ring-opening and resin-cleavage of peptide 1e, cyc(GFKSYGLE)-S-
Rink 
cyc(Gly-Phe-Lys-Ser-Tyr-Gly-Leu-Glu)-Ser-CONH2 (1e). LCMS: m/z 967.7 (calcd [M+H]+ = 
968.4), m/z 989.7, (calcd [M+Na]+ = 990.4), m/z 484.5 (calcd [(M+2)/2]+ = 484.7), Purity: >95% 
(HPLC analysis at 220 nm). Retention time: 10.12 
Oxd-Tyr-Gly-Leu-Glu-Gly-Phe-Lys (3e). LCMS: m/z 925.7 (calcd [M+H]+ = 926.4), Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 9.5 min 
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Figure A43 HPLC trace and mass spectrum of peptide 1e, cyc(GFKSYGLE)-S-CONH2 after 
resin cleavage 
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Figure A44 HPLC trace of peptide 3e, Oxd-YGLEGFK-OH 
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Figure A45  Macrocyclic ring-opening and resin-cleavage of peptide 1f, cyc(AFSIGFE)-S-Rink 
cyc(Ala-Phe-Ser-Ile-Gly-Phe-Glu)-Ser-CONH2 (1f). LCMS: m/z 837.8 (calcd [M+H]+ = 838.4), 
m/z 859.7 (calcd [M+Na]+ = 860.4), Purity: >95% (HPLC analysis at 220 nm). Retention time: 
11.9 
Oxd-Ile-Gly-Phe-Glu-Ala-Phe (3f). LCMS: m/z 795.8 (calcd [M+H]+ = 795.3), m/z 818.7, (calcd 
[M+Na]+ = 817.3), Purity: >95% (HPLC analysis at 220 nm). Retention time: 12.8 min 
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Figure A46 HPLC trace and mass spectrum of peptide 1f, cyc(AFSIGFE)-S-CONH2 after resin 
cleavage 
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Figure A47 HPLC trace and mass spectrum of peptide 3f, Oxd-IGFEAF-NH2 
 
1
2
.8
O
NH
O
N
H
H
N
N
H
O
O
O
H
N
N
H
O
O
N
H
O
3f
O
NH2
HO
O
[M + Na]
+[M + H]
+
O
NH
O
N
H
H
N
N
H
O
O
O
H
N
N
H
O
O
N
H
O
3f
O
NH2
HO
O
231 
 
 
Figure A48 Macrocyclic ring-opening and resin-cleavage of peptide 1g, cyc(AFSFE)-T-Rink 
 
cyc(Ala-Phe-Ser-Phe-Glu)-Thr-CONH2 (1g). LCMS: m/z 681.90 (calcd [M+H]+ = 682.3), m/z 
1363.7  (calcd [2M+H]+ = 1364.6), Purity: >95% (HPLC analysis at 220 nm). Retention time: 
12.07 
Oxd-Phe-Glu-Ala-Phe (3g). LCMS: m/z 625.8 (calcd [M+H]+ = 626.2), Purity: >95% (HPLC 
analysis at 220 nm). Retention time: 11.31 min 
  
NH
HN
O
O
OH
DSC, DIEA
DMAP,DMF
H2O:ACN
DIEA
O
NH
O
N
H
H
N
N
H
O
O
O
H
N
OH
O
O
3g
NH
O
HN
O
HN
O H
N
O
NH
O
1g
N
O
NH
O
N
O
HN
O H
N
O
NH
O
2g
O
O
N
H
O
HO
O
O
OH
O
232 
 
 
 
Figure A49 HPLC trace and mass spectrum of peptide 1g, cyc(AFSFE)-T-CONH2 after resin 
cleavage 
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Figure A50 HPLC trace and mass spectrum of peptide 3g, Oxd-FEAF-OH 
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Figure A51  Macrocyclic ring-opening and resin-cleavage of peptide 1h, cyc(GFCE)-C-Rink 
cyc(Gly-Phe-Cys-Glu)-Cys-CONH2 (1h). LCMS: m/z 539.0 (calcd [M+H]+ = 539.1), m/z 
1076.0, (calcd [dimer]+ = 1076.2) m/z 1098.5 (calcd [dimer+Na]+ = 1099.2), Purity: >95% (HPLC 
analysis at 220 nm). Retention time: 12.8 
Thz-Glu-Gly-Phe (3h). LCMS: m/z 480.9 (calcd [M+H]+ = 481.1), Purity: >95% (HPLC analysis 
at 220 nm). Retention time: 9.1 min 
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Figure A52 HPLC trace and mass spectrum of peptide 1h, cyc(GFCE)-S-CONH2 after resin 
cleavage 
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Figure A53 HPLC trace and mass spectrum of peptide 3h, Thz-EGF-OH 
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Figure A54  Macrocyclic ring-opening and resin-cleavage of peptide 1i, cyc(AMPFISFPE)-C-
Rink 
cyc(Ala-Met-Pro-Phe-Ile-Ser-Phe-Pro-Glu)-Cys-CONH2 (1i). LCMS: m/z 1121.7 (calcd 
[M+H]+ = 1122.5), m/z 1143.7, (calcd [M+Na]+ = 1144.5) 561.5 (calcd [M+Na]+ = 561.7), Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 15.1 min 
Oxd-Phe-Pro-Glu-Ala-Met-Pro-Phe-Ile (3i). LCMS: m/z 1063.6 (calcd [M+H]+ = 1064.4), m/z 
1087.8, (calcd [M+Na]+ = 1086.4) m/z 532.5 (calcd [M+Na]+ = 532.7), Purity: >95% (HPLC 
analysis at 220 nm). Retention time: 14.5 min 
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Figure A55 HPLC trace and mass spectrum of peptide 1i, cyc(AMPFISFPE)-C-CONH2 after 
resin cleavage 
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Figure A56 HPLC trace and mass spectrum of peptide 3i, Oxd-FPEAMPFI-OH  
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Figure A57  LC-IM-MS/MS data for linear peptide 3a, Oxd-FAEGF-OH. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time 
 Calcd [M+H]+ = 683.2671, Found [M+H]+ = 683.2670 
 
 
 
241 
 
 
 
 
 
Figure A58  LC-IM-MS/MS data for linear peptide 3b, Oxd-FFAE-OH. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time 
 Calcd [M+H]+ = 626.2457, Found [M+H]+ = 626.2450 
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Figure A59  LC-IM-MS/MS data for linear peptide 3c, Oxd-GVFAE-OH. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time 
 Calcd [M+H]+ = 635.2671, Found [M+H]+ = 635.2663 
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Figure A60  LC-IM-MS/MS data for linear peptide 3d, Oxd-FAEG-OH. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time 
 Calcd [M+H]+ = 536.1987, Found [M+H]+ = 536.1993 
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Figure A61  LC-IM-MS/MS data for linear peptide 3e, Oxd-YGLEGFK-OH. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time 
 Calcd [M+H]+ = 926.4254, Found [M+H]+ = 926.4267 
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Figure A62  LC-IM-MS/MS data for linear peptide 3f, Oxd-IGFEAF-OH. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time 
 Calcd [M+H]+ = 796.3512, Found [M+H]+ = 796.3514 
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Figure A63  LC-IM-MS/MS data for linear peptide 3g, Oxd-FEAF-OH. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time 
 Calcd [M+H]+ = 626.2457, Found [M+H]+ = 626.2445 
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Figure A64  LC-IM-MS/MS data for linear peptide 3h, Thz-EGF-OH. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time 
 Calcd [M+H]+ = 481.1388, Found [M+H]+ = 481.1361 
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Figure A65  LC-IM-MS/MS data for linear peptide 3i, Oxd-FPEAMPFI-OH. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time 
 Calcd [M+H]+ = 1064.4757, Found [M+H]+ = 1064.4731 
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Figure A66  LC-IM-MS/MS data for linear peptide, Oxd-MRE-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
547.2293, Found [M+H]+ = 547.2303 
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Figure A67  LC-IM-MS/MS data for linear peptide, Oxd-AFE-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time Calcd [M+H]+ = 
478.1932, Found [M+H]+ = 478.1918 
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Figure A68  LC-IM-MS/MS data for linear peptide Oxd-TFVE-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
607.2722, Found [M+H]+ = 607.2716 
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Figure A69  LC-IM-MS/MS data for linear peptide Oxd-FRVE-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
662.3257, Found [M+H]+ = 662.3265 
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Figure A70  LC-IM-MS/MS data for linear peptide Oxd-YFAE-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
641.2566, Found [M+H]+ = 641.2561 
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Figure A71  LC-IM-MS/MS data for linear peptide Oxd-NYAE-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
608.2311, Found [M+H]+ = 608.2335 
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Figure A72  LC-IM-MS/MS data for linear peptide Oxd-YIGE-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
593.2566, Found [M+H]+ = 593.2584 
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Figure A73  LC-IM-MS/MS data for linear peptide Oxd-FNTE-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
622.2467, Found [M+H]+ = 622.2461 
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Figure A74  LC-IM-MS/MS data for linear peptide Oxd-VRFAE-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
733.3628, Found [M+H]+ = 733.3651 
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Figure A75  LC-IM-MS/MS data for linear peptide Oxd-FRYAE-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
797.3577, Found [M+H]+ = 797.3595 
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Figure A76  LC-IM-MS/MS data for linear peptide Oxd-NYAAE-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
679.2682, Found [M+H]+ = 679.2676 
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Figure A77  LC-IM-MS/MS data for linear peptide Oxd-YIGAE-NH2. a) extracted MS spectrum, and b) 
filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 664.2937, Found 
[M+H]+ = 664.2947 
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Figure A78  LC-IM-MS/MS data for linear peptide Oxd-YFVGE-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
726.3093, Found [M+H]+ = 726.3115 
 
 
 
 
 
 
 
 
 
 
 
262 
 
 
 
 
 
 
Figure A79  LC-IM-MS/MS data for linear peptide Oxd-KIFEG-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
705.3566, Found [M+H]+ = 705.3576 
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Figure A80  LC-IM-MS/MS data for linear peptide Oxd-HVDEF-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
758.3104, Found [M+H]+ = 758.3105 
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Figure A81  LC-IM-MS/MS data for linear peptide Oxd-TLDEF-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
736.3148, Found [M+H]+ = 736.3156 
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Figure A82  LC-IM-MS/MS data for linear peptide Oxd-RQFEA-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
762.3529, Found [M+H]+ = 762.3531 
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Figure A83  LC-IM-MS/MS data for linear peptide Oxd-KIFAGE-NH2. a) extracted MS spectrum, and 
b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 776.3937, 
Found [M+H]+ = 776.3944 
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Figure A84  LC-IM-MS/MS data for linear peptide Oxd-AHDVGE-NH2. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd 
[M+H]+ = 739.3006, Found [M+H]+ = 739.2987 
 
 
 
 
 
 
 
 
 
 
 
268 
 
 
 
 
 
Figure A85  LC-IM-MS/MS data for linear peptide Oxd-TYDAFE-NH2. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd 
[M+H]+ = 857.3312, Found [M+H]+ = 857.3307 
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Figure A86  LC-IM-MS/MS data for linear peptide Oxd-TFKRVE-NH2. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd 
[M+H]+ = 891.4683, Found [M+H]+ = 891.4704 
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Figure A87  LC-IM-MS/MS data for linear peptide Oxd-IGFEAF-NH2. a) extracted MS spectrum, 
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 
795.3672, Found [M+H]+ = 795.3683 
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Figure A88  LC-IM-MS/MS data for linear peptide Oxd-RVDYGAE-NH2. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd 
[M+H]+ = 921.4061, Found [M+H]+ = 921.4053 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
272 
 
 
 
 
 
 
Figure A89  LC-IM-MS/MS data for linear peptide Oxd-AVFMNAE-NH2. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd 
[M+H]+ = 893.3822, Found [M+H]+ = 893.3811 
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Figure A90  LC-IM-MS/MS data for linear peptide Oxd-KVRNYAE-NH2. a) extracted MS spectrum, and 
b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+2H]2+ = 496.2514, 
Found [M+2H]2+ = 496.2513 
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Figure A91  LC-IM-MS/MS data for linear peptide Oxd-RYQVANE-NH2. a) extracted MS spectrum, and 
b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+2H]2+ = 496.2332, 
Found [M+2H]2+ = 496.2330 
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Figure A92  LC-IM-MS/MS data for linear peptide Oxd-KARFGVE-NH2. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd 
[M+2H]2+ = 459.7432, Found [M+2H]2+ = 459.7430 
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Figure A93  LC-IM-MS/MS data for linear peptide Oxd-AQVFRFTE-NH2. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd 
[M+H]+ = 1109.5374, Found [M+H]+ = 1109.5393 
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Figure A94  LC-IM-MS/MS data for linear peptide Oxd-YTFNDKLE-NH2. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd 
[M+H]+ = 1141.5160, Found [M+H]+ = 1141.5174 
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Figure A95  LC-IM-MS/MS data for linear peptide Oxd-RVKNGFEA-NH2. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd 
[M+H]+ = 1032.5221, Found [M+H]+ = 1032.5232 
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Figure A96  LC-IM-MS/MS data for linear peptide Oxd-YLFDWREK-NH2. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd 
[M+H]+ = 1268.6058, Found [M+H]+ = 1268.6067 
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Figure A97  LC-IM-MS/MS data for linear peptide Oxd-GYVKDFRAE-NH2. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd 
[M+H]+ = 1196.5695, Found [M+H]+ = 1196.5672 
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Figure A98 LC-IM-MS/MS data for linear peptide Oxd-AYKFGPSAE-NH2. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd 
[M+2H]2+ = 541.2511, Found [M+2H]2+ = 541.2519 
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Figure A99  LC-IM-MS/MS data for linear peptide Oxd-ATKFESRVE-NH2. a) extracted MS 
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd 
[M+2H]2+ = 589.7937, Found [M+2H]2+ = 589.7917 
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CHAPTER 5 SUPPLEMENTAL MATERIAL 
All of the following figures have been reproduced with permission from: Elashal, H. E.; Cohen, 
R. D.; Raj, M. Chem. Commun. 2016, 52, 9699. 
 
 
 
Figure A100 1H NMR spectrum for linear protected peptide 3b, 
AK(Boc)D(tBu)PY(tBu)R(Pbf)G-OH, recorded at 600 MHz 
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Figure A101 13C NMR spectrum for linear protected peptide 3b, 
AK(Boc)D(tBu)PY(tBu)R(Pbf)G-OH, recorded at 151 MHz  
 
Figure A102 HRMS (+ESI) data for linear protected peptide 3b, 
AK(Boc)D(tBu)PY(tBu)R(Pbf)G-OH 
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Figure A103 1H NMR spectrum for cyclic protected peptide 3c, 
cyc(AK(Boc)D(tBu)PY(tBu)R(Pbf)G), recorded at 600 MHz 
 
Figure A104 13C NMR spectrum for cyclized protected peptide 3c, 
cyc(AK(Boc)D(tBu)PY(tBu)R(Pbf)G), recorded at 151 MHz 
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Figure A105 HRMS (+ESI) data for cyclized protected peptide 3c, 
cyc(AK(Boc)D(tBu)PY(tBu)R(Pbf)G) 
 
 
Figure A106  1H NMR spectrum for cyclic unprotected peptide 3d, cyc(AKDPYRG), recorded at 
600 MHz 
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Figure A107 HRMS (+ESI) data for cyclized unprotected peptide 3d, cyc(AKDPYRG) 
 
 
 
Figure A108 Synthesis of macrocyclic peptide from unprotected linear peptide acid AKDPYRG 
obtained from Wang resin. Various possibilities of the cyclization of linear unprotected peptide 
AKDPYRG. Double cyclization of unprotected peptide cyc2(AKDPYRG) was observed as shown 
by LCMS. 
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Figure A109 1 H NMR spectrum for linear unprotected peptide, AKDPYRG, recorded at 600 
MHz 
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Figure A110 13C NMR spectrum for linear unprotected peptide, AKDPYRG, recorded at 151 
MHz 
 
 
Figure A111 HRMS (+ESI) data for linear unprotected peptide, AKDPYRG 
 
 
 
 
Figure A112 1H NMR spectrum for catalyst PFFFOMe 5’, recorded at 600 MHz 
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Figure A113 13C NMR spectrum for catalyst PFFFOMe 5’, recorded at 151 MHz 
 
 
 
Figure A114 HRMS (+ESI) data for catalyst PFFFOMe 5’ 
 
 
291 
 
 
Figure A115 (a) Synthesis of peptide Fmoc-ARFPPFRAOxd, 9 with semi-permanent protecting 
group on the C-terminus using cyclic urethane technique (CUT). (b) HPLC and MS chromatogram 
of C-terminal protected peptide Fmoc ARFPPFRA-Oxd, 9. 
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Figure A116 MS data for protected C-terminal peptide Fmoc-ARFPPFRA-Oxd, 9. 
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Figure A117 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Ac-Gly-Pro-Met-Leu-Ala-Oxd (1A). LCMS: m/z 642.20 (calcd [M+H]+ = 642.28), Purity: >95% 
(HPLC analysis at 220 nm). Retention time: 11.36  
Ac-Gly-Pro-Met-Leu-Ala (2a). LCMS: m/z 530.1 (calcd [M+H]+ = 530.26), Purity: >95% (HPLC 
analysis at 220 nm). Retention time: 11.49 min 
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Figure A118 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Gly-Pro-Met-Leu-Ala-Oxd (1A’). LCMS: m/z 600.2 (calcd [M+H]+ = 600.27), Purity: >95% 
(HPLC analysis at 220 nm). Retention time: 8.11 min 
 Gly-Pro-Met-Leu-Ala (2a’). LCMS: m/z 488.40 (calcd [M+H]+ = 488.25), Purity: >95% (HPLC 
analysis at 220 nm). Retention time: 7.37 min 
 
295 
 
 
 
 
Figure A119 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Fmoc-Gly-Pro-Met-Leu-Ala-Oxd (1A’’). LCMS: m/z 822.3 (calcd [M+H]+ = 822.34), 844.2 
(calcd [M+Na]+ = 844.34); Purity: >95% (HPLC analysis at 220 nm). Retention time: 18.2 min. 
Fmoc-Gly-Pro-Met-Leu-Ala (2a’’). LCMS: m/z 710.1 (calcd [M+H]+ = 710.31), (HPLC analysis 
at 220 nm). Retention time: 20.8 min. Gly-Pro-Met-Leu-Ala (2a’’-Fmoc or 2a’). LCMS: m/z 488.4 
(calcd [M+H]+ = 488.25), (HPLC analysis at 220 nm). Retention time: 7.89 min. 
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Figure A120 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Ac-Leu-Phe-Lys-Asn-Ala-Oxd (1B). LCMS: m/z 746.3 (calcd [M+H]+ = 746.38), Purity: >95% 
(HPLC analysis at 220 nm). Retention time: 9.14 min.  
Ac-Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2b). LCMS: m/z 976.5 (calcd [M+H]+ = 976.51), Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 22.97 min. 
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Figure A121 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Leu-Phe-Lys-Asn-Ala-Oxd (1C). LCMS: m/z 704.3 (calcd [M+H]+ = 704.37), Purity: >95% 
(HPLC analysis at 220 nm).  
Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2c). LCMS: m/z 934.5 (calcd [M+H]+ = 934.57), Purity: >95% 
(HPLC analysis at 220 nm). Retention time: 16.45 min. 
 
 
 
 
 
 
 
298 
 
 
 
 
Figure A122 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Fmoc-Leu-Phe-Lys-Asn-Ala-Oxd (1D). LCMS: m/z 926.4 (calcd [M+H]+ = 926.43), 948.3 (calcd 
[M+Na] + = 948.43), Purity: >95% (HPLC analysis at 220 nm). Retention time: 15.7 min. 
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Fmoc-Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2d). LCMS: m/z 1156.5 (calcd [M+H]+ = 1156.57), 
1178.5 (calcd [M+Na] + = 1178.57), Purity: >95% (HPLC analysis at 220 nm). Retention time: 
26.65 min. 
Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2d-Fmoc or 2c). LCMS: m/z 934.5 (calcd [M+H]+ = 934.57), 
Purity: >95% (HPLC analysis at 220 nm). Retention time: 16.37 min. 
 
 
 
Figure A123 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Phe-Glu-Ser-Gln-Ile-Oxd (1E). LCMS: m/z 735.3 (calcd [M+H]+ = 735.32), Purity: >95% (HPLC 
analysis at 220 nm). 
 Phe-Glu(tBu)-Ser(tBu)-Gln(Trt)-Ile (2e). LCMS: m/z 977.5 (calcd [M+H]+ = 977.53), Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 16.96 min. 
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Figure A124 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Ac-Arg-Asp-Pro-Met-Leu-Gly-Oxd (1F). LCMS: m/z 842.4 (calcd [M+H]+ = 842.38), 864.4 
(calcd [M+Na] + = 864.38), Purity: >95% (HPLC analysis at 220 nm). Retention time: 14.57 
min.  
Ac-Arg(Pbf)-Asp(tBu)-Pro-Met-Leu-Gly (2f). LCMS: m/z 1038.5 (calcd [M+H]+ = 1038.49), 
Purity: >95% (HPLC analysis at 220 nm). Retention time: 17.87 min. 
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Figure A125 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Arg-Asp-Pro-Met-Leu-Gly-Oxd (1G). LCMS: m/z 801.3 (calcd [M+H]+ = 801.36), 823.3 (calcd 
[M+Na]+ = 823.36) Purity: >95% (HPLC analysis at 220 nm).  
Arg(Pbf)-Asp(tBu)-Pro-Met-Leu-Gly (2g). LCMS: m/z 996.4 (calcd [M+H]+ = 996.48), 1018.5 
(calcd [M+Na] + = 1018.48), Purity: >95% (HPLC analysis at 220 nm). Retention time: 15.09 min 
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Figure A126 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Ac-Tyr-Leu-Phe-Lys-Asn-Ala-Oxd (1H). LCMS: m/z 909.4 (calcd [M+H]+ = 909.44) Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 10.13 min.  
Ac-Tyr(tBu)-Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2h). LCMS: m/z 1195.6 (calcd [M+H]+ = 
1195.64), 1217.6 (calcd [M+Na]+ = 1217.64) Purity: >95% (HPLC analysis at 220 nm). Retention 
time: 23.86 min 
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Figure A127 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Tyr-Leu-Phe-Lys-Asn-Ala-Oxd (1I). LCMS: m/z 867.3 (calcd [M+H]+ = 867.43), 434.2 (calcd 
[M+2H]2+ = 434.21), 889.3 (calcd [M+Na]+ = 889.43), Purity: >95% (HPLC analysis at 220 nm). 
Retention time: 7.49 min.  
Tyr(tBu)-Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2i). LCMS: m/z 1153.6 (calcd [M+H]+ = 1153.63), 
Purity: >95% (HPLC analysis at 220 nm). Retention time: 21.08 min. 
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Figure A128 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Ac-Val-Trp-Arg-Ala-Oxd (1J). LCMS: m/z 685.3 (calcd [M+H]+ = 685.76), 707.4 (calcd [M+Na] 
+ = 707.76), Purity: >95% (HPLC analysis at 220 nm). Retention time: 14.88 min.  
Ac-Val-Trp-Arg(Pbf)-Ala (2j). LCMS: m/z 825.4 (calcd [M+H]+ = 825.63), 847.4 (calcd [M+Na] 
+ = 847.63), Purity: >95% (HPLC analysis at 220 nm). Retention time: 18.69 min. 
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Figure A129 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Ac-Thr-Cys-Asp-Val-Oxd (1K). LCMS: m/z 591.3 (calcd [M+H]+ = 591.5), Purity: >95% (HPLC 
analysis at 220 nm). Retention time: 10.16 min.  
Ac-Thr(tBu)-Cys(tBu)-Asp(tBu)-Val (2k). LCMS: m/z 647.3 (calcd [M+H]+ = 647.36), Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 19.98 min. 
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Figure A130 HPLC spectra of the cyclized starting material and the crude reaction mixture after hydrolysis; 
the product peak is labeled. 
Fmoc-Tyr-Leu-Phe-Lys-Asn-Ala-Oxd (1L). LCMS: m/z 1089.5 (calcd [M+H]+ = 1089.50), Purity: >95% 
(HPLC analysis at 220 nm). Retention time: 14.79 min.  
Fmoc-Tyr(tBu)-Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2l). LCMS: m/z 1375.6 (calcd [M+H]+ = 1375.69), 
1397.6 (calcd [M+Na]+ = 1397.69) Purity: >95% (HPLC analysis at 220 nm). Retention time: 18.48 min 
 Tyr(tBu)-Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2l-Fmoc). LCMS: m/z 1153.6 (calcd [M+H]+ = 1153.69), 
Purity: >95% (HPLC analysis at 220 nm). Retention time: 14.9 min 
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Figure A131 HPLC spectra of the cyclized starting material and the crude reaction mixture after hydrolysis; 
the product peak is labeled. 
Ac-Val-Trp-His-Ala-Oxd (1M). LCMS: m/z 666.3 (calcd [M+H]+ = 666.6), Purity: >95% (HPLC analysis 
at 220 nm). Retention time: 9.2 min  
Ac-Val-Trp-His(Trt)-Ala (2m). LCMS: m/z 796.4 (calcd [M+H]+ = 796.5), Purity: >95% (HPLC analysis 
at 220 nm). Retention time: 15.58 min 
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Figure A132 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Ac-Thr-Cys-Gly-Gly-His-Ala-Oxd (1N). LCMS: m/z 699.2 (calcd [M+H]+ = 699.66), Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 14.46 min  
Ac-Thr(Trt)-Cys-Gly-Gly-His(Trt)-Ala (2n). LCMS: m/z 1071.4 (calcd [M+H]+ = 1071.5), 
1093.4 (calcd [M+Na]+ = 1093.5) Purity: >95% (HPLC analysis at 220 nm). Retention time: 20.52 
min 
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Figure A133 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
hydrolysis; the product peak is labeled. 
Fmoc-Thr-Cys-Gly-Gly-His-Ala-Oxd (1O). LCMS: m/z 879.3 (calcd [M+H]+ = 879.66), 901.3 
(calcd [M+Na] + = 900.66), Purity: >95% (HPLC analysis at 220 nm). Retention time: 19.05 min  
Fmoc-Thr(Trt)-Cys-Gly-Gly-His(Trt)-Ala (2o). LCMS: m/z 1251.4 (calcd [M+H]+ = 1251.57, 
Purity: >95% (HPLC analysis at 220 nm). Retention time: 23.46 min  
Thr(Trt)-Cys-Gly-Gly-His(Trt)-Ala (2o-Fmoc). LCMS: m/z 1029.4 (calcd [M+H]+ = 1029.57), 
Purity: >95% (HPLC analysis at 220 nm). Retention time: 15.62 min 
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Figure A134 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in methanol solution; the product peak is labeled. 
Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-Oxd (4A). LCMS: m/z 779.3 (calcd [M+H]+ = 779.37), Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 7.09 min  
Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-OMe (5). LCMS: m/z 681.3 (calcd [M+H]+ = 681.46, Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 8.047 min 
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Figure A135 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in solution of benzyl amine in DMF; the product peak is labeled. 
Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-Oxd (4A). LCMS: m/z 779.3 (calcd [M+H]+ = 779.37), Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 7.09 min  
Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-NHBz (6). LCMS: m/z 756.3 (calcd [M+H]+ = 756.57, Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 9.58 min 
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Figure A136 HPLC spectra of the cyclized starting material and the crude reaction mixture after 
incubation in sodium borohydride solution in THF; the product peak is labeled. 
Ac-Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-Oxd (4’A). LCMS: m/z 821.3 (calcd [M+H]+ = 821.66), m/z 843.2 
(calcd [M+Na] + = 843.66), Purity: >95% (HPLC analysis at 220 nm). Retention time: 8.407 min  
Ac-Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-CH2OH (7). LCMS: m/z 695.3 (calcd [M+H]+ = 695.37); 717.3 
(calcd [M+Na]+ = 717.37) Purity: >95% (HPLC analysis at 220 nm). Retention time: 7.4 min 
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CHAPTER 6 SUPPLEMENTAL MATERIAL 
All of the following figures have been reproduced with permission from: Elashal, H. E.; Sim, Y. 
E.; Raj, M. Chem. Sci. 2017, 8, 117.  
 
Figure A137 HRMS Spectra Ac-Gly-Pro-Met-Leu-Ala(L)-COS(CH2)2CO2C2H5 - 3G 
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Figure A138 NMR spectra Ac-Gly-Pro-Met-Leu-Ala(L)-COS(CH2)2CO2C2H5 - 3G 
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Figure A139 HPLC and MS traces for thiolysis product. 
Ac-Gly-Pro-Met-Leu-Ala-COS(CH2)2OH (3g). LCMS: m/z 590.2 (calcd [M+H]+ = 590.6), m/z 
612.2 (calcd [M+ Na] + = 612.6). Purity: >95% (HPLC analysis at 220 nm). Retention time:10.28 
min  
Ac-Gly-Pro-Met-Leu-Ala-OH. LCMS: m/z 530.2 (calcd [M+H]+ = 530.5), m/z 552.2 (calcd 
[M+Na]+ = 552.5). Purity: >95% (HPLC analysis at 220 nm). Retention time: 9.36 min 
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Figure A140 HPLC and MS traces for thiolysis product. 
Ac-Gly-Pro-Met-Leu-Ala-COS(CH2)2CO2C2H5 (3G). LCMS: m/z 646.3 (calcd [M+H]+ = 
646.7). Purity: >95% (HPLC analysis at 220 nm). Retention time: 13.87 min 
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Figure A141 HPLC and MS traces for thiolysis product. 
Ac-Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-COS(CH2)2CO2C2H5 (3h). LCMS: m/z 825.3 (calcd 
[M+H]+ = 825.7), m/z 847.3 (calcd [M+Na] + = 847.7). Purity: >95% (HPLC analysis at 220 nm). 
Retention time: 11.94 min 
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Figure A142 HPLC and MS traces for thiolysis product. 
Ac-Arg-Ala-Phe-Lys-Tyr-Gly-Leu-Glu-COS(CH2)2CO2C2H5 (3i). LCMS: m/z 1140.9 (calcd 
[M+H]+ = 1140.5), m/z 1163.9 (calcd [M+Na] + = 1163.5). Purity: >95% (HPLC analysis at 220 
nm). Retention time: 19.45 min 
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Figure A143 HPLC and MS traces for thiolysis product. 
Ac-Gly-Val-Ala-Leu-Phe-COS(CH2)2CO2C2H5 (3j). LCMS: m/z 664.3 (calcd [M+H]+ = 
664.6), m/z 686.3 (calcd [M+Na] + = 686.6). Purity: >95% (HPLC analysis at 220 nm). 
Retention time: 16.30 min. 
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Figure A144 HPLC and MS traces for thiolysis product. 
Ac-Tyr(tBu)-Phe-Asp(tBu)-Ile-Arg(Pbf)-Ala-Val-COS(CH2)2CO2C2H5 (3k). LCMS: m/z 
1404.7 (calcd [M+H]+ = 1404.3), m/z 1426.5 (calcd [M+Na] + = 1426.3). Purity: >95% (HPLC 
analysis at 220 nm). Retention time: 25.09 min. 
Ac-Tyr-Phe-Asp-Ile-Arg-Ala-Val-COS(CH2)2CO2C2H5 (3K). LCMS: m/z 1040.7 (calcd 
[M+H]+ = 1040.8), m/z 1063.6 (calcd [M+Na] + = 1063.8). Purity: >95% (HPLC analysis at 220 
nm). Retention time: 14.61 min. 
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Figure A145 HPLC and MS traces for thiolysis product. 
Ac-Ser-Gly-Ile-Ser-Gly-Pro-Leu-Ser-COS(CH2)2CO2C2H5 (3L). LCMS: m/z 875.3 (calcd 
[M+H]+ = 875.7), m/z 897.2 (calcd [M+Na] + = 897.7). Purity: >95% (HPLC analysis at 220 
nm). Retention time: 12.0 min. 
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Figure A146 HPLC and MS traces for thiolysis product. 
Ac-Arg-Phe-Ala-Thr-COS(CH2)2CO2C2H5 (3M). LCMS: m/z 651.8 (calcd [M+H]+ = 651.5), 
m/z 673.8 (calcd [M+Na]+ = 673.5). Purity: >95% (HPLC analysis at 220 nm). Retention time: 
11.01 min. Isolated yield = 50 % 
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Figure A147 HPLC and MS traces for thiolysis product. 
Ac-Gly-Pro-Met-Leu-Ala-COS(CH2)2CO2C2H5 (3G). LCMS: m/z 645.8 (calcd [M+H]+ = 
645.5), m/z 667.7 (calcd [M+Na] + = 667.5). Purity: >95% (HPLC analysis at 220 nm). 
Retention time: 13.97 min 
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Figure A148 HPLC and MS traces for thiolysis product. 
Ac-RMITYGNSARKGRSNTFID-COS(CH2)2CO2C2H5 (3P). LCMS: m/z 1172.8 (calcd 
[M+2H] 2+ = 1172.5), m/z 782.1 (calcd [M+3H] 3+ = 782.0), m/z 586.6 (calcd [M+4H] 4+= 
586.7). Purity: >95% (HPLC analysis at 220 nm). Retention time: 10.67 min. Isolated yield = 31% 
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Figure A149 HPLC and MS traces for thiolysis product. 
Ac-GNSARKGRSNTFID-COS(CH2)2CO2C2H5 (3Q). LCMS: m/z 840.4 (calcd [M+2H] 2+ = 
840.9), m/z 560.7 (calcd [M+3H] 3+ = 560.9). Purity: >95% (HPLC analysis at 220 nm). Retention 
time: 9.88 min. Isolated yield = 39 % 
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Figure A150 HPLC and MS traces for ligated product. 
Ac-Gly-Pro-Met-Leu-Ala-Cys(MPAA)-Arg-Phe-Ala-Ser. LCMS: m/z 1285.5 (calcd [M+Na] + = 
1285.8). Purity: >95% (HPLC analysis at 220 nm). Retention time: 13.2 min.  
Ac-Gly-Pro-Met-Leu-Ala-Cys-Arg-Phe-Ala-Ser. LCMS: m/z 1093.4 (calcd [M+H]+ = 1093.3), 
m/z 547.2 (calcd [M+2] 2+ = 547.6). Purity: >95% (HPLC analysis at 220 nm). Retention time: 
11.32 min. 
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Figure A151 HPLC and MS traces for ligated product. 
Ac-Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-Cys-Arg-Phe-Ala-Ser. LCMS: m/z 1273.6 (calcd [M+H]+ 
= 1273.4), m/z 636.9 (calcd [M+2] 2+ = 637.2). Purity: >95% (HPLC analysis at 220 nm). 
Retention time: 10.01 min. 
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Figure A152 HPLC and MS traces for ligated product. 
Ac-GNSARKGRSNTFIDCPTGPRPNEPMWITY-NH2. LCMS: m/z 3308.6 (calcd [M+H]+ = 
3308.4), m/z 1654.8 (calcd [M+2]2+ = 1654.7). Purity: >95% (HPLC analysis at 220 nm). 
Retention time: 11.14 min 
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Figure A153 MALDI of ligated Product 29 amino acid long peptide  
Ac-GNSARKGRSNTFIDCPTGPRPNEPMWITY-NH2 
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Figure A154 HPLC spectra of the cyclic urethane containing peptide 2a’ 
Fmoc-Gly-Ala-Oxd-Phe-Ala-Gly-NH2 (2a’). LCMS: m/z 756.40 (calcd [M+H]+ = 756.10), 778.5 
(calcd [M+Na]+ = 778.0). Purity: >95% (HPLC analysis at 254 nm). Retention time: 17.9 min. 
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Figure A155 HPLC spectra of the cyclic urethane containing peptide 2b’ 
Fmoc-Gly-Gly-Oxd-Phe-Ala-Gly-NH2 (2b’). LCMS: m/z 742.40 (calcd [M+H]+ = 742.50), 371.9 
(calcd [(M+2] 2+ = 371.75). Purity: >95% (HPLC analysis at 254 nm). Retention time: 20.1 min. 
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Figure A156 HPLC spectra of the cyclic urethane containing peptide 2c’ 
Fmoc-Gly-Met-Oxd-Phe-Ala-Gly-NH2 (2c’). LCMS: m/z 816.0 (calcd [M+H]+ = 816.20), 408.2 
(calcd (M+2) 2+ = 408.8). Purity: >95% (HPLC analysis at 254 nm). Retention time: 21.8 min. 
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Figure A157 HPLC spectra of the cyclic urethane containing peptide 2d’ 
Fmoc-Gly-His-Oxd-Phe-Ala-Gly-NH2 (2d’). LCMS: m/z 822.10 (calcd [M+H]+ = 822.60), 411.2 
(calcd (M+2)2+ = 411.79). Purity: >95% (HPLC analysis at 254 nm). Retention time: 16.9 min. 
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Figure A158 HPLC spectra of the cyclic urethane containing peptide 2e’ 
Fmoc-Gly-Tyr-Oxd-Phe-Ala-Gly-NH2 (2e’). LCMS: m/z 848.20 (calcd [M+H]+ = 848.62), 424.1 
(calcd [(M+2) 2+ = 424.81). Purity: >95% (HPLC analysis at 254 nm). Retention time: 21.1 min. 
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Figure A159 HPLC spectra of the cyclic urethane containing peptide 2f’ 
Fmoc-Gly-Trp-Oxd-Phe-Ala-Gly-NH2 (2f’). LCMS: m/z 871.20 (calcd [M+H]+ = 871.6), 436.0 
(calcd (M+2) 2+ = 436.33). Purity: >95% (HPLC analysis at 254 nm). Retention time: 19.8 min. 
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Figure A160 HPLC spectra of the cyclic urethane containing peptide 2g’ 
Fmoc-Gly-Val-Oxd-Phe-Ala-Gly-NH2 (2g’). LCMS: m/z 784.60 (calcd [M+H]+ = 784.58), 392.5 
(calcd (M+2) 2+ = 392.79). Purity: >95% (HPLC analysis at 254 nm). Retention time: 16.6 min. 
 
 
